Voruciclib poly morphs and methods of making and using the same
Patent Information
- Application Number
- JP2023217619
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-11
- Filing Date
- 2023-12-25
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drugs can exist in various polymorphic forms that affect drug performance and bioavailability, necessitating the development of stable and well-characterized crystalline forms to ensure consistent efficacy and safety.
The development of novel polymorphs of vorciclib, including crystalline forms and salts with specific counterions, characterized by unique X-ray diffraction patterns, to enhance stability and bioavailability.
The novel polymorphs of vorciclib provide improved stability, dosage consistency, and therapeutic efficacy, making them suitable for treating a wide range of diseases, including hematological cancers and chronic conditions.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] The present disclosure provides novel polymorphs of the CDK inhibitor voruciclib, as well as methods of making and using same. [Background technology]
[0002] Certain chemical compounds, including various drugs, may exist in polymorphic forms. Polymorphic forms generally refer to different crystalline forms with different physical properties, but may also include solvates or hydrates, and amorphous forms (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Q6A, version dated 6 October 1999). Differences in polymorphic forms can affect drug performance, bioavailability, and Polymorphism can affect the quality and performance of a drug, including its use, stability, etc. Various physicochemical measurements and techniques can be used to explore and distinguish between polymorphs, including melting point determination, infrared spectroscopy (IR), X-ray diffraction, thermal analysis (DSC, TGA, etc.), Raman spectroscopy, optical microscopy, and NMR. Summary of the Invention
[0003] The present disclosure provides polymorphs, e.g., crystalline forms, of voruciclib. In some embodiments, the polymorph comprises the free base voruciclib. In some embodiments, the polymorph comprises a salt of voruciclib with a counterion corresponding to an acid selected from 1,5-naphthalenedisulfonic acid, 1-hydroxy-2-naphthoic acid, benzenesulfonic acid, benzoic acid, dibenzoyl-L-tartaric acid, ethanesulfonic acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malonic acid, oxalic acid, orthophosphoric acid, sulfuric acid, p-toluenesulfonic acid, etc.
[0004] In one embodiment, the disclosure provides a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°, 15.18°±0.2°, 15.66°±0.2°, 17.50°±0.2°, 18.94°±0.2°, 19.54°±0.2°, 22.22°±0.2°, 23.38°±0.2°, 24.10°±0.2°, 24.98°±0.2°, 25.94°±0.2°, 27.26°±0.2°, 28.50°±0.2°, and 32.82°±0.2°2θ. In some embodiments, the crystalline form comprises voruciclib malonate.
[0005] In one embodiment, the present disclosure provides the following: 5.06°±0.2°, 6.42°±0.2°, 9.34°±0.2°, 10.14°±0.2°, 12.30°±0.2°, 13.66°±0.2°, 14.14°±0.2°, 15.82°±0.2°, 17.02°±0.2°, 19.74°±0.2°, 20.38°±0.2°. 20°±0.2°, 21.82°±0.2°, 22.66°±0.2°, 24.62°±0.2°, 25.78°±0.2°, 26.58°±0.2°, 28.66°±0.2°, and 29.98°±0.2°2θ. In some embodiments, the crystalline form comprises voruciclib dibenzoyltartrate.
[0006] In one embodiment, the present disclosure provides the following: 4.94°±0.2°, 6.78°±0.2°, 9.34°±0.2°, 10.94°±0.2°, 12.70°±0.2°, 13.38°±0.2°, 14.90°±0.2°, 15.66°±0.2°, 17.54°±0.2°, 18.82°±0.2°, 22.02°±0.2°, 23.98°±0.2°, 24. Provided is a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 78°±0.2°, 25.30°±0.2°, 26.66°±0.2°, and 29.98°±0.2°2θ. In some embodiments, the crystalline form comprises voruciclib phosphate.
[0007] In one embodiment, the disclosure provides a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 6.86°±0.2°, 12.66°±0.2°, 13.58°±0.2°, 14.74°±0.2°, 15.98°±0.2°, 19.38°±0.2°, 23.94°±0.2°, 24.78°±0.2°, and 25.94°±0.2°2θ. In some embodiments, the crystalline form comprises voruciclib oxalate.
[0008] In one embodiment, the present disclosure provides a method for detecting the rotational speed of a lens, comprising: 9.02°±0.2°, 10.50°±0.2°, 11.06°±0.2°, 12.30°±0.2°, 12.82°±0.2°, 13.90°±0.2°, 14.82°±0.2°, 15.30°±0.2°, 15.94°±0.2°, 17.26°±0.2°, 19.34°±0.2°, 20.50°±0.2°, 21.50°±0.2°, 22.50°±0.2°, 23.50°±0.2°, 24.50°±0.2°, 25.50°±0.2°, 26.50°±0.2°, 27.50°±0.2°, 28.50°±0.2°, 29.50°±0.2°, 30.50°±0.2°, 31.50°±0.2°, 32.50°±0.2°, 33.50°±0.2°, 34.50°±0.2°, 35.50°±0.2°, 36.50°±0.2°, 37.50°±0.2°, 38.50°±0.2°, 39.50°±0.2°, 40.50°±0.2°, 41.50°±0.2°, 42.50°±0.2°, 43.50°±0.2°, 44.50°±0.2°, 45.50°±0.2°, 46.50°±0 27.38°±0.2°, and 28.66°±0.2°2θ. In some embodiments, the crystalline form comprises voruciclib napadisylate.
[0009] In one embodiment, the present disclosure provides a crystalline anhydrate crystalline form of voruciclib. In one embodiment, the present disclosure provides a crystalline hydrate crystalline form of voruciclib. In one embodiment, the present disclosure provides a composition comprising a crystalline form of voruciclib described herein and a pharmaceutically acceptable excipient.
[0010] In one embodiment, the disclosure provides a method of treating a disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a crystalline form of voruciclib as described herein, wherein the disease is selected from the group consisting of chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, B-cell lymphoproliferative disorders, B-cell acute lymphoblastic leukemia, Waldenstrom's hypergammaglobulinemia, Burkitt's leukemia, Hodgkin's disease, multiple myeloma, acute myeloid leukemia, and juvenile myelomonocytic leukemia. , hairy cell leukemia, mast cell leukemia, mastocytosis, myeloproliferative disorders (MPD), myeloproliferative neoplasms, polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), myelodysplastic syndromes, chronic myeloid leukemia (BCR-ABL1-positive), chronic neutrophilic leukemia, chronic eosinophilic leukemia, primary central nervous system (CNS) lymphoma, primary multifocal lymphoma of the peripheral nervous system (PNS), thymic carcinoma, brain cancer, glioblastoma, lung cancer, squamous cell carcinoma, skin cancer (e.g., melanoma), eye cancer, retinoblastoma, intraocular melanoma, oral cavity and oropharynx Head cancer, bladder cancer, stomach cancer, pancreatic cancer, breast cancer, cervical cancer, head and neck cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, prostate cancer, colorectal cancer, bone cancer (e.g., metastatic bone cancer), esophageal cancer, testicular cancer, gynecological cancer, thyroid cancer, epidermoid carcinoma, AIDS-related cancer (e.g., lymphoma), virus-induced cervical cancer (human papillomavirus), nasopharyngeal carcinoma (Epstein-Barr virus), Kaposi's sarcoma, primary effusion lymphoma (Kaposi's sarcoma-associated herpesvirus), hepatocellular carcinoma (hepatitis B virus and hepatitis C virus), T-cell leukemia (human T-cell leukemia virus type 1), skin cancer Benign hyperplasia of the skin, restenosis, benign prostatic hyperplasia, tumor angiogenesis, chronic inflammatory diseases, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, ulcerative colitis, atopic dermatitis, pouchitis, spondyloarthritis, uveitis, Behcet's disease, polymyalgia rheumatica, giant cell arteritis, sarcoidosis, Kawasaki disease, juvenile idiopathic arthritis, hidradenitis suppurativa, Sjogren's syndrome, psoriatic arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis The disease is selected from the group consisting of Crohn's disease, lupus, and lupus nephritis.
[0011] In one embodiment, the disclosure provides a method of treating a hyperproliferative disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a crystalline form of voruciclib as described herein, wherein the hyperproliferative disease is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, B-cell lymphoproliferative disease, B-cell acute lymphocytic leukemia, and Waldenstrom's hypergammaglobulinemia.
[0012] In one embodiment, the disclosure provides a method of treating a hematological cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a crystalline form of voruciclib described herein. In some embodiments, the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic lymphoma (ALL), and chronic lymphocytic leukemia (CLL).
[0013] In one embodiment, the present disclosure provides a composition for treating a hematological cancer in a patient, the composition comprising a crystalline form of voruciclib described herein and a pharmaceutically acceptable excipient. In some embodiments, the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic lymphoma (ALL), and chronic lymphocytic leukemia (CLL).
[0014] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl, or a crystalline form of voruciclib free base, each characterized by an X-ray diffraction pattern substantially in accordance with the X-ray diffraction pattern of FIG. 1.
[0015] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 2. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with the X-ray diffraction pattern of FIG.
[0016] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 8. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns of FIG.
[0017] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns of Figures 12A and 12B.
[0018] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 14. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 18.
[0019] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 22. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in FIG. 26.
[0020] In one embodiment, the present disclosure provides a method for producing a compound having an X-ray diffraction pattern substantially identical to one or more of the X-ray diffraction patterns of FIG. A crystalline form of voruciclib HCl is provided, characterized by an X-ray diffraction pattern consistent with that of the compound. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 32.
[0021] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 36. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 40.
[0022] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in FIG. 45. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in FIG.
[0023] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in FIG. 53. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in FIG. 57.
[0024] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 61. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 65.
[0025] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 69. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 73.
[0026] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 77. In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in Figure 81.
[0027] In one embodiment, the present disclosure provides a crystalline form of voruciclib HCl characterized by an X-ray diffraction pattern substantially in agreement with one or more X-ray diffraction patterns in Figure 82. In one embodiment, the present disclosure provides a crystalline form of voruciclib free base characterized by an X-ray diffraction pattern substantially in agreement with the X-ray diffraction patterns of Figures 85 and 142.
[0028] In one embodiment, the present disclosure provides the 1 H-NMR spectrum 1 1 provides a crystalline form of voruciclib free base characterized by its H-NMR spectrum. In one embodiment, the present disclosure provides a crystalline form of voruciclib malonate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 90 and 91.
[0029] In one embodiment, the present disclosure provides the 1 H-NMR spectrum (Mao1) 1 1 provides a crystalline form of voruciclib malonate characterized by its H-NMR spectrum.
[0030] In one embodiment, the present disclosure provides one or more of the X-ray diffraction patterns of Figures 96 and 97. A crystalline form of voruciclib dibenzoyl-L-tartrate is provided, characterized by a substantially consistent X-ray diffraction pattern.
[0031] In one embodiment, the present disclosure provides a method for manufacturing a cellular phone using the cellular phone of FIG. 1H-NMR spectrum (DiTr1) 1 1 provides a crystalline form of voruciclib dibenzoyl-L-tartrate characterized by its H-NMR spectrum.
[0032] In one embodiment, the present disclosure provides a crystalline form of voruciclib phosphate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 102 and 103.
[0033] In one embodiment, the present disclosure provides the 1 Practically identical to the H-NMR spectrum (Pho1) 1 1 provides a crystalline form of voruciclib phosphate characterized by its H-NMR spectrum.
[0034] In one embodiment, the present disclosure provides a crystalline form of voruciclib oxalate characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 108. In one embodiment, the present disclosure provides a method for manufacturing a hologram of FIG. 1 H-NMR spectrum (Oxa) 1 1 provides a crystalline form of voruciclib oxalate characterized by its H-NMR spectrum.
[0035] In one embodiment, the present disclosure provides a crystalline form of voruciclib napadisylate characterized by an X-ray diffraction pattern substantially in accordance with one or more of the X-ray diffraction patterns of Figures 113 and 114.
[0036] In one embodiment, the present disclosure provides the 1 H-NMR spectrum (Nds1a) 1 1 provides a crystalline form of voruciclib napadisylate characterized by its H-NMR spectrum.
[0037] In one embodiment, the present disclosure provides a crystalline form of voruciclib esylate characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns of Figure 118. In one embodiment, the present disclosure provides a method for manufacturing a cellular phone using the cellular phone of FIG. 1 H-NMR spectrum (Esy1) 1 1 provides a crystalline form of voruciclib esylate characterized by its H-NMR spectrum.
[0038] In one embodiment, the present disclosure provides a crystalline form of voruciclib 1-hydroxy-2-naphthoate characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns in FIG. 121.
[0039] In one embodiment, the present disclosure provides a crystalline form of voruciclib benzoate characterized by an X-ray diffraction pattern substantially in accordance with one or more of the X-ray diffraction patterns in Figures 123 and 124.
[0040] In one embodiment, the present disclosure provides a crystalline form of voruciclib besylate characterized by an X-ray diffraction pattern substantially in accordance with one or more X-ray diffraction patterns of FIG. 126. In one embodiment, the present disclosure provides a crystalline form of voruciclib gentisate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 128 and 129.
[0041] In one embodiment, the present disclosure provides a method for producing a compound having an X-ray diffraction pattern substantially similar to one or more of the X-ray diffraction patterns of FIG. Crystalline forms of voruciclib hydrobromide characterized by a consistent X-ray diffraction pattern are provided. In one embodiment, the present disclosure provides a crystalline form of voruciclib maleate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 133 and 134.
[0042] In one embodiment, the present disclosure provides a crystalline form of voruciclib sulfate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 136 and 137.
[0043] In one embodiment, the present disclosure provides a crystalline form of voruciclib toluenesulfonate characterized by an X-ray diffraction pattern substantially in agreement with one or more of the X-ray diffraction patterns in Figures 139 and 140.
[0044] The foregoing summary, as well as the following detailed description of the present invention, will be better understood when read in conjunction with the appended drawings. [Brief explanation of the drawings]
[0045] [Figure 1] Figure 1 shows the HR powder diffraction patterns of five different batches of voruciclib HCl compared to the powder pattern of Form 1 recorded in previous studies. From bottom to top: Form 1-reference, #1694M-1401, #1694M-1301, #1694M-1201, #P1446A-05_EN027, and #P1446A-05_EN017. The orange area highlights diffraction peaks attributable to crystalline impurities in batches 1694M-1201 and P1446A-05_EN027, while the gray area highlights the crystalline phase detected only in batch 1694M-1301. [Figure 2] Figure 2 shows the DSC curves of five batches of voruciclib HCl (heating rate 10°C / min). An endothermic event associated with melting / decomposition was observed around 263°C for batches 1694M-1401 (red), P1446A-05_EN027 (black), 1694M-1201 (green), P1446A-05_EN017 (purple), and 1694M-1301 (blue). [Figure 3] Figure 3 shows TGA analysis of five batches of voruciclib HCl (heating rate 10 °C / min). Mass loss before decomposition varied from 0.3 to 0.6%. Decomposition began around 250 °C. Batches P1446A-05_EN017 (brown), P1446A-05_EN027 (purple), 1694M-1201 (green), 1694M-1301 (blue), and 1694M-1401 (red). [Figure 4] FIG. 4 shows high-throughput XRPD of Form 1, Batch 1694M-1301 voruciclib HCl, the starting material for the screen. [Figure 5] Figure 5 shows the DSC curve of voruciclib HCl batch 1694M-1301 (heating rate 10°C / min). The endothermic event at Tpeak 263.4°C can be attributed to the melting / decomposition of the compound. [Figure 6] Figure 6 shows the TGMS analysis of the starting material, Batch 1694M-1301, voruciclib HCl (heating rate 10°C / min). A mass loss of 0.3% was observed before decomposition. Decomposition began near 250°C and was accompanied by an endothermic event in the heat flow signal. [Figure 7] Figure 7 shows the LCMS analysis of the starting material, voruciclib HCl, batch 1694M-1301. The peak corresponding to the API had a retention time of 6.3 minutes (Figure 7A), and the positive ion mass spectrum showed an ion with m / z 470.1 (M+H)+ (Figure 7B). [Figure 8] Figure 8 shows a comparison of HR XRPD of Form 1 voruciclib HCl used in high pressure studies. From bottom to top: Form 1 - Reference, Exp. ID Gen13 (10 Tons, 1 min, RT), Exp. ID Gen14 (10 Tons 10 min, RT), Exp. ID Gen15 (10 Tons, 1 min, 80°C), and Exp. ID Gen16 (10 Tons, 10 min, 80°C). [Figure 9] Figure 9 shows the Rietveld refinement of a sample manually ground with a mortar and pestle for approximately 5 minutes, including the calculation of the amorphous fraction based on the background line. The black line represents the resulting powder pattern, the red is the calculated value, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted cell. The purple line represents the calculated amorphous fraction of the sample (10±2%). [Figure 10] Figure 10 shows the Rietveld refinement of a sample ground using a Retch grinder at 30 Hz for 5 minutes, including the calculation of the amorphous fraction based on the background line. The black line represents the resulting powder pattern, the red line is the calculation, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted grid. The purple line represents the calculated amorphous fraction of the sample (7±2%). [Figure 11] Figure 11 shows an overlay of XRPDs of the solids obtained by lyophilization compared to the starting material. From bottom to top: Form 1, starting material; Form 2 obtained from MeOH / water (90 / 10 v / v), Am obtained from 1,4-dioxane / water (90 / 10 v / v), and Am obtained from THF / water (90 / 10 v / v). [Figure 12] Figures 12A and 12B show HT-XRPD of the unique forms identified during screening (from bottom to top); Figure 12A: Form 1 starting material, Form 2 obtained from thermal cycling in 1,4-dioxane (Experiment ID TCP15), Form 3 obtained from thermal cycling in IPA (Experiment ID TCP13), Form 4 obtained from solvent equilibration in THF at RT (Experiment ID SLP30), Form 5 obtained from thermal cycling in 1,4-dioxane (Experiment ID TCP8), Form 6 (low crystalline) obtained from solvent equilibration in water at 50°C (Experiment ID SLP65), Form 7 obtained from thermal cycling in 1,2-dimethoxyethane (Experiment ID TCP5), Form 8 obtained from evaporation crystallization from acetone (Experiment ID ECP34), Form 9 obtained from cooling crystallization in DMF and from a solid dried at ambient conditions (Experiment ID PSM60), Form 10 obtained from cooling crystallization in DMF and from a vacuum-dried solid (Experiment ID PSM60; Figure 12B: Form 11 obtained from cooling crystallization in DMA and from a solid dried at ambient conditions (Experiment ID PSM59); Form 12 obtained after evaporation of the mother liquor from thermal cycling in acetonitrile / water 90 / 10 (vol / vol) (Experiment ID TCP20 ML); Form 13 obtained from cooling crystallization in ethanol (Experiment ID PSM52); Form 14 obtained from thermal cycling in acetonitrile / water 90 / 10 (vol / vol) (Experiment ID TCP20); Form 15 obtained from vapor diffusion into solution from DMF / 1,4-dioxane (Experiment ID VDL8); Form 16 obtained from evaporation crystallization from DMSO (Experiment ID ECP18); Form 17 obtained from anti-solvent addition with TFE / heptane; Form 18 obtained from anti-solvent addition with DMF / isopropyl acetate and from a solid dried at ambient conditions; Form 19 obtained from evaporative crystallization from 20 / 80, and Form 20 obtained after conversion from Form 10 after AAC. [Figure 13] FIG. 13 shows the temperature profile in the thermal cycling experiment. [Figure 14] FIG. 14 shows overlaid HT-XRPD patterns of material from a solvent equilibration experiment in ethanol (Experiment ID SLP19) before and after exposure to AAC. [Figure 15] Figure 15 shows the TGMS analysis (heating rate 10°C / min) of Form 1 (Experiment ID SLP19). The 0.2% mass loss is likely related to residual solvent or moisture. [Figure 16] Figure 16 shows the DSC analysis (heating rate 10°C / min) of Form 1 (Experimental ID SLP19). An endothermic event is observed, possibly associated with melting and decomposition. [Figure 17] Figure 17 shows the HPLC chromatogram of Form 1 (Experimental ID SLP19). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 18] FIG. 18 shows an overlay of the HT-XRPD patterns of material from a thermal cycling experiment in 1,4-dioxane / water 95 / 5 (Experiment ID TCP2) before and after exposure to AAC. [Figure 19] Figure 19 shows the TGMS analysis (heating rate 10°C / min) of Form 2 (Experimental ID TCP15). The total mass loss of 5.4% is associated with solvent loss (equivalent to 0.3 molecules of dioxane). [Figure 20] Figure 20 shows the DSC analysis (heating rate 10°C / min) of Form 2 (Experiment ID TCP15). Two broad endothermic events associated with solvent loss were observed. The small endothermic event at 165°C is likely the transition to Form 1 because the small endothermic event seen at 259°C is consistent with the melting of Form 1. [Figure 21] Figure 21 shows the HPLC chromatogram of Form 2 (Experimental ID TCP5). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 22]FIG. 22 shows overlaid HT-XRPD patterns of material obtained from a thermal cycling experiment in IPA / water 95 / 5 (Experiment ID TCP13) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 23] Figure 23 shows the TGMS analysis (heating rate 10°C / min) of Form 3 (Experimental ID TCP13). The mass loss of 13.2% is associated with solvent loss. [Figure 24] Figure 24 shows the DSC analysis (heating rate 10°C / min) of Form 3 (Experimental ID TCP13). A broad endothermic event is observed, likely related to solvent loss. A very small endotherm is observed at 259°C, likely indicating that the bulk of the material has become amorphous after solvent loss. [Figure 25] Figure 25 shows the HPLC chromatogram of Form 3 (Experimental ID TCP13). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 26] Figure 26 shows overlaid HT-XRPD patterns of material from a solvent equilibration experiment in THF (Experiment ID SLP30) dried at ambient conditions (purple), dried under vacuum (blue), and after exposure to AAC (green). [Figure 27] Figure 27 shows the TGMS analysis (heating rate 10°C / min) of Form 4 (Experimental ID SLP30). The 4.3% mass loss is associated with solvent loss. The subsequent exothermic and endothermic events were assigned to recrystallization and melting / decomposition, respectively. [Figure 28] Figure 28 shows a DSC analysis (heating rate 10°C / min) of Form 4 (Experimental ID SLP30). Three broad endothermic events associated with solvent loss were observed, followed by an exothermic recrystallization event at 217°C, an endothermic melt (260°C), and a decomposition event. [Figure 29] Figure 29 shows an overlay of XRPDs of the solid phases obtained from Experiment ID SLP30 (bottom to top): Form 4a (solid dried at ambient conditions), Form 4 (solid dried under vacuum), and Form 4b obtained after a cyclic DSC experiment to 140°C. [Figure 30]FIG. 30 shows the TGMS analysis of the solid obtained after a cyclic DSC experiment to 155° C. for Form 4. [Figure 31] Figure 31 shows the HPLC chromatogram of Form 4 (Experimental ID SLP30). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 32] FIG. 32 shows overlaid HT-XRPD patterns of material obtained from a thermal cycling experiment in 1,4-dioxane (Experiment ID TCP8) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 33] Figure 33 shows the TGMS analysis (heating rate 10°C / min) of Form 5 (Experimental ID TCP8). The total mass loss of 9.4% is related to solvent loss. [Figure 34] Figure 34 shows a DSC analysis (heating rate 10°C / min) of Form 5 (Experimental ID TCP8). A broad endothermic event, presumably related to solvent loss, was observed, followed by a smaller endotherm at 259°C and a decomposition event. [Figure 35] Figure 35 shows the HPLC chromatogram of Form 5 (Experimental ID TCP8). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 36] FIG. 36 shows overlaid HT-XRPD patterns of material obtained from a solvent equilibration experiment in water (Experiment ID SLP65) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 37] Figure 37 shows the TGMS analysis (heating rate 10°C / min) of Form 6 (Experimental ID SLP65). The mass loss of 2.1% is associated with the loss of water. [Figure 38] Figure 38 shows the DSC analysis (heating rate 10°C / min) of Form 6 (Experimental ID SLP65). A broad endothermic event associated with the loss of water was observed at 151°C. Thermal events above 220°C are associated with the decomposition process. [Figure 39]Figure 39 shows the HPLC chromatogram of Form 6 (Experimental ID SLP65). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 40] FIG. 40 shows overlaid HT-XRPD patterns of material from a thermal cycling experiment in 1,2-dimethoxyethane (Experiment ID TCP5) before and after exposure to AAC. [Figure 41] Figure 41 shows the TGMS analysis (heating rate 10°C / min) of Form 7 (Experimental ID TCP5). The 2.0% mass loss is likely related to solvent loss and / or water. [Figure 42] Figure 42 shows a DSC analysis (heating rate 10°C / min) of Form 7 (Experimental ID TCP5). An endothermic event, presumably related to solvent loss, was observed, followed by an exothermic recrystallization event and melting and decomposition of Form 1. [Figure 43] Figure 43 shows the TGMS analysis of Form 7 after cycling DSC (heating rate 10°C / min) to 155°C. The 2.3% mass loss is likely related to water loss. [Figure 44] Figure 44 shows the HPLC chromatogram of Form 7 (Experimental ID TCP5). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 45] Figure 45 shows an overlay of the HT-XRPD patterns of material from an evaporation experiment in methanol / acetone 75 / 25 (Experiment ID ECP34) before and after exposure to AAC. [Figure 46] Figure 46 shows the TGMS analysis (heating rate 10°C / min) of Form 8 (Experimental ID ECP34). The 5.3% mass loss is likely related to solvent loss and / or water. [Figure 47] Figure 47 shows a DSC analysis (heating rate 10°C / min) of Form 8 (Experimental ID ECP34). A broad endothermic event was observed, possibly related to solvent loss, followed by a smaller endothermic event possibly related to melting. [Figure 48]Figure 48 shows the HPLC chromatogram of Form 8 (Experimental ID ECP34). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 49] FIG. 49 shows overlaid HT-XRPD patterns of the solid obtained from a cooling crystallization experiment in N,N-dimethylformamide (experiment ID PSM60) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 50] Figure 50 shows the TGMS analysis (heating rate 10°C / min) of Form 10 (Experimental ID PSM60). The mass loss of 20.8% is associated with solvent loss. [Figure 51] Figure 51 shows a DSC analysis (heating rate 10°C / min) of Form 10 (Experimental ID PSM60). An endothermic event, presumably associated with solvent loss, was observed, followed by a second endothermic event associated with melting of Form 1. [Figure 52] Figure 52 shows the HPLC chromatogram of Form 10 (Experimental ID PSM60). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 53] FIG. 53 shows an overlay of the HT-XRPD patterns of material from a cooling crystallization experiment in N,N-dimethylacetamide (Experiment ID PSM59) before and after exposure to AAC. [Figure 54] Figure 54 shows the TGMS analysis (heating rate 10°C / min) of Form 11 (Experimental ID PSM59). The 9.1% mass loss is likely related to solvent loss. [Figure 55] Figure 55 shows the DSC analysis (heating rate 10°C / min) of Form 11 (Experimental ID PSM59). Two endothermic events are observed, likely associated with solvent loss and melting of Form 1, respectively. [Figure 56] Figure 56 shows the HPLC chromatogram of Form 11 (Experimental ID PSM59). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 57]Figure 57 shows an overlay of the HT-XRPD patterns of material obtained from the mother liquor of a thermal cycling experiment in ACN / water 90 / 10 (Experiment ID TCP20_ML) before and after exposure to AAC. [Figure 58] Figure 58 shows the TGMS analysis (heating rate 10°C / min) of Form 12 (Experimental ID TCP20_ML). The 5.9% mass loss is associated with solvent loss. [Figure 59] Figure 59 shows a DSC analysis (heating rate 10°C / min) of Form 12 (Experimental ID TCP20_ML). The endothermic events seen between 25 and 180°C are likely associated with solvent loss, while the small endothermic event seen at 255°C may be associated with melting of Form 1. [Figure 60] Figure 60 shows the HPLC chromatogram of Form 12 (Experimental ID TCP20_ML). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 61] Figure 61 shows overlaid HT-XRPD patterns of material from a cryo-evaporation crystallization experiment in ethanol (Experiment ID PSM52) before and after exposure to AAC. [Figure 62] Figure 62 shows the TGMS analysis (heating rate 10°C / min) of Form 13 (Experimental ID PSM52). The 6.3% mass loss is likely related to solvent loss or water. [Figure 63] Figure 63 shows a DSC analysis (heating rate 10°C / min) of Form 13 (Experiment ID AS5, post-AAC). Several broad endothermic events, presumably related to solvent loss, were observed, followed by smaller endothermic events associated with melting of Form 1. [Figure 64] Figure 64 shows the HPLC chromatogram of Form 13 (Experimental ID PSM52). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 65] Figure 65 shows overlaid HT-XRPD patterns of the solid obtained from a thermal cycling experiment in ACN / water 90 / 10 (Experiment ID TCP20) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 66] Figure 66 shows the TGMS analysis (heat rate 10°C / min) of Form 14 (Experimental ID TCP20). The 2.5% mass loss is likely related to solvent loss. [Figure 67] Figure 67 shows the DSC analysis (heating rate 10°C / min) of Form 14 (Experimental ID TCP20). Two endothermic events were observed. [Figure 68] Figure 68 shows the HPLC chromatogram of Form 14 (Experimental ID TCP20). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 69] Figure 69 shows an overlay of the HT-XRPD patterns of material from a vapor diffusion-in-liquid experiment in N,N-dimethylformamide / 1,4-dioxane (Experiment ID VDL8) before and after exposure to AAC. [Figure 70] Figure 70 shows the TGMS analysis (heating rate 10°C / min) of Form 15 (Experiment ID VDL8). The mass loss of 13.2% is associated with solvent loss. [Figure 71] Figure 71 shows the DSC analysis (heating rate 10°C / min) of Form 15 (Experiment ID VDL8). Two endothermic events are observed, likely associated with solvent loss and melting of Form 1, respectively. [Figure 72] Figure 72 shows the HPLC chromatogram of Form 15 (Experimental ID VDL8). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 73] Figure 73 shows an overlay of the HT-XRPD patterns of material from an evaporation experiment in DMSO (Experiment ID ECP18) before and after exposure to AAC. [Figure 74] Figure 74 shows the TGMS analysis (heating rate 10°C / min) of Form 16 (Experimental ID ECP18). The mass loss of 16.6% is associated with solvent loss. [Figure 75]Figure 75 shows the DSC analysis (heating rate 10°C / min) of Form 16 (Experiment ID ECP18). Two endothermic events are observed, likely associated with solvent loss and melting of Form 1, respectively. [Figure 76] Figure 76 shows the HPLC chromatogram of Form 16 (Experimental ID ECP18). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 77] Figure 77 shows overlaid HT-XRPD patterns of material obtained from an anti-solvent experiment in TFE / heptane (Experiment ID AS3) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 78] Figure 78 shows the TGMS analysis (heating rate 10°C / min) of Form 17 (Experimental ID AS3). The 16.9% mass loss is associated with solvent loss. [Figure 79] Figure 79 shows the DSC analysis (heating rate 10°C / min) of Form 17 (Experiment ID AS3). Three endothermic events were observed, likely associated with solvent loss. The final endotherm at 257°C was associated with melting of Form 1. [Figure 80] Figure 80 shows the HPLC chromatogram of Form 17 (Experimental ID AS3). The API peak appeared at 6.3 minutes with 100% chemical purity (area percent). [Figure 81] Figure 81 shows overlaid HT-XRPD patterns of the solid obtained from the anti-solvent experiment in DMF / isopropyl acetate (Experiment ID AS7) and dried under ambient conditions and under vacuum, before and after exposure to AAC. [Figure 82] Figure 82 shows an overlay of the HT-XRPD patterns of material from an evaporation experiment in methanol / diisopropyl ether 20 / 80 (Experiment ID ECP45 / PSM13) before and after exposure to AAC. [Figure 83] Figure 83 shows the TGMS analysis (heating rate 10°C / min) of Form 19 (Experimental ID ECP45 / PSM13). A mass loss of 4.5% was observed, likely related to solvent loss, followed by an exothermic recrystallization event and an endothermic melting event of Form 1. [Figure 84] Figure 84 shows the molecular structure of voruciclib (free base), which has a basic site with a pKa of 6.46. [Figure 85] Figure 85 shows high-throughput XRPD of starting material Form A of voruciclib free base. [Figure 86] Figure 86 shows the DSC curve for the starting voruciclib free base (heating rate 10°C / min), which shows a small endothermic event at 99°C, followed by a small endothermic event at 214°C, and a final melt at 225°C. [Figure 87] Figure 87 shows the TGMS data for the starting voruciclib free base (heating rate 10°C / min), which showed a 0.3% mass loss prior to decomposition, which began around 240°C, where the mass loss was likely related to residual solvent / moisture. The onset of decomposition was confirmed by MS data, where the heat flow signal showed an endothermic event due to melting around 220°C. [Figure 88] Figure 88 shows the HPLC analysis of the starting voruciclib free base, where the peak corresponding to the free base had a retention time of 6.1 minutes and exhibited a chemical purity (area %) of 99.3%. [Figure 89] Figure 89 shows the H-NMR spectrum of the starting voruciclib free base. [Figure 90] Figure 90 shows the XRPD patterns of (from bottom to top) the Form A starting material, the malonic acid reference, Mao1 obtained from ethanol (Experimental ID SSm53), and Mao2 obtained from THF (Experimental ID SSm20). [Figure 91] FIG. 91 shows the XRPD patterns of Mao1 (Experiment ID SSm53) before and after AAC, with the starting material and malonic acid shown as references. [Figure 92] FIG. 92 shows the TGMS analysis (heating rate 10° C. / min) of Mao1 (experiment ID SSm53) obtained from malonic acid and ethanol, showing a 0.2% mass loss before the onset of melting / decomposition around 140° C. [Figure 93]FIG. 93 shows a DSC analysis (heating rate 10° C. / min) of Mao1 (experiment ID SSm53) obtained from malonic acid and ethanol, showing an endothermic event at a peak temperature of 180° C. due to melting / decomposition. [Figure 94] FIG. 94 shows the 1H-NMR spectrum of Mao1 (experimental ID SSm53, bottom) obtained from malonic acid and ethanol compared to the starting material (top). [Figure 95] FIG. 95 shows the HPLC chromatogram of Mao1 (Experiment ID SSm53) obtained from malonic acid and ethanol. [Figure 96] Figure 96 shows the XRPD patterns of (bottom to top) the Form A starting material, dibenzoyl-L-tartaric acid reference, DiTr1 obtained from ethanol (Experiment ID SSm46), and the DiTr1 + DiTr2 mixture obtained from THF (Experiment ID SSm13). [Figure 97] FIG. 97 shows the XRPD patterns of DiTr1 (Experiment ID SSm46) before and after AAC, with the starting material and dibenzoyl-L-tartaric acid shown as references. [Figure 98] Figure 98 shows the TGMS analysis (heating rate 10°C / min) of DiTr1 (experiment ID SSm46) obtained from dibenzoyl-L-tartaric acid in ethanol, showing a mass loss of 0.9% before the onset of melting / decomposition around 180°C. [Figure 99] Figure 99 shows the DSC analysis (heating rate 10°C / min) of DiTr1 obtained from dibenzoyl-L-tartaric acid in ethanol (Experiment ID SSm46), where a small endothermic event was observed at 172°C before the decomposition process with a peak temperature of 207°C. [Figure 100] FIG. 100 shows the 1H-NMR spectrum of DiTr1 (experimental ID SSm46, bottom) obtained from dibenzoyl-L-tartaric acid and ethanol compared to the starting material (top). [Figure 101] FIG. 101 shows the HPLC chromatogram of DiTr1 (Experiment ID SSm46) obtained from dibenzoyl-L-tartaric acid and ethanol. [Figure 102]FIG. 102 shows (from bottom to top) the XRPD patterns of the Form A starting material, Pho1 obtained from acetone (Experiment ID SSm81), and less crystalline Pho2 obtained from THF (Experiment ID SSm15). [Figure 103] FIG. 103 shows the XRPD patterns of Phol (Experiment ID SSm81) before and after AAC, with the starting material and phosphate shown as references. [Figure 104] Figure 104 shows the TGMS analysis (heating rate 10 °C / min) of Pho1 (experiment ID SSm81) obtained with phosphoric acid in acetone, showing a mass loss of 1.9% between 25 and 160 °C before melting, with thermal decomposition starting around 200 °C. [Figure 105] FIG. 105 shows the DSC analysis (heating rate 10° C. / min) of Phol (experiment ID SSm81) obtained with phosphoric acid in acetone. [Figure 106] FIG. 106 shows the 1H-NMR spectrum of Phol (Experiment ID SSm81, bottom) obtained from phosphoric acid and acetone compared to the starting material (top). [Figure 107] FIG. 107 shows the HPLC chromatogram of Phol (Experiment ID SSm81) obtained from phosphoric acid and acetone. [Figure 108] FIG. 108 shows the XRPD patterns of Oxa1 (Experiment ID SSm12) before and after AAC, with the starting material and oxalic acid shown as references. [Figure 109] Figure 109 shows the TGMS analysis (heating rate 10 °C / min) of Oxal (experiment ID SSm12) obtained with oxalic acid in THF, showing a mass loss of 1.4% between 25 and 100 °C, a second mass loss of 1.9% between 100 and 150 °C, and the mass loss above 160 °C is associated with the decomposition of this salt. [Figure 110] Figure 110 shows the DSC analysis (heating rate 10°C / min) of Oxal obtained with oxalic acid in THF (experiment ID SSm12), where the first two endothermic events are due to the loss of solvent / water, while the broad endothermic event around 213°C is associated with the decomposition of the salt. [Figure 111]FIG. 111 shows the 1H-NMR spectrum of Oxa1 (experimental ID SSm12, bottom) obtained from oxalic acid and THF compared to the starting material (top). [Figure 112] FIG. 112 shows the HPLC chromatogram of Oxa1 (Experiment ID SSm12) obtained from oxalic acid and THF. [Figure 113] Figure 113 shows the XRPD patterns of (from bottom to top) the Form A starting material, 1,5-naphthalenedisulfonic acid reference, Nds1a obtained from ethanol, solid phase (Experiment ID SSm35), Nds1b obtained from acetone, solid phase (Experiment ID SSm68), Nds2 obtained from ethanol, liquid phase (Experiment ID SSm35), Nds3 obtained from THF (Experiment ID SSm2), Nds4 obtained from THF, solid phase (Experiment ID SSm3), and Nds5 obtained by conversion of Nds2 after AAC (SSm68 liquid phase, after AAC). [Figure 114] FIG. 114 shows the XRPD patterns of Nds1a (Experiment ID SSm35) before and after AAC, with the starting material and 1,5-naphthalenedisulfonic acid shown as references. [Figure 115] Figure 115 shows the TGMS analysis (heating rate 10 °C / min) of Nds1a (experiment ID SSm35) obtained with 1,5-naphthalenedisulfonic acid in ethanol, showing a mass loss of 1.1% due to residual solvent / water between 25 and 100 °C, with decomposition starting around 250 °C. [Figure 116] Figure 116 shows the DSC analysis (heating rate 10 °C / min) of Nds1a obtained with 1,5-naphthalenedisulfonic acid in ethanol (experiment ID SSm35), showing a series of small, broad endothermic events between 25 and 100 °C associated with the loss of residual solvent. [Figure 117] FIG. 117 shows the 1H-NMR spectrum of Nds1a (experimental ID SSm35, bottom) obtained from 1,5-naphthalenedisulfonic acid and ethanol compared to the starting material (top). [Figure 118]Figure 118 shows the XRPD patterns of (from bottom to top) Form A starting material, Esyl or Form D obtained from ethanesulfonic acid in THF (Experiment ID SSm16), Form D obtained from oxalic acid after evaporation of ethanol (Experiment ID SSm44, liquid phase), and Form D obtained with phosphoric acid in ethanol (Experiment ID SSm48). [Figure 119] Figure 119 shows the TGMS analysis (heating rate 10 °C / min) of Esyl / Form D (Experiment ID SSm16) obtained with ethanesulfonic acid in THF, showing a 4.6% mass loss due to solvent or water between 25 and 200 °C, with decomposition starting around 250 °C. [Figure 120] FIG. 120 shows the 1H-NMR spectrum of Esy1 / Form D (Experimental ID SSm16, bottom) obtained from ethanesulfonic acid and THF compared to the starting material (top). [Figure 121] FIG. 121 shows the XRPD patterns of Xin1 (Experimental ID SSm19) obtained from THF before and after AAC, with the starting material and 1-hydroxy-2-naphthoic acid shown as references. [Figure 122] Figure 122 shows the TGMS analysis (heating rate 10 °C / min) of Xin1 (experiment ID SSm19) obtained with 1-hydroxy-2-naphthoic acid and THF, showing a mass loss of 12% between 25 and 200 °C, associated with the loss of solvent and the onset of decomposition. [Figure 123] Figure 123 shows (from bottom to top) the XRPD patterns of the Form A starting material, the benzoic acid reference, Ben2 obtained from acetone (Experimental ID SSm63), and Mao2 obtained from THF (Experimental ID SSm20). [Figure 124] Figure 124 shows the XRPD patterns of Ben2 (Experiment ID SSm63) before and after AAC, with the starting material and benzoic acid shown as references. [Figure 125] FIG. 125 shows the TGMS analysis (heating rate 10° C. / min) of Ben2 (experiment ID SSm63) obtained with benzoic acid and ethanol. [Figure 126]FIG. 126 shows the XRPD patterns of the solid obtained from THF (Experiment ID SSm10) before and after AAC, with the starting material and benzenesulfonic acid shown as references. [Figure 127] Figure 127 shows the TGMS analysis (heating rate 10 °C / min) of Bes1 (experiment ID SSm10) obtained from benzenesulfonic acid and THF, showing a mass loss of 8.1% due to the loss of THF between 25 and 180 °C, followed by decomposition around 230 °C. [Figure 128] Figure 128 shows the XRPD patterns of (bottom to top) the Form A starting material, the gentisic acid reference, Gen1 obtained from THF (Experimental ID SSm21), and Gen2_lc (solid phase) obtained from ethanol (Experimental ID SSm54). [Figure 129] Figure 129 shows the XRPD patterns of Gen1 (Experiment ID SSm21) before and after AAC, with the starting material and gentisic acid shown as references. [Figure 130] Figure 130 shows the TGMS analysis (heating rate 10°C / min) of Gen1 (experiment ID SSm21) obtained from gentisic acid and THF, showing a mass loss of 9.2% between 25 and 200°C, followed by thermal decomposition. [Figure 131] FIG. 131 shows the XRPD patterns of HBr1 (Experiment ID SSm34) before and after AAC, with the starting material and hydrobromic acid shown as references. [Figure 132] Figure 132 shows the TGMS analysis (heating rate 10°C / min) of HBr1 (experiment ID SSm34) obtained with hydrobromic acid and ethanol, where a mass loss of 5.9% is observed accompanied by several endothermic events in the heat flow signal, and thermal decomposition is observed around 240°C. [Figure 133] Figure 133 shows the XRPD patterns of (bottom to top) the Form A starting material, the maleic acid reference, Mae1 obtained from THF (Experiment ID SSm14), and Mae2 obtained from THF (Experiment ID SSm47). [Figure 134] Figure 134 shows the XRPD patterns of Mae1 (Experiment ID SSm14) before and after AAC, with the starting material and maleic acid shown as references. [Figure 135] Figure 135 shows the TGMS analysis (heating rate 10 °C / min) of Mae1 (experiment ID SSm14) obtained with maleic acid and THF, showing a mass loss of 3.4% from 25 to 110 °C due to solvent / water loss, followed by decomposition. [Figure 136] Figure 136 shows the XRPD patterns of (from bottom to top) the Form A starting material, Sul1 obtained from ethanol and 1 molar equivalent of sulfuric acid (Experiment ID SSm37), Sul2 obtained from ethanol and 0.5 molar equivalent of sulfuric acid (Experiment ID SSm38, solid phase), Sul3 obtained from the mother liquor of an experiment in THF and 0.5 molar equivalent of sulfuric acid (Experiment ID SSm5, liquid phase), and Sul4 obtained from THF and 1 molar equivalent of sulfuric acid (SSm4). [Figure 137] FIG. 137 shows the XRPD patterns of Sul1 (Experiment ID SSm37) before and after AAC, with the starting material shown as a reference. [Figure 138] Figure 138 shows the TGMS analysis (heating rate 10°C / min) of Sul1 (experiment ID SSm37) obtained with 1 molar equivalent of sulfuric acid in ethanol, showing a mass loss of 2.4% between 25 and 120°C and 5.8% between 120 and 200°C, followed by decomposition at temperatures above 240°C. [Figure 139] Figure 139 shows the XRPD patterns of (from bottom to top) the Form A starting material, the p-toluenesulfonic acid reference, Tos1 obtained from THF (Experiment ID SSm8), Tos2 obtained from ethanol (Experiment ID SSm41), and Tos1 + Tos3 obtained by conversion of Tos1 upon AAC exposure (Experiment ID SSm8, post-AAC). [Figure 140] Figure 140 shows the XRPD patterns of Tos2 (Experiment ID SSm41) before and after AAC, with the starting material and p-toluenesulfonic acid shown as references. [Figure 141] Figure 141 shows the TGMS analysis (heating rate 10 °C / min) of Tos2 (experiment ID SSm41) obtained with p-toluenesulfonic acid and ethanol, showing a mass loss of 4.6% due to ethanol between 25 and 110 °C, followed by decomposition. [Figure 142]Figure 142 shows (from bottom to top) the XRPD patterns of Form A starting material, Form B obtained from ethanol (Experiment ID SSm66), and Form C obtained from THF (Experiment ID SSm33). [Figure 143] Figure 143 shows the TGMS analysis (heating rate 10°C / min) of Form B from a control sample in ethanol (Experiment ID SSm66), which showed a small mass loss of 0.3% due to residual solvent before melting. [Figure 144] Figure 144 shows the TGMS analysis (heating rate 10°C / min) of Form C from the mother liquor of an experiment with glutamic acid in THF (Experiment ID SSm17, liquid phase), showing a 2.6% mass loss attributable to THF between 25 and 200°C, followed by decomposition. [Figure 145] Figure 145 shows the molecular structure of the hemioxalate salt of ME-522. The molecular weight of the free base is 469.8 g / mol. [Figure 146] FIG. 146 shows, from bottom to top, overlaid HT-XRPD patterns from oxalic acid, oxalic acid dihydrate, Oxal (from project S18128), and Oxa2 (starting material). [Figure 147] Figure 147 shows a graphical representation of the Rietveld refinement for Oxa2 (starting material). The black line represents the collected data, the red line is the calculated powder pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted grid. The vertical lines indicate diffraction peaks associated with unindexed crystalline impurities. [Figure 148] Figure 148 shows the TGMS thermogram (heating rate 10°C / min) of Oxa2 (starting material). A mass loss of 1.1% was recorded from 40 to 100°C. [Figure 149] Figure 149 shows the DSC curve (heating rate 10°C / min) of Oxa2 (starting material). A single broad endothermic event was observed at a Tpeak of 218.5°C. [Figure 150]Figure 150 shows the UPLC-MS analysis of Oxa2 (starting material). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the API's molecular mass of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 151] Figure 151 shows the H-NMR spectra of Oxa2 (SM, bottom), Oxa1 (from S18128, Experiment ID: SSm12, middle), and the free base (from S18128, top) measured in DMSO-d (bottom). The letters at the bottom of the spectra correspond to the hydrogens in the molecular structure of the API. [Figure 152] Figure 152 shows a DVS isotherm plot of Oxa2 (starting material), where the mass change is plotted as a function of RH. First, a sorption profile from 40% to 95% RH was applied (red diamonds), followed by a desorption profile from 95% to 0% RH (blue squares). Finally, RH was set to 40% of the starting value (green triangles). [Figure 153] Figure 153 shows a photograph of the suspension obtained after adding a small aliquot of water to Oxa2 (starting material). [Fig. 154] Figure 154 shows the HT-XRPD pattern of ME-522 oxalate salt (Experiment ID: QSA8) prepared by lyophilizing the starting material in acetone / water (50 / 50, v / v). [Figure 155] Figure 155 shows the TGMS thermogram (heating rate 10°C / min) of the amorphous oxalate salt (Experiment ID: QSA8) obtained after freeze-drying. A mass loss of 3.2% was recorded between 40 and 140°C. [Figure 156] Figure 156 shows the DSC curve (heating rate 10°C / min) of the amorphous oxalate salt (Experiment ID: QSA8) obtained after freeze-drying. In addition to a broad endothermic event between 185 and 230°C, three endothermic events were detected between 25 and 140°C. [Figure 157]Figure 157 shows the H-NMR spectra measured in DMSO-d of ME-522 free base (SM from project S128128, bottom), amorphous ME-522 oxalate (Experiment ID: QSA8, middle), and ME-522 Oxa2 (SM from inventive project S18128A, top). [Figure 158] Figure 158 shows the HT-XRPD diffractograms of the forms found during polymorph screening performed on ME-522 oxalate (from bottom to top): Oxa1, Oxa1e, Oxa2, Oxa3, Oxa1+Oxa4, Oxa5, Oxa6, and Oxa7. [Figure 159] Figure 159 shows the temperature profile of the thermal cycling experiment. [Figure 160] Figure 160 shows a schematic overview of the forms of Oxa1 and how they relate to each other. All Oxa1 forms are hemioxalate / hemihydrate. Oxa1d and Oxa1e have non-stoichiometric solvent and water present in their structures. From left to right, the unit cell size decreases with the removal of solvent and water. Even the driest form obtained (i.e., Oxa1a) contained approximately 0.24 equivalents of non-stoichiometric water per molecule of API. [Figure 161] Figure 161 shows the crystal packing and H-bonding schemes along the
[0100] direction for Oxa1d (left), Oxa1c (center), and Oxa1a (right), as determined by single-crystal X-ray diffraction. Molecules a and b (labeled in Figure 175) are shown in green and blue, respectively. The oxalate dianion is shown in red, and orange highlights the stoichiometric water molecules (0.5 relative to the API cation). Cavities that can accommodate solvent / water molecules are highlighted in the left image for Oxa1d. In Oxa1d, ethanol was present in the cavity. In Oxa1c and Oxa1a, water was present in the cavity (as indicated by the purple spheres). The size of the unit cell decreases from left to right. [Figure 162]FIG. 162 shows an overlay of HT-XRPD patterns of Oxa1 forms, from bottom to top: Oxa1, Oxa1a, Oxa1b, Oxa1c, Oxa1d, and Oxa1e. [Figure 163] Figure 163 shows a graphical representation of the Rietveld refinement for Oxa1 (Experiment ID: SSm12, Project S18128). The black line represents the collected data, the red is the calculated powder pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted lattice. [Fig. 164] Figure 164 shows an overlay of HT-XRPD patterns for material from Experiment ID: TCP29, from bottom to top: Oxa1e (dried at ambient conditions), Oxa1 (vacuum dried), and Oxa1 (after 2 days at 40°C / RH 75%). [Figure 165] Figure 165 shows the TGMS thermogram (heating rate 10°C / min) of Oxa1 (experiment ID: TCP29). A mass loss of 5.6% was recorded between 40 and 140°C. [Figure 166] Figure 166 shows the DSC curve (heating rate 10 °C / min) of Oxa1 (experiment ID: TCP29). Three endothermic events between 25 and 160 °C are likely related to the loss of water / solvent. A broad endothermic event between 209 and 230 °C is associated with the thermal decomposition of the salt. [Figure 167] Figure 167 shows the UPLC-MS analysis of Oxa1 (Experiment ID: TCP29). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the API's molecular mass of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 168] Figure 168 shows the H-NMR spectra of Oxa1 (Experiment ID: TCP29, bottom), Oxa1 (from S18128, Experiment ID: SSm12, middle), and ME-522 free base (from S18128, top) measured in DMSO-d6 (bottom). [Figure 169]Figure 169 shows the crystal packing and H-bonding scheme along the
[0100] direction of Oxa1a. Molecules a and b (labeled in Figure 175) are shown in green and blue, respectively. The oxalate dianion is shown in red, and orange highlights the stoichiometric water molecules (0.5 relative to the API cation 1), while symmetrically independent (non-stoichiometric) water molecules are shown as purple circles. [Figure 170] Figure 170 shows the X-ray powder pattern of Oxa1a, simulated from single crystal data. [Figure 171] Figure 171 shows a graphical representation of the Rietveld refinement for Oxa1b. The black line represents the collected data, the red line is the calculated XRPD pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted grid. [Fig. 172] Figure 172 shows the crystal packing and H-bonding scheme along the
[0100] direction of Oxalc. Molecules a and b (labeled in Figure 175) are shown in green and blue, respectively. The oxalate dianion is shown in red, orange highlights the stoichiometric water molecules (0.5 relative to the API cation), and purple circles represent symmetrically independent (non-stoichiometric) water molecules. [Figure 173] Figure 173 shows the asymmetric unit of Oxa1c, where two ME-522 cations were found along with an oxalate anion and a water molecule. Interstitial water molecules were also identified but omitted for clarity. For clarity, the atom numbering scheme is shown only for the oxalate anion and water molecule. The blue dashed lines indicate intermolecular hydrogen bonds between the dianion, cation, and water. [Fig. 174] Figure 174 shows the X-ray powder pattern of Oxa1c, simulated from single crystal data. [Figure 175] Figure 175 shows the molecular structure found in Oxald and the atom numbering scheme for the two symmetrically independent cations. The image on the left shows the cation named a in the cif file, while the image on the right shows cation b. [Figure 176]Figure 176 shows the crystal packing and hydrogen bonding scheme along the
[0100] direction of Oxald. Molecules a and b (labeled in Figure 175) are shown in green and blue, respectively. The oxalate dianion is shown in red, orange highlights the stoichiometric water molecules (0.5 relative to 1 API cation), pink represents symmetrically independent (non-stoichiometric) water molecules, and purple represents ethanol molecules. [Figure 177] Figure 177 shows the X-ray powder pattern of Oxa1d, simulated from single crystal data. [Figure 178] Figure 178 shows an overlay of HT-XRPD patterns for material obtained in Experiment ID: TCP29, from bottom to top: Oxa1 (vacuum dried), Oxa1e (dried at ambient conditions), Oxa1 (after 2 days at 40°C / RH75%), and Oxa1d (generated from single crystal data). [Figure 179] Figure 179 shows overlaid HT-XRPD patterns of Oxa2 from the starting material (bottom), Oxa2 from 2-propanol (Experiment ID: TCP18, middle), and Oxa2 from 2-propanol after AAC exposure (Experiment ID: TCP18, top). In the starting material, a unique diffraction peak was identified at approximately 6.6° 2θ, as indicated by the arrow. [Figure 180] Figure 180 shows the TGMS thermogram (heating rate 10°C / min) of Oxa2 (experiment ID: TCP18). A mass loss of 2.1% was recorded between 40 and 140°C. [Figure 181] Figure 181 shows the DSC curve (heating rate 10°C / min) of Oxa2 (experiment ID: TCP18). A small endothermic event with a Tpeak of 99°C was followed by a broad endothermic event with a Tpeak of 214°C. [Figure 182] Figure 182 shows the UPLC-MS analysis of Oxa2 (Experiment ID: TCP18). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the API's molecular mass of 470.2 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 183]Figure 183 shows the H-NMR spectra of the free base (SM of S18128, bottom), Oxa2 (Experiment ID: TCP18, center), and Oxa2 (SM, S18128A) measured in DMSO-d. Integral and peak values apply to Oxa2 (Experiment ID: TCP18, center). The doublet signal at 1.05 ppm corresponds to the CH group of 2-propanol. [Figure 184] Figure 184 shows overlaid HT-XRPD patterns from solids obtained from 2-propanol / water (90 / 10, Experiment ID: TCP30). From bottom to top: Oxa3a (dried at ambient conditions), Oxa1 + Oxa4 (vacuum dried), and Oxa3b (after AAC). [Figure 185] FIG. 185 shows an overlay of the HT-XRPD patterns of Oxa1 (experiment ID: TCP29, bottom) and Oxa1+Oxa4 (experiment ID: TCP30, top). [Figure 186] Figure 186 shows overlaid HT-XRPD patterns of Oxa5 (Experiment ID: SSm2, bottom) and the same material after 1 day of exposure to AAC (top). [Figure 187] Figure 187 shows overlaid HT-XRPD patterns of material obtained from chloroform (Experiment ID: TCP21). The lower pattern represents Oxa6 (vacuum dried) and the upper pattern is Oxa3 (vacuum dried, post-AAC). [Figure 188] Figure 188 shows an overlay of HT-XRPD patterns of Oxa7 (Experiment ID: TCP23) from a thermal cycling experiment in ethanol. The lower pattern shows the vacuum-dried sample, while the upper pattern is of the same sample after exposure to AAC (40°C / RH75%, 2 days). [Figure 189] Figure 189 shows the TGMS thermogram (heating rate 10°C / min) of Oxa7 (experiment ID: TCP23). A mass loss of 3.4% was recorded between 40 and 140°C. [Figure 190]Figure 190 shows the DSC curve (heating rate 10°C / min) of Oxa7 (experiment ID: TCP23). Two small endothermic events at 85°C and 154°C were followed by a broad endothermic event with a Tpeak of 214°C. [Figure 191] Figure 191 shows the UPLC-MS analysis of Oxa7 (Experiment ID: TCP23). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the API's molecular mass of 470.2 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 192] Figure 192 shows the H-NMR spectra of the free base (SM of S18128, bottom panel) and Oxa7 (experimental ID: TCP23, top panel) measured in DMSO-d (bottom panel). The triplet signals at 1.1 and 1.2 ppm, as well as the quartet signals at 3.5 and 4.0 ppm, correspond to the CH and CH groups of ethanol, respectively. [Figure 193] Figure 193 shows the molecular structure of the monophosphate salt of ME-522. The molecular weight of the free base is 469.8 g / mol. [Figure 194] Figure 194 shows overlaid HT-XRPD patterns of Pho1 (project S18128, bottom), Pho2 (project S18128, middle), and Pho3 (starting material, inventive project S18128B, top). [Figure 195] Figure 195 shows a graphical representation of the Rietveld refinement for Pho3 (starting material). The black line represents the collected data, the red line is the calculated powder pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted grid. The vertical lines indicate diffraction peaks associated with unindexed crystalline impurities. [Figure 196] Figure 196 shows the TGMS thermogram (heating rate 10°C / min) of Pho3 (starting material). A mass loss of 5.4% was recorded between 40 and 160°C. [Figure 197]Figure 197 shows the DSC curve (heating rate 10°C / min) of Pho3 (starting material). In addition to a broad endothermic event with a peak temperature of 246°C, several endothermic events were observed up to 200°C. [Figure 198-1] Figures 198A and 198B show the cDSC curves (heating rate 10°C / min) of Pho3 (starting material). In the first experiment (Figure 198A), the material was heated to 170°C and cooled to room temperature. After analyzing the material by HT-XRPD, the compound was again heated to 170°C, cooled to room temperature, and finally heated to 300°C (Figure 198B). [Figure 198-2] Figures 198A and 198B show the cDSC curves (heating rate 10°C / min) of Pho3 (starting material). In the first experiment (Figure 198A), the material was heated to 170°C and cooled to room temperature. After analyzing the material by HT-XRPD, the compound was again heated to 170°C, cooled to room temperature, and finally heated to 300°C (Figure 198B). [Figure 199] Figure 199 shows the overlaid HT-XRPD patterns of as-received Pho3 and the poorly crystalline (pc) material obtained after cDSC. [Figure 200] Figure 200 shows the UPLC-MS analysis of Pho3 (starting material). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the molecular mass of the free base of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 201] Figure 201 shows the H-NMR spectra of Pho3 (SM, bottom), ME-522 free base (from S18128, middle), and Pho1 (from S18128, top) measured in DMSO-d. The letters at the bottom of the spectra correspond to the hydrogen atoms in the molecular structures of the APIs. [Figure 202]Figure 202 shows a DVS isotherm plot of Pho3 (starting material), where the mass change is plotted as a function of RH. First, a sorption profile from 40% to 95% RH was applied (red diamonds), followed by a desorption profile from 95% to 0% RH (blue squares). Finally, RH was set to 40% of the starting value (green triangles). [Figure 203] Figure 203 shows the HT-XRPD pattern of ME-522 phosphate salt (Experiment ID: QSA8) prepared by lyophilizing the starting material in acetone / water (50 / 50, v / v). [Figure 204] Figure 204 shows the TGMS thermogram (heating rate 10°C / min) of the amorphous phosphate obtained by freeze-drying (Experiment ID: QSA8). A mass loss of 3.0% was recorded between 40 and 160°C. [Figure 205] Figure 205 shows the DSC curve (heating rate 10°C / min) of the amorphous phosphate salt obtained by freeze-drying (Experiment ID: QSA8). In addition to a broad endothermic event between 200 and 270°C, three endothermic events were detected between 25 and 150°C. [Figure 206] Figure 206 shows the H-NMR spectra measured in DMSO-d of amorphous ME-522 phosphate (Experiment ID: QSA8, bottom), ME-522 Pho3 (SM, middle), and ME-522 free base (SM from project S128128, top). [Figure 207] Figure 207 shows the HT-XRPD diffractograms of the morphologies found in the present study for ME-522 phosphate. From bottom to top: Pho1, Pho3, Pho4, Pho5, Pho6, Pho7, Pho8, and Pho9. [Figure 208] Figure 208 shows the temperature profile of the thermal cycling experiment. [Figure 209] FIG. 209 shows the overlaid HT-XRPD patterns of Phol (Experiment ID: TCP23, vacuum dried) and Phol (Experiment ID: TCP23, vacuum dried after AAC). [Figure 210]Figure 210 shows the TGMS thermogram (heating rate 10°C / min) of Phol (Experiment ID: TCP23). A mass loss of 1.4% was recorded between 40 and 120°C. [Figure 211] Figure 211 shows the DSC curve (heating rate 10°C / min) of Phol (experiment ID: TCP23). In addition to a sharp endotherm at 200°C and a broad endotherm from 217 to 259°C, a broad endotherm event was observed up to 80°C. [Figure 212] Figures 212A and 212B show the cDSC curves (heating rate 10°C / min) of Phol (Experiment ID: TCP23). In the first experiment (Figure 212A), the material was heated to 140°C and cooled to room temperature. After analyzing the material by HT-XRPD, the compound from the first cDSC cycle was again heated to 140°C, cooled to room temperature, and finally heated to 300°C in a second cDSC cycle (Figure 212B). [Figure 213] FIG. 213 shows an overlay of HT-XRPD patterns of Pho1 (Experiment ID: TCP23) before and after cDSC. [Figure 214] Figure 214 shows the UPLC-MS analysis of Phol (Experiment ID: TCP23). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the API's molecular mass of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 215] FIG. 215 shows the 1H-NMR spectra of Phol (Experiment ID: TCP23, bottom) and ME-522 free base (from S18128, top) measured in DMSO-d6. [Figure 216] Figure 216 shows the DVS isotherm plot of Phol (Experiment ID: TCP23), where the mass change is plotted as a function of RH. First, a sorption profile from 40% to 95% RH was applied (red diamonds), followed by a desorption profile from 95% to 0% RH (blue squares). Finally, RH was set to 40% of the starting value (green triangles). [Figure 217]FIG. 217 shows a photograph of the material obtained after adding a small amount of water to a solid sample of Phol (Experiment ID: TCP23). [Figure 218] Figure 218 shows the HT-XRPD pattern of Pho2 (Experiment ID: SSm15, from project S18128). [Figure 219] Figure 219 shows overlaid HT-XRPD patterns from a solid obtained by cooling crystallization from ethanol (Experiment ID: SSm2). From bottom to top: Pho3 (dried at ambient conditions) and Pho1 (vacuum dried). [Figure 220] Figure 220 shows an overlay of HT-XRPD patterns of materials obtained by thermal cycling in 1,2-dimethoxyethane (Experiment ID: TCP16). From bottom to top: Pho4 (ambient dried), Pho1 (vacuum dried), and Pho4 (ambient dried after AAC). [Figure 221] Figure 221 shows an overlay of HT-XRPD patterns of material obtained by thermal cycling in acetone (Experiment ID: TCP19). From bottom to top: Pho5 (ambient dried), Pho1+ peak (vacuum dried), and Pho8 (ambient dried after AAC). [Figure 222] Figure 222 shows overlaid HT-XRPD patterns of poorly crystalline (pc) material (Experiment ID: TCP26) obtained from TBME. From bottom to top: Pho6 (ambient dried), Pho6 (vacuum dried), amorphous material (ambient dried after AAC), and amorphous material (vacuum dried after AAC). [Figure 223] Figure 223 shows the TGMS thermogram (heating rate 10°C / min) of Pho6 (Experiment ID: TCP26). A total mass loss of 3.6% was recorded from 30 to 180°C. [Figure 224] Figure 224 shows the DSC curve (heating rate 10°C / min) of Pho6 (Experiment ID: TCP26). During the heating period, there were three endothermic events up to 143°C, followed by an exothermic event at 146°C. This was followed by an endothermic event at 176°C, followed by a broad endothermic event from 211 to 267°C. [Figure 225]Figure 225 shows the UPLC-MS analysis of Pho6 (Experiment ID: TCP26). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the molecular mass of the free base of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 226] Figure 226 shows the H-NMR spectra of the free base (SM of S18128, bottom) and Pho6 (experimental ID: TCP26, top) measured in DMSO-d. The cigaret signal at 1.12 ppm represents the protons of the three CH groups of TBME. [Figure 227] Figure 227 shows an overlay of HT-XRPD patterns of Pho7 from a thermal cycling experiment in 2-propanol / water (90 / 10 v / v; Experiment ID: TCP30). From bottom to top, the XRPD patterns represent the ambient-dried sample, the vacuum-dried material, the ambient-dried sample after AAC exposure (40°C / 75% RH for 2 days), and the vacuum-dried material after AAC exposure (40°C / 75% RH for 2 days). Additional diffraction peaks are indicated by arrows. [Figure 228] Figure 228 shows the TGMS thermogram (heating rate 10°C / min) of Pho7 (Experiment ID: TCP30). A mass loss of 4.0% was recorded from 25 to 180°C. [Figure 229] Figure 229 shows the DSC curve (heating rate 10°C / min) of Pho7 (Experiment ID: TCP30). Several endothermic and exothermic events were detected up to 200°C, followed by a broad endothermic event from 213 to 261°C. [Figure 230] Figure 230 shows the UPLC-MS analysis of Pho7 (Experiment ID: TCP30). The peak corresponding to the API had a retention time of 1.2 minutes, and the positive ion spectrum showed an ion with m / z of 470.2 [M+H], consistent with the molecular mass of the free base of 469.8 g / mol. The table shows the retention times, peak areas, and peak heights of the API and unidentified impurities. [Figure 231]Figure 231 shows the H-NMR spectra of the free base (SM of S18128, bottom) and Pho7 (experimental ID: TCP30, top) measured in DMSO-d. The doublet signal at 1.06 ppm represents the protons of the two CH groups of 2-propanol. [Figure 232] Figure 232 shows an overlay of HT-XRPD patterns for material from a thermal cycling experiment in acetone (Experiment ID: TCP19). From bottom to top: Pho5 (ambient dried), Pho1+ peak (vacuum dried), Pho8 (ambient dried after AAC), and Pho8+ peak (vacuum dried after AAC). [Figure 233] FIG. 233 shows the overlaid HT-XRPD patterns of Pho9 (dried at ambient conditions) and Pho1+Pho4 (vacuum dried) obtained by cooling crystallization experiment from THF (Experiment ID: SSm1). [Figure 234] Figure 234 shows the molecular structure of ME-522 free base (MW 469.8 g / mol). [Figure 235] Figure 235 shows overlaid HT-XRPD patterns of ME-522 hydrochloride (starting material received for this study), ME-522 free base as received for the salt formation experiment performed in S18128, and ME-522 free base obtained from conversion of the HCl salt to the free base (Experiment ID GEN4). [Figure 236] Figures 236A and 236B show TGA (Figure 236A) and TGMS (Figure 236B) analyses (heating rate 10°C / min) of the free base recovered from the HCl conversion (Experiment ID GEN4). A 3.3% mass loss was observed before thermal decomposition (observed at temperatures above 240°C). [Figure 237] Figure 237 shows the DSC curve (heating rate 10°C / min) of the free base (Experiment ID: GEN4) obtained after conversion from the HCl salt. One broad endothermic event due to the loss of water was recorded between 25 and 70°C. The exothermic / endothermic event recorded between 160 and 182°C can be attributed to a recrystallization event. This was followed by a small endothermic event at 217°C, followed by a sharp endothermic event at 226°C. [Figure 238]Figure 238 shows the UPLC-MS chromatogram of the free base (Experiment ID: GEN4) obtained after conversion from the HCl salt. The API peak appeared at 1.2 minutes with 100% chemical purity (area %). The molecular peak at 470.2 m / z in the mass spectrum may correspond to the positively charged species [M+H]+ (API MW: 469 g / mol). [Figure 239] Figure 239 shows an overlay of the H-NMR spectra (500 MHz, DMSO-d) of ME-522 free base received for a previous project (green line) and ME-522 free base produced in this study (Experiment ID GEN4, red line). [Figure 240] Figure 240 shows the HT-XRPD pattern of ME-522 malonate salt (Experimental ID GEN8) prepared by lyophilizing a solution of the free base containing 1 equivalent of malonic acid in THF / water / acetone (32.5 / 32.5 / 35, v / v / v). [Figure 241] Figures 241A and 241B show TGA (Figure 241A) and TGMS (Figure 241B) analyses (heating rate 10°C / min) of the amorphous malonate salt (experiment ID GEN8) obtained after lyophilization. A mass loss of 3.6% was observed before thermal decomposition (observed at temperatures above 120°C). [Figure 242] Figure 242 shows the UPLC-MS chromatogram of the malonate salt (Experiment ID GEN8) obtained after lyophilization. The API peak appeared at 1.2 minutes with a chemical purity (area %) of 99.8%. The molecular peak at 470.2 m / z in the mass spectrum may correspond to the positively charged species [M+H]+ (API MW: 469 g / mol). [Figure 243]Figure 243 shows an overlay of H-NMR spectra (500 MHz, DMSO-d6) of ME-522 free base obtained thus far in this study (Experiment ID GEN4, green line), ME-522 malonate (Mao1) found in a previous study (S18128, Experiment SSm53), and ME-522 malonate obtained by lyophilization (Experiment ID GEN8, red line). The chemical shift observed at 2.85 ppm corresponds to malonic acid. Additional resonance shifts corresponding to residual THF were observed (3.60 and 1.76 ppm). [Figure 244] Figure 244 shows the HT-XRPD diffractograms of the forms found during the polymorph screening performed on ME-522 malonate (from bottom to top): Mao1, Mao3, Mao4, and Mao5. [Figure 245] Figure 245 shows the experimental conditions for the thermal cycling experiment. Slurries of ME-522 malonate salt were prepared in pure solvents and solvent mixtures, placed in a Crystal16™ reactor, and subjected to the thermal profile described in Figure 245. After the temperature profile, the precipitated solids were dried under ambient conditions and vacuum and analyzed by HT-XRPD before and after exposure to AAC (40°C / RH75%, 2 days). The mother liquor was used for solubility characterization. The solution was then dried under vacuum, and the resulting dried solids were analyzed by XRPD. [Figure 246] FIG. 246 shows the XRPD patterns of Mao1 (experiment ID TCP7) obtained in a thermal cycling experiment conducted in THF before (lower trace) and after (upper trace) exposure to AAC. [Figure 247] Figure 247 shows a graphical representation of the Rietveld refinement (Rietveld, 1969) for ME-522 Mao1 (experiment ID TCP7) obtained from a thermal cycling experiment carried out in THF. The black line represents the obtained powder pattern, the red line is the calculated pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted lattice (lattice parameters as well as atomic positions were obtained from the single crystal data reported in study S18128). [Figure 248]Figures 248A and 248B show TGA (Figure 248A) and TGMS (Figure 248B) analyses of Mao1 (experiment ID TCP7) from a thermal cycling experiment conducted in THF (heating rate 10 °C / min). A mass loss of 0.7% is observed before melting / decomposition starting around 160 °C. This mass loss can be attributed to residual water based on the MS signal. [Figure 249] Figure 249 shows a DSC analysis (heating rate 10°C / min) of Mao1 (experiment ID TCP7) from a thermal cycling experiment conducted in THF. An endothermic event attributed to melting / thermal decomposition was observed with a peak temperature of 181.1°C. [Figure 250] FIG. 250 shows the 1H-NMR spectra of Mao1 (Experiment ID TCP7, bottom) obtained in a thermal cycling experiment conducted in THF compared to the amorphous malonate salt (Experiment ID GEN8, top). [Figure 251] Figure 251 shows the UPLC chromatogram of Mao1 (Experiment ID TCP7) from a thermal cycling experiment conducted in THF. The chemical purity of the API was 99.4% (area %). [Figure 252-1] Figures 252A and 252B show the mass change (Figure 252A) and isotherm plot (Figure 252B) from DVS analysis performed on Mao1 (Experiment ID TCP7) from a thermal cycling experiment conducted in THF. The DVS analysis consisted of one sorption cycle from 40% to 95% RH, one desorption cycle from 95% to 0% RH, and one sorption cycle from 0% to 40% RH. The weight balance per step was set at dm / dt < 0.0002, with a minimum of 1 hour or a maximum of 6 hours. [Figure 252-2] Figures 252A and 252B show the mass change (Figure 252A) and isotherm plot (Figure 252B) from DVS analysis performed on Mao1 (Experiment ID TCP7) from a thermal cycling experiment conducted in THF. The DVS analysis consisted of one sorption cycle from 40% to 95% RH, one desorption cycle from 95% to 0% RH, and one sorption cycle from 0% to 40% RH. The weight balance per step was set at dm / dt < 0.0002, with a minimum of 1 hour or a maximum of 6 hours. [Figure 253] Figure 253 shows a photograph of the suspension obtained after adding a small aliquot of water to the Mao1 solids. [Figure 254] Figure 254 shows the HT-XRPD pattern of Mao1 (Experiment ID: Ssm4) obtained from the scale-up experiment, and an image of the material used for XRPD analysis. [Figure 255] Figure 255 shows a graphical representation of the Rietveld refinement (Rietveld, 1969) for ME-522 Mao1 (experiment ID Ssm4) obtained in a scaled-up cooling crystallization experiment in THF. The black line represents the obtained powder pattern, the red line is the calculated pattern, and the gray line is the difference between the two. The blue bars at the bottom indicate the peak positions of the fitted lattice (lattice parameters as well as atomic positions were obtained from the single crystal data reported in experiment S18128). [Figure 256] Figures 256A and 256B show TGA (Figure 256A) and TGMS (Figure 256B) analyses of Mao1 (experiment ID Ssm4) from a scaled-up cooling crystallization experiment in THF (heating rate 10°C / min). A mass loss of 0.08% was observed before melting / decomposition starting around 160°C. [Figure 257] Figure 257 shows a DSC analysis (heating rate 10°C / min) of Mao1 (experiment ID Ssm4) from a scaled-up cooling crystallization experiment conducted in THF. An endothermic event attributed to melting / thermal decomposition was observed with a peak temperature of 182.4°C. [Figure 258] Figure 258 shows an overlay of the H-NMR spectra (500 MHz, DMSO-d) of ME-522 free base from a free-basing scale-up experiment (Experiment ID: GEN10, top) and Mao1 from a cooling crystallization experiment from THF (Experiment ID: Ssm4). [Figure 259] Figure 259 shows the UPLC chromatogram of Mao1 (Experiment ID Ssm4) from a scaled-up cooling crystallization experiment conducted in THF. The chemical purity of the API was 100% (area %). The mass associated with the main peak was 470.3 m / z, corresponding to the positively charged species [M+H]+. [Figure 260]Figure 260 shows an overlay of the HT-XRPD patterns of the amorphous solid obtained after a thermal cycling experiment conducted in cyclohexane (Experiment ID TCP3) and Mao4 (upper pattern) after exposure of the amorphous solid obtained in TCP3 to AAC. [Figure 261] Figures 261A and 261B show TGA (Figure 261A) and TGMS (Figure 261B) analyses of Mao4 obtained after exposure of the amorphous solid (from cyclohexane) obtained with TCP3 to AAC (heating rate 10 °C / min). A mass loss of 3.5% due to water was observed in the temperature range of 40 to 150 °C (API:malonic acid:water 1:1:1.1). [Figure 262] Figure 262 shows the DSC analysis (heating rate 10 °C / min) of Mao4 obtained after exposure of the amorphous solid (from cyclohexane) obtained with TCP3 to AAC. A broad endothermic event attributed to water loss was observed between 25 and 100 °C, followed by an endothermic event attributable to melting / thermal decomposition at a peak temperature of 177.1 °C. [Figure 263] Figure 263 shows the UPLC-MS chromatogram of Mao4 obtained after exposure of the amorphous solid (from cyclohexane) obtained with TCP3 to AAC. The chemical purity of the API was 98.5% (area %). [Figure 264] Figure 264 shows the 1H-NMR spectra of Mao4 obtained after exposure to AAC of the amorphous solid obtained with TCP3 (from cyclohexane, Experiment ID TCP3, bottom) compared with Mao1 from Experiment ID TCP7 (top). [Figure 265-1] Figures 265A and 265B show the mass change (Figure 265A) and isotherm plot (Figure 265B) analyses obtained from DVS analysis performed on Mao4 obtained after exposure of the amorphous solid (from cyclohexane) obtained from TCP3 to AAC. The DVS analysis consisted of one sorption cycle from 40% to 95% RH, one desorption cycle from 95% to 0% RH, and one sorption cycle from 0% to 40% RH. Samples were incubated at each relative humidity value for 1 hour. [Figure 265-2]Figures 265A and 265B show the mass change (Figure 265A) and isotherm plot (Figure 265B) analyses obtained from DVS analysis performed on Mao4 obtained after exposure of the amorphous solid (from cyclohexane) obtained from TCP3 to AAC. The DVS analysis consisted of one sorption cycle from 40% to 95% RH, one desorption cycle from 95% to 0% RH, and one sorption cycle from 0% to 40% RH. Samples were incubated at each relative humidity value for 1 hour. [Figure 266] FIG. 266 shows the HT-XRPD patterns of Mao4 (experiment ID TCP3, post-AAC) and Mao1 (upper pattern) collected after DVS measurement. [Figure 267] Figure 267 shows overlaid HT-XRPD patterns of Mao5 (experiment ID TCP6_ML) obtained after evaporative crystallization of the mother liquor recovered from a thermal cycling experiment conducted in methanol and Mao4 (upper pattern) obtained after exposure to AAC. [Figure 268-1] Figures 268A and 268B show TGA (Figure 268A) and TGMS (Figure 268B) analyses of Mao5 (experiment ID TCP6_ML) obtained after evaporative crystallization of the mother liquor recovered from a thermal cycling experiment performed in methanol (heating rate 10 °C / min). A mass loss of 1.5% due to water was observed in the temperature range 40-100 °C (1.5% water corresponds to 0.5 molecules of water per molecule of malonate). [Figure 268-2] Figures 268A and 268B show TGA (Figure 268A) and TGMS (Figure 268B) analyses of Mao5 (experiment ID TCP6_ML) obtained after evaporative crystallization of the mother liquor recovered from a thermal cycling experiment performed in methanol (heating rate 10 °C / min). A mass loss of 1.5% due to water was observed in the temperature range 40-100 °C (1.5% water corresponds to 0.5 molecules of water per molecule of malonate). [Figure 269]Figure 269 shows a DSC analysis (heating rate 10 °C / min) of Mao5 (experiment ID TCP6_ML) obtained after evaporative crystallization of the mother liquor recovered from a thermal cycling experiment conducted in methanol. A broad endothermic event attributed to water loss was observed between 90 and 130 °C, followed by an exothermic event at 135.4 °C likely due to recrystallization. An endothermic event was recorded at 176.1 °C. [Figure 270] Figure 270 shows the UPLC-MS chromatogram of Mao5 (experimental ID TCP6_ML) obtained after evaporative crystallization of the mother liquor recovered from a thermal cycling experiment conducted in methanol. The chemical purity of the API was 99.2% (area %). [Figure 271] Figure 271 shows a thermal ellipsoid diagram at the 50% probability level for the asymmetric unit content in the structure of voruciclib oxalate, along with the atomic labeling scheme. Hydrogen bonds are depicted with thin dashed lines. Molecules are shown in the correct relative orientation they assume in the structure. [Fig. 272] Figure 272 shows the hydrogen bonds in the structure of voruciclib oxalate. O3-H3...O13i, O8-H8...O1Wii, and O1W-H1WA...O14iii interactions bridge the building blocks shown in Figure 271. Atoms with the letter A in their atom labels are generated by symmetry operation i: -x+2, y-0.5, -z+1; letter B indicates symmetry operation ii: -x+1, y+0.5, -z+1; and letter C corresponds to symmetry operation iii: x-1, y, z. The representation is the same as in Figure 271. The hydrogen atoms bonded to carbon and 2-pentanone have been omitted for clarity. Hydrogen bonds are depicted with thin dashed lines. [Fig. 273] Figure 273 shows packing plots of the structure of voruciclib oxalate projected along the crystallographic a-, b-, and c-axes (panels A, B, and C, respectively). Hydrogen bonds are depicted with thin dashed lines. Panel A shows the solvent channel, which extends along the crystallographic a-axis. Carbon-bonded hydrogen atoms have been omitted for clarity. [Fig. 274]Figure 274 shows a simulated powder diffractogram for the structure of voruciclib oxalate. [Figure 275] Figure 275 shows a thermal ellipsoid diagram at the 50% probability level for two crystallographically independent molecules of voruciclib phosphate, along with an atomic labeling scheme. Hydrogen bonds are depicted with thin dashed lines, and solvent molecules have been omitted for clarity. The molecules are not shown in their proper relative orientation, but rather oriented for maximum clarity. Figure 276 shows all components of the asymmetric unit, including the two target molecules, the two phosphate counterions, and the solvent, all in their proper relative orientation. [Figure 276] Figure 276 shows the contents of the asymmetric unit in the structure of voruciclib phosphate, along with the atom labeling scheme. All of the individual moieties are in the correct relative orientation they would have in the crystal structure. Hydrogen bonds are depicted with thin dashed lines, and three half-occupied solvent molecules are depicted with open lines. [Figure 277] Figure 277 shows how O13-H13...015, O17-H17...011, O14-H14...016i, and O18-H18...012ii hydrogen bonds connect the phosphate ions into an infinite chain extending along the crystallographic b axis. Atoms with the letter A in the atom label arise from the symmetry operation i:x,y+1,z, and the letter B indicates the symmetry operation ii:x,y-1,z. Hydrogen bonds are depicted with thin dashed lines. [Fig. 278]Figure 278 shows how hydrogen bonds O3-H3...011, O8-H8...012, O9-H9...010, O1-H1A...015iii, N1-H1...013iii, and N2-H2...017iv link the voruciclib molecule to the phosphate chain shown in Figure 277. A projection along the phosphate chain perpendicular to the view of Figure 277 is shown. Atoms with the letter A in their atom labels are generated by symmetry operation i: x, y+1, z; the letter B indicates symmetry operation ii: x, y-1, z; the letter C indicates symmetry operation iii: -x+2, y-0.5, -z+1; and the letter D indicates symmetry operation iv: -x+2, y-0.5, -z+1. Hydrogen bonds are depicted with thin dashed lines; hydrogen atoms and solvent molecules not involved in classical hydrogen bonds have been omitted for clarity. [Figure 279] Figure 279 shows the integration of solvent molecules into the supramolecular framework via hydrogen bonds O1T-H1T...016, O1U-H1U...016, O6-H6...01Siv, and O6-H6...01Uv. The hypothetical hydrogen position H1SX allows for a hydrogen bond O1S-H1S...015, but this position clashes with the symmetry equivalent hydrogen atom on H6 (shown here as H6F). Atoms with the letter E in the atom label are generated by the symmetry operation -x+1,y-1.5,-z+1, and the letter F indicates the symmetry operation -x+1,y-0.5,-z+1. Hydrogen bonds are depicted with thin dashed lines. [Figure 280] Figure 280 shows packing plots of the structure of voruciclib phosphate isopropyl alcohol solvate, projected along the crystallographic a-, b-, and c-axes (panels A, B, and C, respectively). To better illustrate the role of the solvent molecules, the solvent carbon atoms are depicted in orange. Hydrogen bonds are depicted with thin dashed lines. Panels A and B show how the solvent channels run parallel to the phosphate chains. Hydrogen atoms not involved in hydrogen bonds have been omitted for clarity. [Figure 281] Figure 281 shows a simulated powder diffractogram for the structure of voruciclib phosphate isopropyl alcohol solvate. [Figure 282] Figure 282 shows the molecular structure of voruciclib malonate. [Figure 283] Figure 283 shows a microphotograph (10x magnification) of voruciclib malonate crystals under polarized light. [Fig. 284] Figure 284 shows the molecular structure and atom numbering scheme for the cation-anion pair of voruciclib malonate. [Figure 285] Figure 285 shows the crystal packing and hydrogen bonding scheme of voruciclib malonate along the
[0010] direction. The voruciclib cation is represented in green, while the malonate anion is in red. Light blue lines represent hydrogen bonds. [Figure 286] Figure 286 shows the simulated powder pattern (black) based on single crystal data at FWHM=0.28° compared with the HT-XRPD pattern (red) obtained for the malonate salt with experiment ID SSm53. [Figure 287] Figure 287 shows a table depicting the stability of polymorphs in various solvents identified in the solid state characterization of voruciclib HCl. [Figure 288] Figure 288 shows non-limiting examples of targeted product attributes for voruciclib (ME-522). [Figure 289] Figure 289 shows the results of an initial salt screen comparing the morphology, crystallinity, and stability of various acid counterions. [Figure 290] Figure 290 shows the results of a secondary salt screen comparing the number of polymorphs, percent residual solvent, gelation, and aqueous solubility (mg / mL). [Figure 291] Figure 291 shows the properties of the HCl, malonate, oxalate, and phosphate salts of voruciclib relative to the product attributes shown in Figure 288. [Figure 292] Figure 292 shows the crossover design of a dog PK study comparing the HCl salt and the malonate salt of voruciclib. [Figure 293] Figure 293 shows the variability analysis for each combination of pretreatment group and administered salt form in a canine crossover PK study comparing the HCl salt and malonate salt of voruciclib. [Fig. 294]Figure 294 shows the malonate / HCl ratio calculated for each dog and PK parameter. [Figure 295] Figure 295 shows plasma concentrations of voruciclib versus time following single-dose crossover oral administration to male beagle dogs. [Figure 296-1] Figures 296A-296D show the XRPD patterns of voruciclib malonate with lot numbers 20-00022-01, 20-00026-01, and 20-00062-01. [Figure 296-2] Figures 296A-296D show the XRPD patterns of voruciclib malonate with lot numbers 20-00022-01, 20-00026-01, and 20-00062-01. [Figure 297] Figure 297 shows the technical specifications of the VÅNTEC-500 area detector. [Figure 298] Figure 298 shows the technical specifications of the Lynxeye detector. DETAILED DESCRIPTION OF THE INVENTION
[0046] While preferred embodiments of the present invention have been shown and described herein, such embodiments are provided by way of example only and are not intended to otherwise limit the scope of the invention. Various alternatives to the described embodiments of the invention may be employed in practicing the invention.
[0047] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referenced herein are incorporated by reference in their entirety.
[0048] The term "solid form" may refer to crystalline solid forms or phases, including crystalline free base and crystalline salts. As used herein, the terms "co-administration," "co-administer," "administered in combination," and "administering in combination" include administering two or more agents to a subject such that both agents and / or their metabolites are present in the subject at the same time. Co-administration includes simultaneous administration of separate compositions, administration of separate compositions at different times, or administration of a composition in which two or more agents are present.
[0049] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or combination of compounds described herein sufficient to effect the intended application, including, but not limited to, the treatment of a disease. A therapeutically effective amount may vary depending on the intended application (in vitro or in vivo), or the subject and disease state to be treated (e.g., the subject's weight, age, and sex), the severity of the disease state, the method of administration, etc., and can be readily determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response (e.g., CDK inhibition) in target cells. The specific dose will vary depending on the particular compound selected, the administration regimen to be followed, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system by which the compound is delivered.
[0050] The terms "QD", "qd", or "qd" mean once daily. The terms "BID", "bid", or "bid" mean twice daily. The terms "TID", "tid", or "tid" mean three times daily. The terms "QID", "qid", or "qid" mean four times daily.
[0051] A "therapeutic effect," as that term is used herein, encompasses the therapeutic benefits and / or prophylactic benefits described above. A prophylactic effect includes delaying or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0052] The term "pharmaceutically acceptable salts" refers to salts derived from a variety of organic and inorganic counterions, including those of fumarate, maleate, phosphate, L-tartarate, esylate, besylate, hydrobromide, hydrochloride, citric acid, gentisate, oxalate, sulfate, etc. Pharmaceutically acceptable acid addition salts may be formed with inorganic and organic acids.
[0053] "Pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents. Insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the present invention is contemplated. Supplementary active ingredients may also be incorporated into the described compositions.
[0054] The term "in vivo" refers to events that occur within the body of a subject. The term "in vitro" refers to events that occur outside a subject's body. In vitro assays include cell-based assays in which live or dead cells are used, and can also include cell-free assays in which intact cells are not used.
[0055] The term "extragranular" means material that is outside the granules, e.g., A substance that is added to a granule (a compacted multi-component mass formed by a granulation process) and is physically mixed with the granule, but is not contained within the granule.
[0056] The term "intragranular" refers to the granules (multi-particles formed by the granulation process). Granules refer to materials present in a wet granulation (i.e., a compact of ingredients). The composition may be formed by processes such as dry granulation (manufactured using air, heat, melting, freezing, foaming, and other processes) or dry granulation.
[0057] The term "acidifier" means a substance that increases acidity. The terms "transmission" or "transmission mode" when used in conjunction with powder X-ray diffraction refer to transmission (also called Debye-Scherrer) sampling mode. The terms "reflection" or "reflection mode" when used in conjunction with powder X-ray diffraction refer to reflection (also called Bragg-Brentano) sampling mode.
[0058] Unless otherwise stated, chemical structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds in which one or more hydrogen atoms are replaced by deuterium or tritium, or compounds in which one or more carbon atoms are replaced by 13 C or 14 Compounds replaced by C-enriched carbons are within the scope of the present invention.
[0059] When ranges are used herein to describe examples of physical or chemical properties, such as molecular weight or chemical formula, all combinations and subcombinations of ranges, as well as specific embodiments therein, are intended to be included. The use of the terms "about" or "approximately" when referring to a numerical value or numerical range means that the stated numerical value or numerical range is an approximation within experimental variation (or statistical experimental error), and thus the numerical value or numerical range may vary, for example, by 1% to 15% of the stated numerical value or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") includes embodiments, such as, for example, embodiments of any composition of matter, method, or process that "consists of" or "consists essentially of" the described features.
[0060] As used herein, "enantiomeric purity" refers to the relative amount of a particular enantiomer present relative to the other, expressed as a percentage. For example, if a compound potentially having either the (R)- or (S)-isomeric configuration exists as a racemic mixture, the enantiomeric purity is about 50% for either the (R)- or (S)-isomer. If the compound has predominantly one isomer relative to the other, e.g., 80% (S)-isomer and 20% (R)-isomer, the enantiomeric purity of the compound for the (S)-isomer is 80%. The enantiomeric purity of a compound can be determined in several ways, including, but not limited to, chromatography using a chiral support, polarimetry of polarization rotation, nuclear magnetic resonance spectroscopy using chiral shift reagents, including, but not limited to, lanthanide-containing chiral complexes or Pirkle reagents, or derivatization of the compound with a chiral compound such as Mosher's acid followed by chromatography or nuclear magnetic resonance spectroscopy.
[0061] In a preferred embodiment, the enantiomer-enriched composition has a higher therapeutic utility per unit mass than the racemic mixture of the composition. The enantiomers can be isolated from the mixture by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and chiral salt formation and crystallization, or the preferred enantiomer can be prepared by asymmetric synthesis. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions, Wiley Interscience, New York, 1981; Eliel, Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962; and Eliel and Wilen, Stereochemistry of Organic Compounds, Wiley-Interscience, New York, 1994.
[0062] The terms "enantiomerically enriched" and "non-racemic" as used herein refer to a composition in which the weight percentage of an enantiomer is greater than or equal to that of that enantiomer in a control mixture of a racemic composition. "Enantiomerically pure" refers to a composition that has a greater amount of one enantiomer than the other (e.g., greater than 1:1 by weight). For example, an enantiomerically enriched preparation of an (S)-enantiomer refers to a preparation of a compound that has more than 50% by weight of the (S)-enantiomer relative to the (R)-enantiomer, such as at least 75% by weight or at least 80% by weight. In some embodiments, enrichment may be well over 80% by weight to provide a "substantially enantiomerically enriched" or "substantially non-racemic" preparation, meaning a preparation of a composition that has at least 85% by weight of one enantiomer relative to the other, such as at least 90% by weight or at least 95% by weight. The terms "enantiomerically pure" or "substantially enantiomerically pure" refer to a composition that contains at least 98% of a single enantiomer and less than 2% of the opposite enantiomer.
[0063] "Moiety" means a specific segment or functional group of a molecule. A chemical moiety is often a recognized chemical entity that is incorporated into or appended to a molecule. "Tautomers" are structurally distinct isomers that interconvert via tautomerization. "Tautomerization" is a form of isomerization, including prototropic tautomerization or proton-shift tautomerization, and is considered a subset of acid-base chemistry. "Prototropic tautomerization" or "proton-shift tautomerization" involves the migration of a proton, accompanied by a change in bond order, often swapping a single bond with an adjacent double bond. When tautomerization is possible (e.g., in solution), it is possible to reach chemical equilibrium between tautomers. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. The formation of solid forms in different tautomeric states is known as "desmotropy" and such forms are known as "desmotropes".
[0064] The compositions of the present invention also include crystalline forms of Formula (1), including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrous forms), and conformational polymorphs, as well as mixtures thereof. "Crystalline form," "form," and "polymorph" are intended to include all crystalline forms of a compound, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrous forms), and conformational polymorphs, as well as mixtures thereof, unless a specific crystalline form is referenced.
[0065] "Solvate" means a crystalline phase of a compound that is in physical association with one or more solvent molecules. A crystalline phase of a compound that is in physical association with one or more water molecules is termed a "hydrate."
[0066] "Amorphous form" means a form of a compound, or a salt or molecular complex of a compound, that does not have long range crystalline order. Voruciclib Voruciclib is a CDK inhibitor described, for example, in U.S. Pat. Nos. 7,271,193, 7,915,301, 8,304,449, 7,884,127, and 8,563,596, the entire contents of which are incorporated herein by reference.
[0067] [ka]
[0068] In some embodiments, voruciclib refers to (+)-trans-2-(2-chloro-4-trifluoromethylphenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl)-chromen-4-one. In some embodiments, voruciclib refers to 2-(2-chloro-4-trifluoromethylphenyl)-5,7-dihydroxy-8-((2R,3S)-2-hydroxymethyl-1-methylpyrrolidin-3-yl)-4H-chromen-4-one.
[0069] Crystalline morphology In one embodiment, the disclosure provides a crystalline solid form of voruciclib. In one embodiment, the disclosure provides a crystalline solid form of voruciclib free base. In one embodiment, the disclosure provides a crystalline solid form of voruciclib salt. The disclosure provides polymorphs, e.g., crystalline forms, of voruciclib. In some embodiments, the polymorph comprises voruciclib free base. In some embodiments, the polymorph comprises a voruciclib salt comprising a counterion corresponding to an acid selected from 1,5-naphthalenedisulfonic acid, 1-hydroxy-2-naphthoic acid, benzenesulfonic acid, benzoic acid, dibenzoyl-L-tartaric acid, ethanesulfonic acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malonic acid, oxalic acid, orthophosphoric acid, sulfuric acid, p-toluenesulfonic acid, etc.
[0070] Any crystalline form described herein can be characterized by X-ray diffraction. In some embodiments, X-ray diffraction refers to X-ray powder diffraction. In some embodiments, X-ray diffraction may be measured using transmission or reflection mode. In one embodiment, the X-ray diffraction pattern of any embodiment herein is measured in transmission mode. In one embodiment, the X-ray diffraction pattern of any embodiment herein is measured in reflection mode. It is known in the art that X-ray powder diffraction patterns may be obtained containing one or more measurement errors depending on the measurement conditions (such as the equipment, sample preparation, or instrument used). In particular, it is generally known that the intensities of X-ray powder diffraction patterns may vary depending on the measurement conditions and sample preparation. For example, those skilled in the art of X-ray powder diffraction will recognize that the relative intensities of peaks may vary depending on the orientation of the sample under test and based on the type and settings of the instrument used. Those skilled in the art will also recognize that the position of reflections may be affected by the precise height of the sample placed in the diffractometer, the planarity of the sample surface, and the zero-point calibration of the diffractometer. Thus, one skilled in the art will understand that the diffraction pattern data presented herein should not be construed as absolute, and that any crystalline form that provides substantially the same powder diffraction pattern as disclosed herein is within the scope of the present disclosure. For further information, see Jenkins and Snyder, Introduction to X-Ray Powder Diffractometry, John Wiley & Sons, 1996. Please refer to.
[0071] Different crystalline forms may offer surprising advantages over amorphous forms, including improved thermodynamic stability, increased dissolution rate, improved performance in the stomach and gastric environment (including avoidance or reduction of precipitation from solution upon change to higher pH), improved exposure in mammals, and better processability for formulating the drug into a final product suitable for the patient.
[0072] In one embodiment, the present disclosure provides a crystalline form of voruciclib malonate and / or a polymorphic crystalline form of voruciclib malonate (Mao1), characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from the following:
[0073] [Table 1]
[0074] In some embodiments, each peak may independently include a variation of ±0.1°, ±0.2°, or ±0.3°. In one embodiment, the present disclosure provides a crystalline form of voruciclib oxalate and / or a polymorphic crystalline form of voruciclib oxalate (Oxa1), characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from the following:
[0075] [Table 2]
[0076] In some embodiments, each peak may independently include a variation of ±0.1°, ±0.2°, or ±0.3°. In one embodiment, the present disclosure provides a crystalline form of voruciclib phosphate and / or a polymorphic crystalline form of voruciclib phosphate (Pho1), characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from the following:
[0077] [Table 3]
[0078] In some embodiments, each peak may independently include a variation of ±0.1°, ±0.2°, or ±0.3°. In one embodiment, the disclosure provides a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°, 15.18°±0.2°, 15.66°±0.2°, 17.50°±0.2°, 18.94°±0.2°, 19.54°±0.2°, 22.22°±0.2°, 23.38°±0.2°, 24.10°±0.2°, 24.98°±0.2°, 25.94°±0.2°, 27.26°±0.2°, 28.50°±0.2°, and 32.82°±0.2°2θ. In some embodiments, the X-ray diffraction pattern comprises at least one peak, at least two peaks, at least three peaks, at least four peaks, at least five peaks, etc. selected from the group of peaks above. In some embodiments, the crystalline form comprises voruciclib malonate. In some embodiments, the crystalline form comprises hydrated voruciclib malonate. In some embodiments, the crystalline form comprises anhydrous voruciclib malonate.
[0079] In one embodiment, the present disclosure provides the following: 5.06°±0.2°, 6.42°±0.2°, 9.34°±0.2°, 10.14°±0.2°, 12.30°±0.2°, 13.66°±0.2°, 14.14°±0.2°, 15.82°±0.2°, 17.02°±0.2°, 19.74°±0.2°, 20.38°±0.2°, 21.82°±0.2°, 22. Provided is a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 66°±0.2°, 24.62°±0.2°, 25.78°±0.2°, 26.58°±0.2°, 28.66°±0.2°, and 29.98°±0.2°2θ. In some embodiments, the X-ray diffraction pattern comprises at least one peak, at least two peaks, at least three peaks, at least four peaks, at least five peaks, etc., selected from the group of peaks above. In some embodiments, the crystalline form comprises voruciclib dibenzoyltartrate. In some embodiments, the crystalline form comprises hydrated voruciclib dibenzoyltartrate. In some embodiments, the crystalline form comprises anhydrous voruciclib dibenzoyltartrate.
[0080] In one embodiment, the disclosure provides a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 4.94°±0.2°, 6.78°±0.2°, 9.34°±0.2°, 10.94°±0.2°, 12.70°±0.2°, 13.38°±0.2°, 14.90°±0.2°, 15.66°±0.2°, 17.54°±0.2°, 18.82°±0.2°, 22.02°±0.2°, 23.98°±0.2°, 24.78°±0.2°, 25.30°±0.2°, 26.66°±0.2°, and 29.98°±0.2°2θ. In some embodiments, the X-ray diffraction pattern comprises at least one peak, at least two peaks, at least three peaks, at least four peaks, at least five peaks, etc. selected from the group of peaks above. In some embodiments, the crystalline form comprises voruciclib phosphate. In some embodiments, the crystalline form comprises hydrated voruciclib phosphate. In some embodiments, the crystalline form comprises anhydrous voruciclib phosphate.
[0081] In one embodiment, the present disclosure provides a crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 6.86°±0.2°, 12.66°±0.2°, 13.58°±0.2°, 14.74°±0.2°, 15.98°±0.2°, 19.38°±0.2°, 23.94°±0.2°, 24.78°±0.2°, and 25.94°±0.2°2θ. In some embodiments, the X-ray diffraction pattern comprises at least one peak, at least two peaks, at least three peaks, at least four peaks, at least five peaks, etc., selected from the group of peaks above. In some embodiments, the crystalline form comprises voruciclib oxalate. In some embodiments, the crystalline form comprises hydrated voruciclib oxalate. In some embodiments, the crystalline form comprises anhydrous voruciclib oxalate.
[0082] In one embodiment, the present disclosure provides a method for detecting the rotational speed of a lens, comprising: 9.02°±0.2°, 10.50°±0.2°, 11.06°±0.2°, 12.30°±0.2°, 12.82°±0.2°, 13.90°±0.2°, 14.82°±0.2°, 15.30°±0.2°, 15.94°±0.2°, 17.26°±0.2°, 19.34°±0.2°, 20.50°±0.2°, 21.50°±0.2°, 22.50°±0.2°, 23.50°±0.2°, 24.50°±0.2°, 25.50°±0.2°, 26.50°±0.2°, 27.50°±0.2°, 28.50°±0.2°, 29.50°±0.2°, 30.50°±0.2°, 31.50°±0.2°, 32.50°±0.2°, 33.50°±0.2°, 34.50°±0.2°, 35.50°±0.2°, 36.50°±0.2°, 37.50°±0.2°, 38.50°±0.2°, 39.50°±0.2°, 40.50°±0.2°, 41.50°±0.2°, 42.50°±0.2°, 43.50°±0.2°, 44.50°±0.2°, 45.50°±0.2°, 46.50°±0 27.38°±0.2°, and 28.66°±0.2°2θ. In some embodiments, the X-ray diffraction pattern comprises at least one peak, at least two peaks, at least three peaks, at least four peaks, at least five peaks, etc., selected from the group of peaks above. In some embodiments, the crystalline form comprises voruciclib napadisylate. In some embodiments, the crystalline form comprises hydrated voruciclib napadisylate. In some embodiments, the crystalline form comprises anhydrous voruciclib napadisylate.
[0083] Pharmaceutical Composition In one embodiment, the present invention provides a pharmaceutical composition comprising a crystalline form of voruciclib free base. In one embodiment, the present invention provides a pharmaceutical composition comprising a crystalline form of a voruciclib salt. The pharmaceutical composition is typically formulated to provide a therapeutically effective amount of a solid form of voruciclib, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate, or derivative thereof, as the active ingredient. If desired, the pharmaceutical composition contains a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, carriers, diluents, penetration enhancers, solubilizers, or adjuvants, including inert solid diluents and fillers. The pharmaceutical composition may also contain an acidulant as described herein.
[0084] In some embodiments, the concentration of a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, provided in a pharmaceutical composition of the invention may be, independently, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 400%, 420%, 440%, 460%, 480%, 490%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, less than 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, or 0.001%. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0085] In some embodiments, the concentration of a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, provided in a pharmaceutical composition of the invention may be, independently, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.80%, 20.90%, 21.75%, 21.80%, 22.75%, 23.75%, 24.75%, 25.75%, 26.75%, 27.75%, 28.75%, 29.75%, 30.75%, 31.75%, 32.75%, 33.75%, 34.75%, 35.75%, 36.75%, 37.75%, 38.75%, 39.75 9.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%, 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75 %,11.50%,11.25%,11%,10.75%,10.50%,10.25%,10%,9.75%,9.50%,9.25%,9%,8.75%,8.50%,8.25%,8%,7.75%,7.50%,7.25%,7%,6.75%,6.50%,6.25%,6%,5.75%,5.50%,5.25%,5%,4.75%,4.50%,4.25%,4%,3.75%,3.50%,3.25%,3 %, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, or more than 0.001%. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0086] In some embodiments, the concentration of a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, is, independently, from about 0.0001% to about 50%, from about 0.001% to about 40%, from about 0.01% to about 30%, from about 0.02% to about 29 ... 3% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, or approximately 1% to approximately 10%. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0087] In some embodiments, the concentration of voruciclib, including any voruciclib free base polymorphs described herein or any voruciclib salt polymorphs described herein, is independently within the range of from about 0.001% to about 10%, from about 0.01% to about 5%, from about 0.02% to about 4.5%, from about 0.03% to about 4%, from about 0.04% to about 3.5%, from about 0.05% to about 3%, from about 0.06% to about 2.5%, from about 0.07% to about 2%, from about 0.08% to about 1.5%, from about 0.09% to about 1%, or from about 0.1% to about 0.9%, on a weight / weight, weight / volume, or volume / volume basis, relative to the total mass or volume of the pharmaceutical composition. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0088] In some embodiments, the amount of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, is independently 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0 g, 1 ... In one embodiment, the solid form is 0.001 g or less. In some embodiments, the amount of a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is independently 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.00 8g, 0.0085g, 0.009g, 0.0095g, 0.01g, 0.015g, 0.02g, 0.025g, 0.03g, 0.035g, 0 .04g, 0.045g, 0.05g, 0.055g, 0.06g, 0.065g, 0.07g, 0.075g, 0.08g, 0.085g, 0.0 9g, 0.095g, 0.1g, 0.15g, 0.2g, 0.25g, 0.3g, 0.35g, 0.4g, 0.45g, 0.5g, 0.55g, 0.6g, 0.65g, 0.7g, 0.75g, 0.8g, 0.85g, 0.9g, 0.95g, 1g, 1.5g, 2g, 2.5, or more than 3g. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each described herein.
[0089] Each of the solid forms of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, is effective over a wide dosage range. For example, for adult human treatment, dosages may independently range from 0.01 to 1000 mg, 0.5 to 100 mg, with 1 to 50 mg per day, 2 to 40 mg per day, and 5 to 25 mg per day being examples of dosages that may be used. The exact dosage will vary depending on the route of administration, the form in which the compound is administered, the sex and age of the subject to be treated, the weight of the subject to be treated, and the preference and experience of the attending physician. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0090] In selected embodiments, the present invention provides pharmaceutical compositions for oral administration comprising voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and a pharmaceutical excipient suitable for oral administration. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0091] In selected embodiments, the present invention provides solid pharmaceutical compositions for oral administration containing: (i) an effective amount of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, and (ii) a pharmaceutical excipient suitable for oral administration. In selected embodiments, the composition further contains (iii) an effective amount of another active pharmaceutical ingredient. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0092] In selected embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral ingestion. Pharmaceutical compositions of the present invention suitable for oral administration can be provided as a powder, or in discrete dosage forms such as capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient in granules, a solution or suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil emulsion, or as a liquid, or an aerosol spray. Pharmaceutical compositions of the present invention also include powders for reconstitution, powders for oral ingestion, bottles (such as powders or liquids in bottles), orally dissolving films, lozenges, pastes, tubes, gums, and packs. Such dosage forms may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with a liquid carrier, or a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with excipients such as, but not limited to, binders, lubricants, inert diluents, and / or surfactants or dispersing agents. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0093] The present invention also encompasses anhydrous pharmaceutical compositions and dosage forms, since water can accelerate the degradation of some compounds. For example, in the pharmaceutical field, water may be added (e.g., 5%) as a means of simulating long-term storage to determine properties such as the shelf life or stability of a formulation over time. Anhydrous pharmaceutical compositions and dosage forms of the present invention can be prepared using anhydrous or low-moisture content ingredients and low-moisture or low-humidity conditions. The present invention also encompasses anhydrous pharmaceutical compositions and dosage forms containing lactose. Pharmaceutical compositions and dosage forms of the invention can be anhydrous if substantial contact with moisture and / or humidity is expected during manufacturing, packaging, and / or storage. Anhydrous pharmaceutical compositions can be prepared and stored such that their anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulation kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers, blister packs, and strip packs.
[0094] Each of the solid forms of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, can be combined in an intimate mixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms, depending on the form of preparation desired for administration. In preparing compositions for oral dosage forms, any of the usual pharmaceutical media, such as water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents, can be used as the carrier for oral liquid formulations (such as suspensions, solutions, and elixirs) or aerosols. Alternatively, for oral solid formulations, carriers such as starch, sugars, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, diluents, granulating agents, lubricants, glidants, binders, and disintegrants can be used, in some embodiments without lactose. For example, suitable carriers include powders, capsules, and tablets for solid oral formulations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.
[0095] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethylcellulose, sodium carboxymethylcellulose), polyvinylpyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methylcellulose, microcrystalline cellulose, and mixtures thereof.
[0096] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof.
[0097] Disintegrants can be used in the compositions of the present invention to provide tablets that disintegrate when exposed to an aqueous environment. Using too much disintegrant can produce tablets that disintegrate in the bottle. Using too little can be insufficient to cause disintegration, thereby varying the rate and extent of release of the active ingredient from the dosage form. Therefore, a sufficient amount of disintegrant, neither too little nor too much, that does not adversely vary the release of the active ingredient, can be used to form dosage forms of the compounds disclosed herein. The amount of disintegrant used can vary based on the type of formulation and mode of administration and can be readily discerned by those skilled in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, can be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pregelatinized starch, other starches, clays, other algins, other celluloses, gums, or mixtures thereof.
[0098] Lubricants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to, Examples of lubricants include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium stearyl fumarate, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Additional lubricants include, for example, syloid silica gel, coagulated aerosol of synthetic silica, silicified microcrystalline cellulose, or mixtures thereof. Lubricants, if desired, may be added in an amount of less than about 1 weight percent of the pharmaceutical composition.
[0099] When aqueous suspensions and / or elixirs are desired for oral administration, the essential active ingredient therein may be combined with a diluent such as water, ethanol, propylene glycol, glycerin, and various combinations thereof, with various sweetening or flavoring agents, coloring substances or dyes, and, if so desired, with emulsifying and / or suspending agents.
[0100] Tablets may be uncoated, or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over a longer period. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be used. Formulations for oral use may be provided as hard gelatin capsules, in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules, in which the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin, or olive oil.
[0101] Surfactants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, i.e., a mixture of hydrophilic surfactants can be used, a mixture of lipophilic surfactants can be used, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant can be used.
[0102] An experimental parameter used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Suitable hydrophilic surfactants may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of about 10 or less. Surfactants with lower HLB values are more lipophilic or hydrophobic and have greater solubility in oil, while surfactants with higher HLB values are more hydrophilic and have greater solubility in aqueous solutions. Generally, compounds with HLB values greater than about 10 are considered hydrophilic surfactants, as are anionic, cationic, or zwitterionic compounds to which the HLB scale does not generally apply. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds with an HLB value of about 10 or less. However, the HLB value of a surfactant is merely a general guide commonly used to enable the formulation of industrial, pharmaceutical, and cosmetic emulsions.
[0103] The hydrophilic surfactant may be ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts, fusidate salts, fatty acid derivatives of amino acids, oligopeptides, and polypeptides, glyceride derivatives of amino acids, oligopeptides, and polypeptides, lecithin and hydrogenated lecithin, lysolecithin and hydrogenated lysolecithin, phospholipids and derivatives thereof, lysophospholipids and derivatives thereof, carnitine fatty acid ester salts, alkyl sulfate salts, fatty acid salts, sodium docusate, acyl lactylates, mono- and di-acetylated tartaric acid esters of mono- and di-glycerides, succinylated mono- and di-glycerides, and citric acid mono- and di-glycerides. esters; and mixtures thereof.
[0104] Among the above groups, ionic surfactants include, for example, lecithin, lysolecithin, phospholipids, lysophospholipids, and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citrate esters of mono- and di-glycerides; and mixtures thereof.
[0105] Ionic surfactants include lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, and lactylic esters of fatty acids. Ingredients include: stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono- and diacetylated tartaric acid esters of mono- and diglycerides, citric acid esters of mono- and diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, laurate Carnitine may be in the ionized form of palmitoylcarnitine, palmitoylcarnitine, myristoylcarnitine, and salts and mixtures thereof.
[0106] Hydrophilic nonionic surfactants may include, but are not limited to, alkyl glucosides; alkyl maltosides; alkyl thioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkylphenols; polyoxyalkylene alkylphenol fatty acid esters such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic interesterification products of polyols and at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives thereof, and analogs thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic interesterification products of polyols and at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.
[0107] Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate. Ingredients: Palm Oil, PEG-30 Glyceryl Laurate, PEG-40 Glyceryl Laurate, PEG-40 Palm Kernel Oil, PEG-50 Hydrogenated Castor Oil, PEG-40 Castor Oil, PEG-35 Castor Oil, PEG-60 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-60 Corn Oil, PEG-6 Caprate / Caprylate Glyceride, PEG-8 Caprate / Caprylate Glyceride, Polyglyceryl-10 Laurate, PEG-30 Cholesterol, PEG-25 Fat Examples of suitable glycerin-based copolymers include PEG-100 glycerin, PEG-30 soybean sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10-oleate, Tween 40, Tween 60, sucrose monostearate, sucrose molaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series, and poloxamer.
[0108] Suitable lipophilic surfactants include, by way of example only, fatty alcohols, glycerol fatty acid esters, acetylated glycerol fatty acid esters, lower alcohol fatty acid esters, propylene glycol fatty acid esters, sorbitan fatty acid esters, polyethylene glycol sorbitan fatty acid esters, sterols and sterol derivatives, polyoxyethylated sterols and sterol derivatives, polyethylene glycol alkyl ethers, sugar esters, sugar ethers, mono- and diglyceride lactic acid derivatives, and the hydrophobic transesterification products of polyols and at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols, oil-soluble vitamins / vitamin derivatives, and mixtures thereof.In this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or the hydrophobic transesterification products of polyols and at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
[0109] In one embodiment, the composition may contain a solubilizer to ensure good solubilization and / or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This may be particularly important for compositions for parenteral use, such as compositions for injection. Solubilizers may also be added to increase the solubility of other components, such as hydrophilic drugs and / or surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.
[0110] Examples of suitable solubilizing agents include, but are not limited to, alcohols and polyols such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol, pentaerythritol, sorbitol, mannitol, xylitol, transquitol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrin and cyclodextrin derivatives; tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methacrylate; Ethers of polyethylene glycol having an average molecular weight of about 200 to about 6000, such as hydroxy PEG; amides and other nitrogen-containing compounds, such as 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, and polyvinylpyrrolidone; ethyl propionate, tributyl citrate, triethyl acetyl citrate, tributyl acetyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, epsilon-caprolactone, esters such as lactone and its isomers, δ-valerolactone and its isomers, β-butyrolactone and its isomers; and other solubilizing agents known in the art such as dimethylacetamide, dimethylisosorbide, N-methylpyrrolidone, monooctanoin, diethylene glycol monoethyl ether, and water.
[0111] A mixture of solubilizers may be used. Examples include, but are not limited to, triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyethylene glycol 200-100, glycofurol, transquitol, polyethylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol, and propylene glycol.
[0112] The amount of solubilizer that may be included is not particularly limited. The amount of any solubilizer may be limited to a biotolerable amount, which can be easily determined by one of ordinary skill in the art. In some situations, for example, to maximize drug concentration, it may be advantageous to include an amount of solubilizer that is greatly in excess of the biotolerable amount, with the excess solubilizer being removed using conventional techniques such as distillation or evaporation before providing the composition to a patient. Thus, when present, the solubilizer may be present in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by weight, based on the combined weight of the drug and other excipients. If desired, very small amounts of solubilizer, such as 5%, 2%, 1%, or even less, may be used. Typically, the solubilizer may be present in an amount of about 1% to about 100% by weight, more typically about 5% to about 25% by weight.
[0113] The composition may further comprise one or more pharmaceutically acceptable additives and excipients, including, but not limited to, detackifiers, antifoaming agents, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, tonicifiers, flavors, colorants, odorants, opacifiers, suspending agents, binders, fillers, polymers, and the like. Plasticizers, lubricants, and mixtures thereof.
[0114] Additionally, acids or bases may be incorporated into pharmaceutical compositions to facilitate processing, improve stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS), and the like. Additionally, bases that are salts of pharmaceutically acceptable acids such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, and uric acid are also suitable. Salts of polybasic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate may also be used. When the base is a salt, the cation may be any convenient pharmaceutically acceptable cation, such as ammonium, alkali metals, and alkaline earth metals. Examples may include, but are not limited to, sodium, potassium, lithium, magnesium, calcium, and ammonium.
[0115] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, etc. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, and uric acid.
[0116] Dosage and Administration Regimen The dosage of a solid form of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, will vary depending on the mammal being treated, the severity of the disorder or condition, the rate of administration, the kinetics of the compound, and the discretion of the prescribing physician. However, effective doses range from about 0.001 to about 100 mg per kg of body weight per day, such as about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this amounts to about 0.05 to 7 g / day, such as about 0.05 to about 2.5 g / day. In some cases, dosage levels below the lower end of the above-stated ranges may be quite appropriate, while even larger doses that do not cause any adverse side effects may be used, for example, by dividing such larger doses into several smaller doses for administration throughout the day.
[0117] In selected embodiments, a solid form of voruciclib, comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, is administered in a single dose. Typically, such administration is by injection, e.g., intravenous injection, for the purpose of rapid introduction of the active pharmaceutical ingredient. However, other routes may be used as appropriate. A single dose of a solid form of voruciclib, comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, may be used to treat an acute medical condition.
[0118] In selected embodiments, a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein is administered in multiple doses. Administration may be about once, twice, three times, four times, five times, six times, or seven or more times per day. Administration may be about once per month, once every two weeks, once a week, or once every two days. In other embodiments, a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein is administered about once per day to about six times per day. In another embodiment, administration of a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein continues for less than about seven days. In yet another embodiment, administration continues for about six days, ten days, fourteen days, twenty-eight days, two months, six months, or more than one year. In some cases, continuous administration is achieved and maintained for as long as necessary. In one embodiment, the solid form of voruciclib is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0119] Administration of the active pharmaceutical ingredient of the invention may be continued for as long as necessary. In selected embodiments, a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. The solid form of voruciclib, including the polymorph, is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In selected embodiments, the solid form of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, is administered continuously over an extended period of time, e.g., to treat chronic effects. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0120] In some embodiments, an effective dose of voruciclib, including any voruciclib free base polymorph described herein, or any voruciclib salt polymorph described herein, is from about 1 mg to about 500 mg, about 10 mg to about 300 mg, about 20 mg to about 250 mg, about 25 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 120 mg, about 10 mg to about 90 mg, about 20 mg to about 80 mg, about 30 mg to about 70 mg, about 40 mg to about 60 mg, or about 60 mg to about 80 mg. 0 mg, about 45 mg to about 55 mg, about 48 mg to about 52 mg, about 50 mg to about 150 mg, about 60 mg to about 140 mg, about 70 mg to about 130 mg, about 80 mg to about 120 mg, about 90 mg to about 110 mg, about 95 mg to about 105 mg, about 150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg to about 230 mg, about 180 mg to about 220 mg, about 190 mg to about 210 mg, about 195 mg to about 205 mg, or about 198 to about 202 mg. In some embodiments, the effective dose of a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein is about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg. In some embodiments, the effective dose of a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0121] In some embodiments, an effective dose of voruciclib, including any voruciclib free base polymorph described herein, or any voruciclib salt polymorph described herein, is from about 0.01 mg / kg to about 4.3 mg / kg, from about 0.15 mg / kg to about 3.6 mg / kg, from about 0.3 mg / kg to about 3.2 mg / kg, from about 0.35 mg / kg to about 2.85 mg / kg, from about 0.15 mg / kg to about 2.85 mg / kg, from about 0.3 mg / kg to about 2.15 mg / kg, from about 0.45 mg / kg to about 1.7 mg / kg, or from about 0.5 mg / kg to about 1.7 mg / kg. / kg, about 0.15mg / kg to about 1.3mg / kg, about 0.3mg / kg to about 1.15mg / kg, about 0.45mg / kg to about 1mg / kg, about 0.55mg / kg to about 0.85mg / kg, about 0.65mg / kg to about 0.8mg / kg, about 0.7mg / kg~about 0.75mg / kg, about 0.7mg / kg~about 2.15mg / kg, about 0.85mg / kg~about 2mg / kg, about 1mg / kg~about 1.85mg / kg, about 1.15mg / kg~about 1.7mg / kg, about 1.3mg / kg mg / kg to about 1.6 mg / kg, about 1.35 mg / kg to about 1.5 mg / kg, about 2.15 mg / kg to about 3.6 mg / kg, about 2.3 mg / kg to about 3.4 mg / kg, about 2.4 mg / kg to about 3.3 mg / kg, about 2.6 mg / kg to about 3.15 mg / kg, about 2.7 mg / kg to about 3 mg / kg, about 2.8 mg / kg to about 3 mg / kg, or about 2.85 mg / kg The effective dose of a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is about 0.35 mg / kg, about 0.7 mg / kg, about 1 mg / kg, about 1.4 mg / kg, about 1.8 mg / kg, about 2.1 mg / kg, about 2.5 mg / kg, about 2.85 mg / kg, about 3.2 mg / kg, or about 3.6 mg / kg. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0122] In some embodiments, a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, is administered at a dose of 10 to 400 mg once daily (QD), including 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, and 500 mg. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0123] In some embodiments, a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is administered in a dose of 10 to 400 mg BID, including doses of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, and 500 mg BID. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0124] In some embodiments, a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is administered in a dose of 10 to 400 mg TID, including doses of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, and 500 mg TID. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0125] An effective amount of a solid form of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, may be administered by any of the accepted modes of administration for active pharmaceutical ingredients with similar effect, including rectal, buccal, intranasal, and transdermal routes, by intra-arterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or as an inhalant, in either a single dose or multiple doses.
[0126] Pharmaceutical compositions for overcoming the effects of acid suppressants The compositions and methods described herein can be used to overcome the effects of acid suppressants, which can significantly limit the exposure of weakly acidic drugs in mammals. Smelick, et al., Mol. Pharmaceutics 2013, 10, 4055-4062. Acid suppressants include omeprazole, esophageal These include proton pump inhibitors such as meprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, and ilaprazole; H2 receptor antagonists such as cimetidine, ranitidine, and famotidine; and antacids such as the bicarbonates, carbonates, and hydroxides of aluminum, calcium, magnesium, potassium, and sodium, as well as mixtures of antacids with agents targeting gastric secretion. Overcoming the effects of acid-suppressing drugs is a significant challenge in the treatment of patients with cancer, inflammatory diseases, immune disorders, and autoimmune diseases, as these patients typically receive co-administration of acid-suppressing drugs due to the gastric irritation often associated with their conditions. Acid-suppressing drugs are one of the most commonly prescribed medications in North America and Western Europe. Recently approved oral cancer treatments have pH-dependent solubility, raising the possibility of drug-drug interactions with acid-suppressing drugs. It is estimated that 20–33% of all cancer patients use some form of acid-suppressing drug. In certain cancers, such as pancreatic or gastrointestinal cancers, the use of acid-suppressing medications is as high as 60-80% of patients. Smelick, et al., Mol. Pharmaceutics 2013, 10, 4055-4062.
[0127] In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant selected from the group consisting of fumaric acid, tartaric acid, ascorbic acid, alginic acid, sodium alginate, potassium alginate, and Carbopol 971P (carboxypolymethylene). In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, Protacid F 120 NM, Protacid AR 1112 (also known as Kelacid NF), Carbomer 941 (polyacrylic acid), and Carbopol 971P (carboxypolymethylene). In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein. In one embodiment, the acidulant is extragranular. In one embodiment, the acidulant is intragranular.
[0128] Alginate is a polysaccharide polymer of β-D-mannuronic acid (M) and α-L-gluconic acid (G) linked by 1-4 glycosidic bonds. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant that is alginic acid or a salt thereof, wherein the alginic acid or salt thereof exhibits an M / G ratio selected from the group consisting of 0.1 to 0.5, 0.2 to 0.6, 0.3 to 0.7, 0.4 to 0.8, 0.5 to 0.9, 0.6 to 1.0, 0.7 to 1.1, 0.8 to 1.2, 0.9 to 1.3, 1.0 to 1.4, 1.1 to 1.5, 1.2 to 1.6, 1.3 to 1.7, 1.4 to 1.8, 1.5 to 1.9, 1.6 to 2.0, 1.7 to 2.1, 1.8 to 2.2, 1.9 to 2.3, 2.0 to 2.4, and 2.1 to 2.5. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant that is alginic acid or a salt thereof, wherein the alginic acid or salt thereof exhibits an M / G ratio selected from the group consisting of less than 0.5, less than 1.0, less than 1.5, less than 2.0, and less than 2.5. ... In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant which is alginic acid or a salt thereof, wherein the alginic acid or salt thereof exhibits an M / G ratio selected from the group consisting of greater than 0.5, greater than 1.0, greater than 1.5, greater than 2.0, and greater than 2.5. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant which is alginic acid or a salt thereof, wherein the alginic acid or salt thereof exhibits an M / G ratio selected from the group consisting of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, and 2.5. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0129] The M / G ratio, as well as the fraction of M and G groups, the fraction of MM and GG "diads," the fraction of "triads" (e.g., MGG), and the fraction of longer sequences of M and G groups, can be determined by methods known to those skilled in the art, including magnetic resonance (NMR) spectroscopy (with or without digestion) and mass spectrometry. Larsen, et al., Carbohydr. Res., 2003, 338, 2325-2336.
[0130] In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant in a concentration (by weight) selected from the group consisting of 1% to 5%, 5% to 10%, 10% to 15%, 15% to 20%, 20% to 25%, 25% to 30%, and 30% to 35%. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant at a concentration (by weight) selected from the group consisting of 1% to 5%, 5% to 10%, 10% to 15%, 15% to 20%, 20% to 25%, 25% to 30%, and 30% to 35%, wherein the acidulant is selected from the group consisting of fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, sodium alginate, potassium alginate, Protacid F 120 NM, Protacid AR 1112 (also known as Kelacid NF), and Carbopol 971P (carboxypolymethylene). In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0131] In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant at a concentration (by weight) selected from the group consisting of less than 1%, less than 5%, less than 10%, less than 15%, less than 20%, less than 25%, less than 30%, and less than 35%. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant at a concentration (% by weight) selected from the group consisting of less than 1%, less than 5%, less than 10%, less than 15%, less than 20%, less than 25%, less than 30%, and less than 35%, wherein the acidulant is selected from the group consisting of fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, sodium alginate, potassium alginate, Protacid F 120 NM, Protacid AR 1112 (also known as Kelacid NF), and Carbopol 971P (carboxypolymethylene), each of which is a maltodextrin or maltodextrin, as described herein. The compound is selected from voruciclib dibenzoyltartrate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate.
[0132] In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant at a concentration (by weight) selected from the group consisting of greater than 1%, greater than 5%, greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, and greater than 35%. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant at a concentration (% by weight) selected from the group consisting of greater than 1%, greater than 5%, greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, and greater than 35%, wherein the acidulant is selected from the group consisting of fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, sodium alginate, potassium alginate, Protacid F 120 NM, Protacid AR 1112 (also known as Kelacid NF), and Carbopol 971P (carboxypolymethylene). In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0133] In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant in a concentration (by weight) selected from the group consisting of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, and about 40%. In one embodiment, the pharmaceutical composition comprises voruciclib including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, as well as about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about and about 40% by weight of an acidulant, wherein the acidulant is selected from the group consisting of fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, sodium alginate, potassium alginate, Protacid F 120, NM, Protacid AR 1112 (also known as Kelacid NF), and Carbopol 971P (carboxypolymethylene). In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0134] In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is selected from the group consisting of fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, racemic tartaric acid, ascorbic acid, isoascorbic acid (also known as erythorbic acid and D-araboascorbic acid), alginic acid, sodium alginate, potassium alginate, Protacid F 120 NM, Protacid AR 1112 (Ke lacid NF), and Carbopol 971P (carboxypolymethylene), and combinations thereof. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is fumaric acid at a concentration of about 15% to about 33% by weight. In one embodiment, the pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is alginic acid or a salt thereof (e.g., sodium alginate or potassium alginate) at a concentration of about 5% to about 33% by weight. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is L-tartaric acid at a concentration of about 25% to about 33% by weight. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is ascorbic acid at a concentration of about 20% to about 50% by weight, and Carbopol 971P (carboxypolymethylene) at a concentration of about 2.5% to about 10% by weight. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is fumaric acid at a concentration of about 5% to about 15% by weight and alginic acid or a salt thereof at a concentration of about 15% to about 33% by weight. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an extragranular acidulant, wherein the extragranular acidulant is L-tartaric acid at a concentration of about 5% to about 15% by weight and alginic acid at a concentration of about 15% to about 33% by weight.
[0135] In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant, wherein the acidulant is selected from the group consisting of fumaric acid, maleic acid, phosphoric acid, L-tartaric acid, citric acid, gentisic acid, oxalic acid, and sulfuric acid. In one embodiment, a pharmaceutical composition comprises voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, and an acidulant, wherein the acidulant is selected from the group consisting of fumaric acid, maleic acid, phosphoric acid, L-tartaric acid, citric acid, gentisic acid, oxalic acid, and sulfuric acid, and the acidulant is a counterion of the salt contained in any crystalline form described herein.
[0136] In one embodiment, the pharmaceutical composition comprises, in addition to the acidulant, an excipient to prolong the exposure of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, to an acidic microenvironment. In one embodiment, the excipient is a polymer of natural, synthetic, or semi-synthetic origin. The polymer may contain acidic, anionic, or nonionic monomers, oligomers, or polymers, or a mixture of acidic, anionic, and nonionic monomers or copolymers. In one version, the excipients include hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, tocopherol polyethylene oxide succinate (D-α-tocopherol polyethylene glycol succinate, TPGS, or vitamin E TPGS), methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, methyl acrylate, ethyl acrylate, copolymer of methyl acrylate and ethyl acrylate, hydroxypropyl methylcellulose acetate succinate, gelatin, corn starch, pea starch, modified corn starch, potato starch, modified potato starch, sodium starch glycolate, croscarmellose, crospovidone, copovidone, polyethylene glycol The acidulant is preferably selected from the group consisting of ethanol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, polyvinyl alcohol, and copolymers of polyvinyl alcohol and polyethylene oxide. Where applicable, copolymers of the aforementioned polymers may be used. The copolymer may be a block, branched, or terminal copolymer. In one embodiment, the polymer exhibits swelling, binding, or gelling properties that inhibit disintegration, dissolution, and erosion of the pharmaceutical composition to prolong or increase overall dissolution. In one embodiment, the inclusion of the polymer increases the dissolution rate and extent compared to the use of an acidulant alone. In one embodiment, the swelling, binding, or gelling properties are pH-dependent, where the polymer swells, binds, or gels differently at one pH or pH range than at another. In one embodiment, this may decrease dissolution at lower pHs than at higher pHs, or vice versa. In another embodiment, this results in similar dissolution of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, at acidic, neutral, or basic pH, which results in similar plasma exposure regardless of gastric pH.
[0137] The dissolution profile of a formulation containing one or more swelling, gelling, or binding excipients may exhibit zero-order, first-order, or second-order derivative kinetic orders at one or more pH values, or a mixture of different kinetic orders at different pH values. In one embodiment, the pharmaceutical composition provides a consistent level of drug to the mammalian gastrointestinal tract upon dissolution. When voruciclib containing any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein is absorbed, this results in sustained plasma levels of drug over a period of time, and is comparable to the dissolution profile of an immediate-release formulation of voruciclib containing any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. max Delay and c maxIn another embodiment, this results in similar exposure in mammals regardless of gastric pH.
[0138] Methods for treating solid tumor cancers, hematological malignancies, inflammatory diseases, autoimmune disorders, immune disorders, and other diseases The pharmaceutical compositions described herein can be used in methods for treating diseases. In a preferred embodiment, they are for use in treating hyperproliferative disorders. They can also be used in the treatment of other disorders described herein and in the following paragraphs.
[0139] In some embodiments, the present invention provides a method for treating a hyperproliferative disorder, comprising administering to a mammal a therapeutically effective amount of a crystalline solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, or a therapeutically effective amount of a pharmaceutical composition comprising a crystalline solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. In a preferred embodiment, the mammal is a human. In some embodiments, the hyperproliferative disorder is cancer. In a preferred embodiment, the cancer is selected from the group consisting of chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and Waldenstrom's hypergammaglobulinemia. In a preferred embodiment, the cancer is selected from the group consisting of non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma), acute myeloid leukemia, thymic cancer, brain cancer, lung cancer, squamous cell carcinoma, skin cancer, eye cancer, retinoblastoma, intraocular melanoma, oral and oropharyngeal cancer, bladder cancer, stomach cancer, pancreatic cancer, bladder cancer, breast cancer, cervical cancer, head and neck cancer, renal cancer, kidney cancer, liver cancer, ovarian cancer, prostate cancer, colorectal cancer, bone cancer (e.g., metastatic bone cancer), esophageal cancer, testicular cancer, gynecological cancer, thyroid cancer, CNS, PNS, AIDS-related cancers (e.g., lymphoma and Kaposi's sarcoma), cervical cancer (human papillomavirus), B-cell lymphoproliferative disorders and nasopharyngeal carcinoma (Epstein-Barr virus), Kaposi's sarcoma and primary effusion lymphoma (Kaposi's sarcoma-associated herpesvirus), hepatocellular carcinoma (hepatitis B virus), and / or ovarian cancer. In some embodiments, the hyperproliferative disorder is selected from the group consisting of virally induced cancers such as T-cell leukemia (human T-cell leukemia virus type 1), B-cell acute lymphoblastic leukemia, Burkitt's leukemia, juvenile myelomonocytic leukemia, hairy cell leukemia, Hodgkin's disease, multiple myeloma, mast cell leukemia, and mastocytosis. In selected embodiments, the method relates to the treatment of a non-cancerous hyperproliferative disorder, such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or a condition of the prostate (e.g., benign prostatic hyperplasia (BPH)). In some embodiments, the hyperproliferative disorder is an inflammatory disorder, an immune disorder, or an autoimmune disorder. In some embodiments, the hyperproliferative disorder is selected from the group consisting of tumor angiogenesis, chronic inflammatory diseases, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, and melanoma, ulcerative colitis, atopic dermatitis, pouchitis, spondyloarthritis, uveitis, Behcet's disease, polymyalgia rheumatica, giant cell arteritis, sarcoidosis, Kawasaki disease, juvenile idiopathic arthritis, hidradenitis suppurativa, Sjogren's syndrome, psoriatic arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, lupus, and lupus nephritis. In one embodiment, the solid form of voruciclib in any of the above embodiments, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0140] In one embodiment, the method of any of the above embodiments further comprises administering to the mammal an acid suppressant, in one embodiment, the acid suppressant is selected from the group consisting of proton pump inhibitors such as omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, and ilaprazole; H2 receptor antagonists such as cimetidine, ranitidine, and famotidine; and antacids such as bicarbonates, carbonates, and hydroxides of aluminum, calcium, magnesium, potassium, and sodium.
[0141] In some embodiments, the present invention provides pharmaceutical compositions of a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein for use in the treatment of cancer, such as thymic cancer, brain cancer (e.g., glioma), lung cancer, squamous cell carcinoma, skin cancer (e.g., melanoma), eye cancer, retinoblastoma, intraocular melanoma, oral cancer, oropharyngeal cancer, bladder cancer, gastric cancer, pancreatic cancer, bladder cancer, breast cancer, cervical cancer, head and neck cancer, renal cancer, kidney cancer, liver cancer, ovarian cancer, prostate cancer, colorectal cancer, colon cancer, esophageal cancer, testicular cancer, gynecological cancer, ovarian cancer, thyroid cancer, CNS cancer, PNS cancer, AIDS-related cancers (e.g., lymphoma and Kaposi's sarcoma), virally-induced cancer, and epidermoid cancer. In some embodiments, the present invention provides pharmaceutical compositions of a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein for use in the treatment of a non-cancerous hyperproliferative disorder, such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hyperplasia (BPH)). In some embodiments, the present invention provides pharmaceutical compositions of a solid form of voruciclib comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein for use in the treatment of a disorder, such as myeloproliferative disorder (MPD), myeloproliferative neoplasm, polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), myelodysplastic syndrome, chronic myeloid leukemia (BCR-ABL1-positive), chronic neutrophilic leukemia, chronic eosinophilic leukemia, or mastocytosis. The present invention also provides compositions for use in treating diseases associated with angiogenesis or neovascularization in mammals, which may manifest as tumor angiogenesis, chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, and hemangiomas. In one embodiment, the solid form of voruciclib in any of the above embodiments is voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, each as described herein. voruciclib, and voruciclib napadisylate.
[0142] In some embodiments, the present invention provides methods of treating solid tumor cancer with a composition comprising a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. In some embodiments, the present invention provides methods of treating pancreatic cancer, breast cancer, ovarian cancer, melanoma, lung cancer, squamous cell carcinoma including head and neck cancer, or hematological cancer. In one embodiment, the invention provides a solid form of voruciclib, comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, in combination with bendamustine, venetoclax, vemurafenib, Abraxane, enasidenib, pomalidomide, lenalidomide, azacitidine, decitabine, hypomethylating agents, gemcitabine, albumin-bound paclitaxel, rituximab, obinutuzumab, ofatumumab, pembrolizumab, nivolumab, durvalumab, avelumab, atezolizumab, bortezomib, marizomib, ixazomib, disulfiram, epigallocatechin-3-gallate, salinosporamide A, carfilzomib, ONX The present invention provides methods for treating pancreatic cancer, breast cancer, ovarian cancer, melanoma, lung cancer, head and neck cancer, colorectal cancer, or hematological cancer using a combination of 0912, CEP-18770, MLN9708, epoxomicin, or MG13 with a second agent selected from the group consisting of: 0912, CEP-18770, MLN9708, epoxomicin, or MG13.In one embodiment, the invention provides methods for treating pancreatic cancer, breast cancer, ovarian cancer, melanoma, lung cancer, head and neck cancer, colorectal cancer, or hematological cancer using a CDK inhibitor in combination with bendamustine, venetoclax, vemurafenib, abraxane, enasidenib, pomalidomide, lenalidomide, azacitidine, decitabine, hypomethylating agents, gemcitabine, albumin-bound paclitaxel, rituximab, obinutuzumab, ofatumumab, pembrolizumab, nivolumab, durvalumab, avelumab, or atezolizumab, and in certain methods described herein, the proteasome inhibitor is selected from the group consisting of bortezomib, marizomib, ixazomib, disulfiram, epigallocatechin-3-gallate, salinosporamide A, carfilzomib, ONX 0912, CEP-18770, MLN9708, epoxomicin, or MG13, where the CDK inhibitor is a solid form of voruciclib comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each described herein.
[0143] In some embodiments, the present invention provides methods of treating solid tumor cancers with a composition comprising a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. In some embodiments, the present invention provides methods of treating pancreatic cancer, breast cancer, ovarian cancer, melanoma, lung cancer, and squamous cell carcinoma, including head and neck cancer. In one embodiment, the present invention provides a method for treating pancreatic cancer, breast cancer, ovarian cancer, melanoma, lung cancer, head and neck cancer, and colorectal cancer using a solid form of voruciclib, including any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0144] In some embodiments, the present invention relates to a method of treating an inflammatory, immune, or autoimmune disorder in a mammal with a composition comprising a solid form of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein. In selected embodiments, the present invention also relates to a method of treating an inflammatory, immune, or autoimmune disorder in a mammal with a composition comprising a solid form of voruciclib, including any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein. Also disclosed are methods of treating diseases with compositions comprising a solid form of ciclib, wherein the disease is selected from the group consisting of tumor angiogenesis, chronic inflammatory diseases, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, and melanoma, ulcerative colitis, atopic dermatitis, pouchitis, spondyloarthritis, uveitis, Behcet's disease, polymyalgia rheumatica, giant cell arteritis, sarcoidosis, Kawasaki disease, juvenile idiopathic arthritis, hidradenitis suppurativa, Sjogren's syndrome, psoriatic arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, lupus, and lupus nephritis. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each as described herein.
[0145] In some embodiments, the invention relates to a method of treating a hyperproliferative disorder in a mammal with a composition comprising a solid form of voruciclib, comprising any of the voruciclib free base polymorphs described herein or any of the voruciclib salt polymorphs described herein, wherein the hyperproliferative disorder is a B-cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), Burkitt's lymphoma, Waldenstrom's hypergammaglobulinemia (WM), Burkitt's lymphoma, multiple myeloma, myelodysplastic syndrome, or myelofibrosis. In some embodiments, the invention relates to a method of treating a hyperproliferative disorder in a mammal with a composition comprising a solid form of voruciclib, comprising any voruciclib free base polymorph described herein or any voruciclib salt polymorph described herein, wherein the hyperproliferative disorder is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, DLBCL (including activated B-cell (ABC) and germinal center B-cell (GCB) subtypes), follicle center lymphoma, Hodgkin's disease, multiple myeloma, indolent non-Hodgkin's lymphoma, and mature B-cell ALL. In one embodiment, the solid form of voruciclib in any of the above embodiments is selected from voruciclib malonate, voruciclib dibenzoyltartrate, voruciclib phosphate, voruciclib oxalate, and voruciclib napadisylate, each of which is described herein.
[0146] In some embodiments, the hyperproliferative disorder is a subtype of CLL. Several subtypes of CLL have been identified. CLL is often caused by the deletion of the immunoglobulin heavy chain variable region (IgV) in leukemia cells. H ) are classified according to their mutation status. RN Damle, et al., Blood 1999, 94, 1840-47; TJ Hamblin, et al., Blood 1999, 94, 1848-54. IgV HPatients with mutations generally have IgV H Patients with this mutation survive longer than those without it. ZAP70 expression (positive or negative) is also used to identify CLL. LZ Rassenti, et al., N. Engl. J. Med. 2004, 351, 893-901. Methylation of ZAP-70 at CpG3 is also a risk factor for CLL, e.g. For example, it is used to identify CLL by pyrosequencing. R. Claus, et al., J. Clin. Oncol. 2012, 30, 2483-91; JA Woyach, et al., Blood 2014, 123, 1810-17. C LL is also classified by disease stage according to the Binet or Rai criteria. JL Binet, et al., Cancer 1977, 40, 855-64; KR Rai, T. Han, Hematol. Oncol. Clin. North Am. 1990, 4, 447-56. Other common mutations, such as 11q deletion, 13q deletion, and 17p deletion, can be assessed using known techniques, such as fluorescence in situ hybridization (FISH). In one embodiment, the present invention relates to a method of treating CLL in a human, wherein the CLL is an IgV H The CLL is selected from the group consisting of mutation-negative CLL, ZAP-70-positive CLL, CLL with ZAP-70 methylation at CpG3, CD38-positive CLL, chronic lymphocytic leukemia characterized by a 17p13.1 (17p) deletion, and CLL characterized by a 11q22.3 (11q) deletion.
[0147] In some embodiments, the hyperproliferative disorder is CLL, in which case the CLL has undergone Richter transformation. A method for assessing Richter transformation, also known as Richter syndrome, is described in Jain and O'Brien, Oncology, 2012, 26, 1146-52. Richter transformation is a subtype of CLL observed in 5-10% of patients. It involves the progression of CLL to high-grade lymphoma and generally carries a poor prognosis.
[0148] In some embodiments, the hyperproliferative disorder is CLL or SLL in a patient susceptible to lymphocytosis. In one embodiment, the invention relates to a method of treating CLL or SLL in a patient presenting with lymphocytosis caused by a disorder selected from the group consisting of a viral infection, a bacterial infection, a protozoal infection, or a post-splenectomy condition. In one embodiment, the viral infection in any of the above embodiments is selected from the group consisting of infectious mononucleosis, hepatitis, and cytomegalovirus. In one embodiment, the bacterial infection in any of the above embodiments is selected from the group consisting of whooping cough, tuberculosis, and brucellosis.
[0149] In some embodiments, the hyperproliferative disorder is a hematological cancer. In certain embodiments, the hematological cancer is a leukemia, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic lymphoma (ALL), and chronic lymphocytic leukemia (CLL). In certain embodiments, the hematological cancer is a non-Hodgkin's lymphoma, such as a B-cell lymphoma or a T-cell lymphoma. B-cell lymphomas include diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, intravascular large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma, and primary central nervous system lymphoma. T-cell lymphomas include precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell lymphoma with smoldering chronic, acute, and lymphomatous subtypes, angioimmunoblastic T-cell lymphoma, extranodal natural killer / T-cell lymphoma, nasal type, enteropathy-associated intestinal T-cell lymphoma (EATL) with I and II subtypes, and anaplastic large cell lymphoma (ALCL).
[0150] Example Example 1: Polymorphism screening - voruciclib HCl The objective of this study was to explore the polymorphic landscape of voruciclib HCl and identify the most suitable form for further development. To this end, an extensive polymorphic screen was conducted using several crystallization methods and a variety of solvents and solvent mixtures. The amorphous phase of voruciclib was used as the starting material for the screening experiments to allow unbiased crystallization.
[0151] Different crystallization methods were used with a variety of solvents and solvent mixtures. The API was highly soluble in solvents with high dielectric constants and hydrogen acceptor properties (DMF, DMSO, DMA, and alcohols), whereas the API had low solubility in all other solvents tested. Some of the polymorph screening experiments were initiated with an amorphous phase as the starting material to allow unbiased crystallization to occur.
[0152] Without being bound by any particular theory, it is believed that although only one anhydrous and non-solvated crystalline phase was directly obtained from several crystallization experiments (Form 1), this API exhibits very complex pseudopolymorphic behavior, with 20 novel solid forms being identified. The crystallization of different forms depends not only on the solvent used but also on the crystallization method. For this reason, without being bound by any particular theory, it is believed that different crystallization conditions may result in different crystallization forms. It is believed that many more solvated forms may exist for this compound. Some of the solvated forms may be non-stoichiometric and may be obtained from different solvents (isostructural pseudopolymorphs).
[0153] Without being bound by any particular theory, Form 1 is believed to be the unique stable, unsolvated, and anhydrous form identified herein, suggesting that Form 1 is a thermodynamically stable form. Experiments examining mixtures of current processing solvents (methanol, 2-propanol, and diisopropyl ether) have shown that the solid phase that precipitates from these solvent mixtures is Form 1, except upon evaporation of the solution, which results in a solvated form.
[0154] Twenty unique solid forms of voruciclib HCl were identified, of which Form 1 was the nonsolvated anhydrous form (identical to the starting material, melting point near 260°C). All other forms appeared to be solvated forms. Upon desolvation, these forms appeared to either convert to Form 1 (based on a melting event at 260°C in the DSC curve) or become amorphous.
[0155] Experiments performed with current processing solvents (methanol, 2-propanol, and diisopropyl ether) resulted in the crystallization of Form 1 by slurry conversion or cooling crystallization, whereas the solvated form was recovered when the solution was evaporated.
[0156] Analytical characterization performed on several batches of voruciclib HCl identified small crystalline phase impurities by XRPD that could be assigned to solvated forms. Although only one anhydrous, nonsolvated crystalline phase was crystallized in this study (Form 1), voruciclib exhibited very complex pseudopolymorphic behavior. The crystallization of different forms depends not only on the solvent used but also on the crystallization method. Many of the solvated forms are nonstoichiometric and can be obtained from different solvents (isostructural pseudopolymorphs).
[0157] Experiments examining mixtures of current processing solvents (methanol, 2-propanol, and diisopropyl ether) showed that the solid phase crystallizing from these solvent mixtures is Form 1, whereas evaporation of the solution results in solvated forms. Therefore, there is always a risk of (trace) solvated forms forming during the manufacture of voruciclib HCl. The origin of the phase impurities observed in some of the analyzed batches can be attributed to evaporation of the crystallization solvent during the crystallization process, filtration, or final drying step.
[0158] Abbreviations: AAC: accelerated aging conditions (40°C and 75% RH); Am: amorphous; API: active pharmaceutical ingredient; AS: experiment ID for antisolvent addition experiment; DSC: differential scanning calorimetry; ECP: experiment ID for evaporation experiment; HPLC: high performance liquid chromatography; HR-XRPD: high resolution X-ray powder diffraction; HT-XRPD: high throughput X-ray powder diffraction; LCMS: liquid chromatography mass spectrometry; MS: mass spectrometry; PSM: experiment ID for cooling crystallization experiment; QSA: experiment ID for solubility characterization experiment; RH: relative humidity; RT: room temperature; S LP: Experiment ID for solvent equilibration experiment; SM: Starting material; TCP: Experiment ID for thermal cycling experiment; TGA: Thermogravimetric analysis; TGMS: Thermogravimetric mass spectrometry; VDL: Experiment ID for vapor diffusion experiment; ACN: Acetonitrile; DMA: N,N-dimethylacetamide; DMF: N,N-dimethylformamide; DMSO: Dimethyl sulfoxide; IPA: 2-propanol; MeOH: Methanol; TBME: Tert-butyl methyl ether; TFE: 2,2,2-trifluoroethanol; THF: Tetrahydrofuran.
[0159] Five batches of voruciclib HCl were subjected to analytical characterization including HR-XRPD (with indexing), DSC, TGMS, and LCMS. Quantification of the crystalline phases was performed from powder patterns recorded by Rietveld refinement using single crystal data of voruciclib HCl Form 1 from previous studies. Figure 1 shows the overlaid XRPD patterns and the final Rietveld refinement. The parameters are shown in Table 1. All batches contained Form 1. Batches of 1694M-1401 and P1446A-05_EN017 were pure Form 1 (no other crystalline phases were detected). Batches of 1694M-1301, 1694M-1201, and P1446A-05_EN027 contained approximately 1-2% crystalline impurities.
[0160] [Table 4]
[0161] DSC curves showed that all five batches exhibited an endothermic event with an onset temperature of 257-258°C and a peak temperature around 263-264°C (Figure 2). TGA analysis of the batches showed that the residual solvent / moisture content varied from 0.3 to 0.5% (Figure 3). Decomposition began around 250°C.
[0162] The chemical purity of the API was assessed by HPLC analysis. The results are summarized in Table 2. Based on the HPLC assay, the chemical purity was comparable for all batches. The HPLC chromatogram of batch P1446A-05_EN017 showed a small shoulder peak in the main peak with an area % of 98.9%. The other batches showed one peak with an area % of 100%.
[0163] [Table 5]
[0164] Characterization of the five batches revealed no significant differences in thermal behavior or chemical purity, although XRPD revealed that three batches exhibited less than 2% crystalline impurities. Batch 1694M-1301 (approximately 39 grams) of voruciclib HCl was used as the starting material for polymorph screening. High-throughput XRPD (HT-XRPD) is shown in the figure for reference purposes.
[0165] DSC analysis showed endothermic events with onset temperatures of 257°C and Tpeak of 263°C. (Figure 5). TGMS analysis showed a 0.3% mass loss prior to decomposition, which was attributed to residual solvent or moisture (Figure 6). The decomposition started around 250 °C and was accompanied by an endothermic event in the heat flow signal.
[0166] Thermal analysis results indicated that the starting material (Form 1) was an anhydrous crystalline phase of voruciclib HCl. The chemical purity of the API was assessed by LCMS analysis. The results showed that the purity of the solid was 100% (area %). The positive ion spectrum showed that the ions (M+H) + The corresponding ion showed an m / z of 470.1, which was consistent with the molecular mass of the free base, 469.8 g / mol.
[0167] The physical stability of Form 1 under pressure was evaluated. Four experiments were performed. Approximately 100 mg of API was pressed in a tablet press (10 ton, 13 mm diameter die) for 1 minute at RT, 10 minutes at RT, 1 minute at 80°C, and 10 minutes at 80°C. The samples were then analyzed by HR-XRPD. The XRPD patterns are overlaid in Figure 8. All samples maintained Form 1, with no apparent changes in the crystallinity and physical appearance of the solid, indicating that Form 1 is stable under pressure at RT and elevated temperatures.
[0168] The physical stability of Form 1 during the milling process was evaluated. One sample was ground at 30 Hz for 5 minutes using a Retch grinder with 1 mm diameter stainless steel balls, and the second sample was manually ground with a mortar and pestle for approximately 5 minutes. These samples were then analyzed by HR-XRPD, and the amorphous content was calculated (assuming the starting material was 100% crystalline). The results for the manually ground sample are shown in Figure 9, which had an amorphous content of approximately 10%. The results for the mechanically ground sample are shown in Figure 10, which contained approximately 7% amorphous phase. No other crystalline phases were observed.
[0169] Polymorph screening experiments are preferably initiated in the amorphous phase to facilitate unbiased crystallization. Therefore, attempts were made to produce amorphous voruciclib HCl. Solutions of the API were prepared in 90 / 10 methanol / water, 90 / 10 THF / water, and 90 / 10 1,4-dioxane / water. The solutions were lyophilized, and the resulting solids were analyzed by HT-XRPD. Experimental details are reported in §6.2.1 on page 20.
[0170] The XRPD diffractograms of the lyophilized solids are shown in Figure 11. Amorphous solids were recovered from 1,4-dioxane / water (90 / 10 v / v) and THF / water (90 / 10 v / v). A crystalline solid distinct from the starting material was recovered from methanol / water (90 / 10 v / v) and designated Form 2.
[0171] The amorphous materials were analyzed by TGMS. All amorphous solids contained approximately 4% solvent. 1,4-Dioxane / Water was chosen for preparing the amorphous materials for screening because this solvent system is a better solvent mixture for lyophilization.
[0172] Solubility Test Thermodynamic solubility was determined by the shake-flask method. A suspension of amorphous API was prepared in 33 solvents. The solid was then equilibrated at RT under continuous stirring for 24 hours. After equilibration, a small aliquot of the mother liquor was filtered and analyzed by HPLC. The solute concentration was determined against a calibration curve of the API.
[0173] The solubility values are ranked according to the United States Pharmacopoeia classification (USP29) and are shown in Table 3. The API is highly soluble in DMA, DMF, and DMSO with solubilities above 400 mg / mL. The API was soluble in alcohol. It was more soluble in short-chain alcohols than in long-chain alcohols, i.e., 230 mg / mL in methanol and 10 mg / mL in 2-butanol. In all other solvents, the solubility was less than 10 mg / mL. These results suggest that the API is more soluble in solvents with high dielectric constants and hydrogen-acceptor properties. A gel was formed in water.
[0174] [Table 6]
[0175] Polymorphism Screening Polymorph screening was performed by combining different crystallization techniques using a variety of solvents and solvent mixtures.
[0176] Solvent equilibration experiments were performed at two temperatures: RT for 2 weeks and 50°C for 1 week. A suspension was prepared with the amorphous API, and after the equilibration period, the solid was separated from the mother liquor. A portion of the solid was dried overnight at ambient conditions and analyzed by HT-XRPD, and a second portion of the solid was dried overnight under vacuum (10 mbar) at 50°C.
[0177] Evaporative crystallization experiments from pure solvents were set up on filtered mother liquors recovered from solvent equilibration experiments at RT and from saturated solutions from solvent mixtures. The mother liquors were slowly evaporated at ambient conditions, followed by further drying under vacuum at 50 °C.
[0178] Cooling crystallization experiments from pure solvents were set up on filtered mother liquors recovered from solvent equilibration experiments performed at 50° C. and from saturated solutions from solvent mixtures. The mother liquors were slowly cooled to 5° C. and aged for 72 h. The precipitated solid was separated from the liquid phase and dried under vacuum (10 mbar) at 50° C. overnight.
[0179] Crystallization by thermal cycling experiments was carried out in solvent mixtures and solvent / water mixtures. Suspensions were prepared with amorphous API and subjected to a temperature profile that included three heating and cooling cycles between 5 and 50 °C.
[0180] Antisolvent addition experiments were performed according to the reverse antisolvent addition method, which means that a small amount of (saturated) API solution was added quickly to 20 mL of antisolvent. Vapor diffusion experiments into solution were performed using a (near) saturated solution of the API in the solvent in which it had high solubility in a small vial. The open vial was placed into a larger vial containing 2 mL of antisolvent. The vial was stored at RT for 2 weeks, after which the precipitated solid was separated from the liquid.
[0181] Vapor diffusion onto solids was performed using amorphous API. The amorphous solid was exposed to the vapors of five different solvents at room temperature for two weeks. A 1.5 mL open HPLC vial containing the amorphous API was placed into a larger container containing 2 mL of solvent.
[0182] All the resulting solids were analyzed by HT-XRPD, and then all the solids were subjected to accelerated aging conditions (40°C / RH75%, AAC) for 2 days and then analyzed again by HT-XRPD.
[0183] Several new XRPD diffractograms were obtained from different crystallization conditions. A list of the forms and the crystallization conditions under which the new forms were found is given in Table 4, and a summary of the different forms is provided below.
[0184] Form 1, identical to the starting material, was found from a variety of solvents and crystallization methods and was stable upon exposure to AAC. Form 2 was the stable form obtained from different types of solvents and almost all crystallization methods except vapor diffusion method.
[0185] Form 3 was mostly observed in experiments conducted in long-chain alcohols and alcohol mixtures. In most cases, Form 3 was unstable upon exposure to AAC and conversion to Form 13 was observed. Form 13 was only obtained once by direct crystallization from evaporative crystallization in ethanol.
[0186] Forms 4 and 5 are most often observed in solvent equilibration and thermal cycling experiments in pure solvents. After AAC, it was converted to a less crystalline form, Form 6. Form 6 was also obtained by drying a gel formed with water.
[0187] Form 7 was obtained from solvent equilibration experiments at RT and thermal cycling in 1,2-dimethoxyethane. This form was stable upon exposure to AAC. Form 8 was mostly recovered from crystallization experiments performed with short-chain alcohols and alcohol mixtures. Form 8 remained stable during AAC.
[0188] Form 9 was crystallized only from DMF and was physically unstable. Some solid-state form transformations were observed. Vacuum-dried solids from cooling crystallization experiments conducted in DMF were identified as Form 10. Form 10 converted to Form 20 after exposure to AAC. Form 20 was not directly observed from crystallization experiments.
[0189] Form 11 was the unstable form found from experiments performed in DMA. Forms 12 and 14 were found from thermal cycling experiments using acetone / water and acetonitrile / water. Both forms were stable upon exposure to AAC, but Form 12 was identified in the dried solid under ambient conditions and converted to Form 14 when dried at 50°C under vacuum.
[0190] Form 15 was obtained from vapor diffusion into solution from DMF / 1,4-dioxane and from cooling crystallization from methanol. This form converted to Form 2 after AAC. Form 16 was always obtained when the crystallization experiments included DMSO and was converted to a different form after AAC.
[0191] Form 17 is an unstable form that converts to Form 13 after AAC and was obtained from anti-solvent addition experiments with TFE / heptane. Form 18 was obtained from antisolvent experiments using DMF / isopropyl acetate and remained stable upon exposure to AAC.
[0192] Form 19 was obtained from evaporation crystallization experiments in methanol / diisopropyl ether (20 / 80) and was stable during AAC.
[0193] [Table 7]
[0194] The unique XRPD diffractograms observed during this study are shown in Figures 12A and 12B. The novel solid forms were further analyzed by DSC, TGMS, and HPLC to confirm the integrity of the compounds and the nature of the forms. For each form, one sample was selected for further analysis. The analytical results are reported in detail herein and are summarized in Table 5.
[0195] Form 1, which is identical to the crystalline starting material, appeared to be the only non-solvated anhydrous form obtained directly from the crystallization experiment. All other forms contained solvent and / or water. Forms 7, 10, 16, and 19 were obtained from specific solvents, but the mass loss observed in TGMS analysis indicated that these forms were non-stoichiometric solvates. Thermal events observed in DSC analysis indicated that each of these forms could be converted to Form 1 upon heating (based on a melting event observed near 260°C).
[0196] Cyclic DSC experiments were performed on Form 7 to determine whether a solvent-free form could be obtained. The solid was heated to 155°C, just after solvent loss and before the first endothermic event. The XRPD of the solid obtained after heating to 155°C was identical to that of the solid before the experiment. TGMS analysis of the dried solid showed a 2.3% mass loss of water. Presumably, the solid absorbed water immediately after removing the sample from the DSC crucible. These results suggest that Form 7 may be a 1,2-dimethoxyethane solvate and / or hydrated form.
[0197] Forms 2, 3, 4, 5, 8, 11, 12, 13, 14, 15, and 17 appeared to be solvated forms obtained from different crystallization solvents, and therefore likely are isostructural solvates (similar crystal structures obtained with different solvents and solvent contents). Thermal analysis showed that Forms 3 and 8 became amorphous upon desolvation, while the other solvated forms could be converted to Form 1 (based on a melting event observed near 260°C).
[0198] Forms 3 and 8 were mostly obtained from alcohols. Form 3 was often converted to Form 13, suggesting that Form 13 may be a hydrated form or a mixed solvate / hydrate.
[0199] Form 4 was obtained from several solvents. Cyclic DSC experiments performed on Form 4 showed similar behavior to that seen with Form 7. The XRPD pattern of the heated solid was slightly different from Form 4 (designated Form 4b). TGMS analysis of the solid recovered after cyclic DSC showed a mass loss of approximately 2%, suggesting that the solid adsorbed water soon after coming to ambient conditions.
[0200] Forms 12 and 14 were obtained from mixtures of acetone / water and acetonitrile / water. Form 12 converted to Form 14 upon vacuum drying. Further cyclic DSC experiments were performed on Forms 12 and 14 by heating the solid samples to 155°C (immediately after solvent loss). The powder pattern of the recovered solid was similar to Form 14. TGMS analysis of the solid obtained after the cyclic DSC experiments contained approximately 1.9% water, suggesting that Form 14 may be a solvated and / or hydrated form.
[0201] Form 6 was a less crystalline form and contained approximately 0.5 molar equivalents of water. After dehydration, the solid became amorphous. Forms 9 and 18 were only identified in the ambient dried solid and converted to other forms upon vacuum drying. Without being bound by any particular theory, it is believed that these forms are likely metastable solvated forms.
[0202] [Table 8]
[0203] Materials and Methods Six batches of voruciclib HCl were provided. Batches P1446A-05_EN017, P1446A-05_EN027, 1694M-1201, 1694M-1301, and 1694M-1401, each weighing 250 mg, were used for analytical purposes only, and batch 1694M-1301, weighing 39 g, was used for polymorph screening. Other chemicals were obtained from Fisher Scientific, Sigma Aldrich, or VWR. Chemicals Used The quality was at least research grade and the HPLC mobile phase was HPLC grade.
[0204] An attempt was made to prepare an amorphous solid. The API was weighed into a standard HPLC vial, and an aliquot of solvent was added until the API dissolved. The solution was frozen in liquid nitrogen and placed under high vacuum using a freeze dryer (Alpha 2-4 LD, Christ). The solid was further dried under vacuum (10 mbar) at 50°C for 24 hours. The resulting solid was analyzed by HT-XRPD. The experimental conditions and results are shown in Table 6. The amorphous material was further analyzed by TGMS to determine the solvent content.
[0205] The amorphous batch of Experiment ID Gen12 was used as the starting material for the screening experiment. The solution was divided into 1.8 mL glass vials and subsequently lyophilized to yield approximately 40 mg of amorphous API per vial.
[0206] [Table 9]
[0207] Solubility determination The solubility of 33 in solvents was determined. To the amorphous solid in a 1.8 mL glass vial, a volume of solvent was added in small increments until a thin suspension was obtained (Table 7). The suspension was allowed to equilibrate at RT with continued stirring. After 24 h, a small aliquot of the mother liquor was removed and filtered through a 0.2 μM PTFE syringe filter. The concentration of the solute was determined by HPLC analysis. A calibration curve was prepared from two independent stock solutions in acetonitrile / water 25 / 75 (vol / vol).
[0208] The remainder of the suspension was used for solvent equilibration experiments at RT over a period of 2 weeks.
[0209] [Table 10]
[0210] Equilibrium experiments at RT and 50 °C Solvent equilibration experiments were performed in 33 solvents. To a vial containing approximately 40 mg of amorphous API, solvent was added in small increments until a thin suspension was obtained. The suspension was allowed to equilibrate with continuous stirring for two weeks at RT (Table 8) and one week at 50°C (Table 9).
[0211] After the equilibration period, the solids were separated by centrifugation. A portion of the solids was collected, placed in a 96-well plate, and dried overnight at ambient conditions. The remaining solids were dried overnight under vacuum (50°C and 10 mbar) and then placed in a 96-well plate. All solids were analyzed by HT-XRPD. All solids were then exposed to accelerated aging conditions (AAC, 40°C / RH 75%) for 2 days and re-analyzed by HT-XRPD.
[0212] [Table 11]
[0213] [Table 12]
[0214] Evaporative crystallization experiments For evaporative crystallization experiments from pure solvents, the mother liquor recovered from the solvent equilibration experiments at RT was used. For evaporative crystallization experiments from solvent mixtures, freshly prepared suspensions were used.
[0215] The mother liquor was filtered using a 0.2 μm PTFE syringe filter. The solution was transferred to a vial (with a cap) and placed under ambient conditions to allow the solvent to slowly evaporate at ambient conditions for 3 days, followed by placing under vacuum at 50° C. until all the solvent had evaporated. The resulting solid The solids were then subjected to accelerated aging conditions (40°C / 75% RH) for 2 days and analyzed again by HT-XRPD.
[0216] [Table 13-1]
[0217] [Table 13-2]
[0218] Cooling crystallization experiment Cooling crystallization experiments from pure solvents were carried out using the mother liquors recovered from the solvent equilibration experiments at 50° C. For cooling crystallization experiments from solvent mixtures, fresh suspensions were prepared.
[0219] The mother liquor was filtered at 50°C using a 0.2 μm PTFE syringe filter. The solution was transferred to a standard HPLC vial and slowly cooled in a Crystal16™ reactor. The solution was cooled to 5°C at 1°C / h and aged at 5°C for 72 h. The precipitated solid was isolated by centrifugation, dried under vacuum overnight (50°C / 10 mbar), and analyzed by HT-XRPD.
[0220] The mother liquors and solutions in which no precipitation occurred were left to evaporate the solvent at ambient conditions, followed by evaporation under vacuum, and the recovered solids were analyzed by HT-XRPD. All solids were then exposed to AAC for 2 days and re-analyzed by HT-XRPD.
[0221] [Table 14-1]
[0222] [Table 14-2]
[0223] Thermal cycle The polymorphic behavior of selected salts was evaluated by thermal cycling in six solvents. Aliquots of solvent were added to vials containing the (amorphous) salts until a suspension was obtained. Experimental details are shown in Table 12.
[0224] The vials were subjected to a temperature profile including three thermal cycles between 5 and 50°C and aged at RT for two days (see Figure 13). After the temperature profile, the samples were dried under vacuum (10 mbar) at RT for 24 hours. The samples were collected and analyzed by HT-XRPD. The solids were then exposed to accelerated aging conditions (AAC, 40°C / RH 75%) for two days and analyzed again by HT-XRPD.
[0225] [Table 15]
[0226] antisolvent Antisolvent addition experiments were performed according to the reverse antisolvent addition method. A highly concentrated solution of voruciclib HCl was prepared in a solvent in which the API is well soluble. The solution was immediately added to 20 mL of an antisolvent (in which the API is not soluble) with vigorous stirring. The precipitated solid was separated by centrifugation, and a portion of the solid was collected and dried under ambient conditions. The remaining portion of the solid was spun under vacuum ( The solid was dried at 50° C. under a pressure of 10 mbar for 24 hours. The solid was then exposed to accelerated aging conditions (AAC, 40° C. / RH 75%) for 2 days and re-analyzed by HT-XRPD.
[0227] [Table 16]
[0228] Vapor diffusion into solution Near-saturated solutions of voruciclib HCl were prepared by dissolving approximately 50 mg of API in solvent in 1.5 mL or 8 mL glass vials. Because the API did not completely dissolve in ethanol and THF, these suspensions were filtered to obtain saturated solutions. The solution in the small vial was placed in a larger vial containing 2 mL of antisolvent (see Table 14). The vials were stored at RT for 2 weeks, after which the precipitated solids were carefully recovered from the liquid and analyzed by HT-XRPD. If no solids precipitated, the solvent was evaporated under ambient conditions, followed by evaporation under vacuum (10 mbar / 50°C), and the recovered solids were analyzed by XRPD. All solids were then exposed to AAC (40°C / RH 75%) and re-analyzed by XRPD.
[0229] [Table 17]
[0230] Vapor diffusion onto solids Vapor diffusion experiments onto solids were conducted using amorphous voruciclib HCl as the starting material. Small vials containing approximately 20 mg of amorphous API were placed into larger vials containing 2 mL of solvent (see Table 15). The vials were stored at RT for 2 weeks, after which the solids were analyzed by HT-XRPD. If solvent was trapped in the small vials, the solvent was evaporated under vacuum (10 mbar / 50°C) and the recovered solids were analyzed by XRPD. All solids were subsequently exposed to AAC (40°C / RH 75%) and re-analyzed by XRPD.
[0231] [Table 18]
[0232] X-ray powder diffraction XRPD patterns were obtained using a Crystallics T2 high-throughput XRPD instrument. Plates were mounted on a Bruker D8 Discover General Area Detector Diffraction System (GADDS) equipped with a VÅNTEC-500 gas area detector corrected for intensity and shape variations (Product Sheet XRD 37, DOC-S88-EXS037V3, Figure 297). Calibration of measurement accuracy (peak positions) was performed using the NIST SRM1976 standard (corundum).
[0233] Data collection was performed at room temperature using monochromatic CuKα radiation in the 2θ region from 1.5° to 41.5°, which is the most characteristic part of the XRPD pattern. Diffraction patterns for each well were collected in two 2θ ranges (1.5°≦2θ≦21.5° for the first frame and 19.5°≦2θ≦41.5° for the second frame) with an exposure time of 45 seconds for each frame. No background subtraction or curve smoothing was applied to the XRPD patterns.
[0234] The carrier material used during XRPD analysis was transparent to X-rays and contributed negligibly to the background. TGA / SDTA and TGMS analysis Mass loss due to solvent or water loss from the crystals was identified by TGMS analysis. Weight vs. temperature curves were obtained by monitoring the sample weight during heating in a TGA / DSC 3+ STARe system (Mettler-Toledo GmbH, Switzerland). Temperature calibration of the TGA / DSC 3+ was performed using indium and aluminum. Samples (approximately 2 mg) were weighed into 100 μL aluminum crucibles and sealed. A pinhole was drilled in the seal, and the crucibles were heated in the TGA from 25 to 300 °C at a heating rate of 10 °C / min. Dry N2 gas was used for purging.
[0235] The gases evolved from the TGA samples were analyzed using an Omnistar GSD 301 T2 mass spectrometer (Pfeiffer Vacuum GmbH, Germany). The MS is a quadrupole mass spectrometer, and masses in the range of 0 to 200 amu are analyzed.
[0236] DSC analysis Melting characteristics were obtained from DSC thermograms recorded on a heat-flux DSC3+ STARe system (Mettler-Toledo GmbH, Switzerland). DSC3+ was used to characterize the melting properties of indium (mp = 156.6 °C; δH f = 28.45 J / g) and zinc (mp = 419.6 °C; δH f = 107.5 J / g) was used to calibrate for temperature and enthalpy. Samples (approximately 2 mg) were sealed in standard 40 μL aluminum pans, pinhole-punched, and heated in the DSC from 25 °C to 300 °C at a heating rate of 10 °C / min. The DSC instrument was purged with dry N2 gas at a flow rate of 50 mL / min during the measurements.
[0237] LCMS analysis method Method name: S18099_01; HPLC system: Agilent 1200; Detector 1: DAD set at 264 nm; Detector 2: HP1100 LC / MSD in positive ion scan mode.
[0238] HPLC conditions: autosampler temperature: 15°C; column: Waters Sunfire C18 (100 x 4.6 mm; 3.5 μm); column temperature: 35°C; flow cell: 10 mm path length; gradient: Table 16; mobile phase A: 0.1% TFA in water; mobile phase B: 0.1% TFA in acetonitrile; flow rate: 1.0 ml / min.
[0239] [Table 19]
[0240] Sample: Concentration: approximately 1 mg / ml; Solvent: water:acetonitrile:TFA (50:50:0.1 v / v / v); Injection volume: 5 μL. The integrity of the compound is expressed as a peak area percentage calculated from the area of each peak other than the "injection peak" in the chromatogram and the total peak area as follows:
[0241]
number
[0242] The peak area percent of the compound of interest is used as an indication of the purity of the components in the sample. Form 1 Form 1 was obtained from a solvent equilibration experiment performed in ethanol and used for characterization in comparison to the starting material (Experiment ID SLP19). Form 1 was physically stable upon exposure to AAC (40°C / RH 75%) for 2 days. HT-XRPD patterns of the material from Experiment ID SLP19 before and after exposure to AAC are shown in Figure 14. TGMS analysis of Form 1 (Figure 15) showed a mass loss of 0.2% over the temperature range of 25-220°C. Without being bound by any particular theory, this mass loss is likely related to residual solvent or moisture. The heat flow curve showed a single endothermic event near 260°C, which is believed to be associated with melting and decomposition, without being bound by any particular theory. The DSC curve for Form 1 (Figure 16) recorded a single endothermic event at 259°C, which is likely associated with melting and decomposition of Form 1, without being bound by any particular theory. The HPLC chromatogram for Form 1, shown in Figure 17, revealed the presence of 100% chemically pure (area percent) API.
[0243] Form 2 Form 2 was obtained from a thermal cycling experiment performed in 1,4-dioxane / water 95 / 5 (vol / vol) and used for characterization (Experiment ID TCP2). Form 2 was physically stable upon exposure to AAC (40°C / RH 75%) for 2 days. HT-XRPD patterns of the material from Experiment ID TCP2 before and after exposure to AAC are shown in Figure 18. TGMS analysis of Form 2 (Figure 19) showed a total mass loss of 5.4% over the temperature range of 25 to 150°C. This mass loss is equivalent to 0.3 molar equivalents of 1,4-dioxane. Form 2 is found in different solvents and, without being bound by any particular theory, is believed to be a non-stoichiometric isostructural solvate. In the DSC curve of Form 2 (Figure 20), two broad endothermic events associated with mass loss were recorded between 25 and 150°C. Without being bound to any particular theory, the small endothermic event at 165°C may have been the transition to Form 1, since a small endothermic event was observed at 259°C (consistent with the melting of Form 1). The HPLC chromatogram of Form 2, shown in Figure 21, revealed the presence of 100% chemical purity (area percent) of the API.
[0244] Form 3 Form 3 was obtained from a thermal cycling experiment conducted in 2-propanol / water 95 / 5 (vol / vol) and used for characterization (Experiment ID TCP2). Form 3 was obtained from an ambient-dried and vacuum-dried solid, but was physically unstable upon exposure to AAC (40 °C / RH 75%) for 2 days, converting to a mixture of Forms 3 and 13. HT-XRPD patterns of the ambient-dried and vacuum-dried solid from Experiment ID TCP13 before and after exposure to AAC are shown in Figure 22. TGMS analysis of Form 3 (Figure 23) showed a 13.2% mass loss in the temperature range of 80 to 160 °C, which, without being bound by any particular theory, is attributed to the loss of IPA (1.3 equivalents of IPA) associated with a large endothermic event in the heat flow signal (Tpeak 103 °C). No melting event was observed after the mass loss, suggesting, without being bound by any particular theory, that the material became amorphous after solvent loss. Without being bound by any particular theory, Form 3 is believed to be a non-stoichiometric isostructural solvate, as it was found with different alcohols. In the DSC curve of Form 3 (Figure 24), a broad endothermic event was recorded at 103°C, which, without being bound by any particular theory, is believed to be related to the loss of IPA. A very small endothermic event was observed at 259°C, consistent with the melting of Form 1, but the overall material is likely amorphous after solvent loss. The HPLC chromatogram of Form 3, shown in Figure 25, revealed the presence of API in 100% chemical purity (area percent).
[0245] Form 4 From a solvent equilibration experiment carried out in tetrahydrofuran, Form 4 was obtained and used for characterization (Experiment ID SLP30). The pattern of the solid dried under ambient conditions (Form 4a) was slightly different from that of the solid dried under vacuum (Form 4). Form 4(a) was physically unstable upon exposure to AAC (40°C / RH 75%) for 2 days and converted to Form 6. The HT-XRPD patterns of the solid from Experiment ID SLP30 before and after exposure to AAC are shown in Figure 26. TGMS analysis of Form 4 (Figure 27) showed that Form 4 was stable over the temperature range of 25-160°C. Form 4 showed a 4.3% mass loss at 220°C. Without being bound by any particular theory, the mass loss was likely associated with the loss of THF (0.3 equivalents of THF). After the mass loss, an exothermic recrystallization event was observed near 220°C, followed by melting and decomposition near 260°C (melting of Form 1). Without being bound by any particular theory, Form 4 is believed to be a non-stoichiometric isostructural solvate because it was obtained from a different solvent. The DSC curve for Form 4 (Figure 28) records three endothermic events, the first two of which occur during the solvent loss process. A small endothermic event is observed at 157°C, the temperature immediately after solvent loss. An exothermic recrystallization event was observed at 217°C, followed by melting (melting of Form 1) and decomposition at 260°C. A cyclic DSC experiment was performed in which the Form 4 solid was heated to 140°C (after solvent removal). The solid was collected and analyzed by XRPD and TGMS, which showed a similar pattern (Form 4b) and a water content of 2%. The HPLC chromatogram of Form 4, shown in Figure 31, revealed the presence of API in 100% chemical purity (area percent).
[0246] Form 5 Form 5 was obtained from a thermal cycling experiment conducted in 1,4-dioxane and used for characterization (Experiment ID TCP8). The ambient-dried solid from Experiment ID TCP8 was a physical mixture of Forms 4a and 5. The vacuum-dried solid was Form 5. Form 5 was physically unstable upon exposure to AAC (40°C / RH 75%) for 2 days and converted to Form 6. HT-XRPD patterns of the solid from Experiment ID TCP8 before and after exposure to AAC are shown in Figure 32. Without being bound to any particular theory, TGMS analysis of Form 5 (Figure 33) showed a total mass loss of 9.4% over the temperature range of 25 to 160°C (0.6 molar equivalents of 1,4-dioxane) due to the loss of 1,4-dioxane. The mass loss occurred in two steps, with two endothermic events. Without being bound to any particular theory, this material likely became amorphous after solvent loss. Without being bound by any particular theory, Form 5 is likely an isostructural solvate, as it was obtained from samples with dioxane and 2-methyl THF. In the DSC curve of Form 5 (Figure 34), a broad endothermic event was recorded at 110°C, likely related to solvent loss. A very small endothermic event was observed at 259°C, consistent with the melting of Form 1, although the entire solid likely became amorphous after solvent removal. The HPLC chromatogram of Form 5, shown in Figure 35, revealed the presence of 100% chemical purity (area percent) of the API.
[0247] Form 6 Form 6 was obtained from a solvent equilibration experiment conducted in water at 50°C and used for characterization (Experiment ID SLP65). Form 6 was a poorly crystalline material and was physically stable upon exposure to AAC (40°C / 75% RH) for 2 days. HT-XRPD patterns of the material from Experiment ID SLP65 before and after exposure to AAC are shown in Figure 36. TGMS analysis of Form 6 (Figure 37) showed a 2.1% mass loss in the temperature range of 25 to 160°C. Without being bound by any particular theory, the mass loss is likely related to water loss (0.6 molar equivalents of water), and the material became amorphous after water loss upon heating. Form 6 was obtained from the aqueous sample after exposure to AAC. Without being bound by any particular theory, it is believed that Form 6 may be a hemihydrate. In the DSC curve of Form 6 (Figure 38), a broad endothermic event associated with water loss was recorded at 151°C. Thermal events seen above 220° C. are associated with decomposition processes. The HPLC chromatogram of Form 6, shown in Figure 39, revealed the presence of API with 100% chemical purity (area percent).
[0248] Form 7 Form 7 was obtained from a thermal cycling experiment conducted in 1,2-dimethoxyethane and used for characterization (Experiment ID TCP5). Both ambient-dried and vacuum-dried solids from Experiment ID TCP5 were Form 7. Form 7 was physically stable upon exposure to AAC (40°C / 75% RH) for 2 days. HT-XRPD patterns of the solid from Experiment ID TCP5 before and after exposure to AAC are shown in Figure 40. TGMS analysis of Form 7 (Figure 41) showed a 2.0% mass loss over the temperature range of 25 to 170°C. Without being bound by any particular theory, it is believed that the mass loss is likely associated with the loss of 1,2-dimethoxyethane and possibly water (mass loss is equivalent to 0.1 molar equivalents of 1,2-dimethoxyethane). Without being bound by any particular theory, it is believed that this material recrystallized to Form 1 after solvent loss. Without being bound by any particular theory, Form 7 is likely a nonstoichiometric dimethoxyethane solvate or mixed dimethoxyethane solvate / hydrate, since it was only observed in samples with 1,2-dimethoxyethane. In the DSC curve of Form 7 (Figure 42), a weak, broad endotherm due to solvent loss was observed between 25 and 160 °C. An endothermic event was recorded at 172 °C, and an exothermic recrystallization event was recorded at 216 °C, followed by an endothermic event at 262 °C (melting of Form 1). Without being bound by any particular theory, Form 7 is likely converted to Form 1 upon heating. Cyclic DSC experiments were performed on solid Form 7 to see if a (stable) unsolvated form could be obtained after solvent loss. The solid recovered after cyclic DSC experiments up to 155 °C was analyzed by XRPD and TGMS. The XRPD pattern was identical, and TGMS analysis showed a 2.3% mass loss (without being bound to any particular theory, this was likely adsorbed water) (Figure 43). The HPLC chromatogram of Form 7, shown in Figure 44, revealed the presence of 100% chemical purity (area percent) of the API.
[0249] Form 8 Form 8 was obtained from an evaporation experiment conducted in methanol / acetone 75 / 25 (vol / vol) and used for characterization (Experiment ID ECP34). Form 8 was physically stable upon exposure to AAC (40°C / RH 75%) for 2 days. HT-XRPD patterns of the material from Experiment ID ECP34 before and after exposure to AAC are shown in Figure 45. TGMS analysis of Form 8 (Figure 46) showed a 5.3% mass loss over the temperature range of 25-130°C. The mass loss was associated with the loss of water and / or acetone (0.5 equivalents of acetone or 1.5 equivalents of water). The heat flow curve showed a broad endothermic event consistent with the mass loss. Without being bound by any particular theory, Form 8 is likely a non-stoichiometric isostructural solvate / hydrate, as it was observed in samples from different solvents. In the DSC curve of Form 8 (Figure 47), a broad endothermic event possibly related to solvent loss was recorded, followed by a smaller endothermic event at 147°C that could be attributed to melting. The HPLC chromatogram of Form 8, shown in Figure 48, revealed the presence of API with 100% chemical purity (area percent).
[0250] Form 10 (and Form 9) Form 10 was obtained (after drying under vacuum) from a cooling crystallization experiment conducted in N,N-dimethylformamide and used for characterization (Experiment ID PSM60). The solid dried at ambient conditions was Form 9, and the solid dried under vacuum was Form 10. Forms 9 and 10 were physically unstable upon exposure to AAC (40°C / RH 75%) for 2 days and transformed into Form 20. HT-XRPD patterns of the solid from Experiment ID PSM60 before and after exposure to AAC are shown in Figure 49. TGMS analysis of Form 10 (Figure 50) showed a mass loss of 20.8% in the temperature range of 25-200°C. The mass loss was likely related to the loss of DMF (1.8 molar equivalents of DMF). The heat flow curve showed an endothermic event at around 80°C due to mass loss, followed by a second endothermic event at around 250°C. Form 10 is a non-stoichiometric DMF solvate, as observed in samples from DMF. In the DSC curve of Form 10 (Figure 51), an endothermic event was recorded at 84°C, likely related to solvent loss. A second endothermic event was observed at 256°C, likely associated with the melting of Form 1. The HPLC chromatogram of Form 10, shown in Figure 52, revealed the presence of 100% area percent chemical purity of the API.
[0251] Form 11 Form 11 was obtained from a cooling crystallization experiment conducted in N,N-dimethylacetamide and used for characterization (Experiment ID PSM59). Form 11 was physically unstable upon exposure to AAC (40°C / 75% RH) for 2 days and converted to Form 2. Further drying under vacuum at 50°C for 72 hours resulted in the solid becoming amorphous. HT-XRPD patterns of the material from Experiment ID PSM59 before and after exposure to AAC are shown in Figure 53. TGMS analysis of Form 11 (Figure 54) showed a 9.1% mass loss over the temperature range of 25-230°C. The mass loss was likely associated with the loss of DMA (0.6 molar equivalents of DMA). The heat flow curve showed a broad endothermic event consistent with the mass loss. A second endothermic event was observed around 250°C (likely representing the melting of Form 1). Form 11 was found in samples from DMA, but was also occasionally found in mixtures with other forms from other solvents, and is likely a non-stoichiometric isostructural solvate. In the DSC curve of Form 11 (Figure 55), an endothermic event was recorded at 85°C, likely due to solvent loss. A second endothermic event was observed near 257°C, which is attributed to the melting of Form 1. The HPLC chromatogram of Form 11, shown in Figure 56, revealed the presence of 100% chemical purity (area percent) of the API.
[0252] Form 12 Form 12 was obtained after evaporation of the mother liquor from a thermal cycling experiment conducted in acetonitrile / water 90 / 10 (vol / vol) and used for characterization (Experiment ID TCP20_ML). Form 12 was physically stable upon exposure to AAC (40 °C / RH 75%) for 2 days. HT-XRPD patterns of the material with Experiment ID TCP20_ML before and after exposure to AAC are shown in Figure 57. TGMS analysis of Form 12 (Figure 58) showed a 5.9% mass loss in the temperature range of 25-200 °C. The mass loss was likely related to the loss of acetonitrile (0.8 molar equivalents of acetonitrile). The heat flow curve showed a broad endothermic event attributable to the mass loss. Decomposition began around 220 °C. Without being bound by any particular theory, Form 12 is likely a non-stoichiometric isostructural solvate, as it was observed in samples (gently dried) from acetonitrile / water and acetone / water. In the DSC curve of Form 12 (Figure 59), endothermic events related to solvent loss were recorded between 25 and 180°C, and a small endothermic event at 255°C that can be attributed to the melting of Form 1 was observed. The HPLC chromatogram of Form 12, shown in Figure 60, revealed the presence of API in 100% chemical purity (area percent).
[0253] Form 13 Form 13 was obtained from a cryo-evaporation crystallization experiment conducted in ethanol and used for characterization (Experiment ID PSM52). Form 13 was physically stable upon exposure to AAC (40°C / 75% RH) for 2 days. HT-XRPD patterns of the material from Experiment ID PSM52 before and after exposure to AAC are shown in Figure 61. TGMS analysis of Form 13 (Figure 62) showed a mass loss of 6.3% over the temperature range of 25-220°C. Due to the small amount of sample available, it is unclear whether the solvent was released during the mass loss (6.3% is equivalent to 1.9 equivalents of water). Several broad endothermic events associated with the mass loss were noted in the DSC curve of Form 13 (Figure 63) (temperature range of 25-170°C). Finally, a small endothermic event was observed at 258° C. (attributed to the melting of Form 1). The HPLC chromatogram of Form 13, shown in Figure 64, revealed the presence of 100% chemical purity (area percent) of the API.
[0254] Form 14 A thermal cycling experiment performed in acetonitrile / water 90 / 10 (vol / vol) yielded Form 14 in a vacuum-dried solid, which was used for characterization (Experiment ID TCP20). The solid dried at ambient conditions was Form 12, and the solid dried under vacuum was Form 14. Form 14 was physically stable upon exposure to AAC (40°C / 75% RH) for 2 days. HT-XRPD patterns of the solid from Experiment ID TCP20 before and after exposure to AAC are shown in Figure 65. TGMS analysis of Form 14 (Figure 66) showed a gradual mass loss of 2.5% over the temperature range of 25 to 170°C. This mass loss is equivalent to 0.3 molar equivalents of acetonitrile. The heat flow curve showed an endothermic event at 165°C immediately following the mass loss. The endothermic event observed near 250°C is likely associated with the melting of Form 1. Form 14 is likely a non-stoichiometric isostructural solvate, as it was found in samples rigorously dried from acetonitrile / water and acetone / water. In the DSC curve of Form 14 (Figure 67), an endothermic event was recorded at 172°C and a minor endothermic event was seen at 258°C (attributed to the melting of Form 1). Without being bound to any particular theory, it is believed that Form 14 likely converts to Form 1 after solvent loss. The HPLC chromatogram of Form 14, shown in Figure 68, revealed the presence of 100% chemical purity (area percent) of the API.
[0255] Form 15 Form 15 was obtained from a liquid vapor diffusion experiment conducted in N,N-dimethylformamide / 1,4-dioxane and used for characterization (Experiment ID VDL8). Form 15 was physically unstable upon exposure to AAC (40°C / 75% RH) for 2 days, converting to a mixture of Forms 2 and 1. HT-XRPD patterns of the solid from Experiment ID VDL8 before and after exposure to AAC are shown in Figure 69. TGMS analysis of Form 15 (Figure 70) showed a 13.2% mass loss in the temperature range of 25-220°C. The mass loss was likely related to the loss of DMF (1 molar equivalent of DMF). The heat flow curve showed an endothermic event (70°C) consistent with the mass loss, followed by another endothermic event near 250°C (melting of Form 1). Form 15 was mostly obtained from experiments using DMF, but Form 15 was occasionally found in mixtures with other forms from other solvents, and is therefore likely an isostructural solvate. In the DSC curve of Form 15 (Figure 71), an endothermic event, likely related to solvent loss, was recorded at 77°C. The final endotherm at 256°C corresponds to the melting of Form 1. The HPLC chromatogram of Form 15, shown in Figure 72, revealed the presence of API in 100% chemical purity (area percent).
[0256] Form 16 Form 16 was obtained from an evaporation experiment conducted in dimethyl sulfoxide and used for characterization (Experiment ID ECP18). Form 16 was physically stable upon exposure to AAC (40°C / 75% RH) for 2 days. HT-XRPD patterns of the material from Experiment ID ECP18 before and after exposure to AAC are shown in Figure 73. TGMS analysis of Form 16 (Figure 74) showed a 16.6% mass loss over the temperature range of 25-240°C. The mass loss was likely associated with the loss of DMSO (1.3 equivalents of DMSO). The heat flow curve showed broad endothermic events consistent with the mass loss. A final endothermic event was observed near 250°C, likely associated with the melting of Form 1. Without being bound by any particular theory, Form 16 is believed to be a non-stoichiometric DMSO solvate, as it was found in samples containing DMSO. In the DSC curve of Form 16 (Figure 75), an endothermic event, possibly related to solvent loss, appears at 102 °C. The final endotherm at 256 °C corresponds to the melting of Form 1. The HPLC chromatogram of Form 16, shown in Figure 76, revealed the presence of 100% chemical purity (area percent) of the API.
[0257] Form 17 Form 17 was obtained from an antisolvent experiment conducted in 2,2,2-trifluoroethanol / heptane and used for characterization (Experiment ID AS3). Both ambient-dried and vacuum-dried solids were Form 17. Form 17 was physically unstable upon exposure to AAC (40°C / 75% RH) for 2 days and converted to Form 13. HT-XRPD patterns of the solid from Experiment ID AS3 before and after exposure to AAC are shown in Figure 77. TGMS analysis of Form 17 (Figure 78) showed a 16.9% mass loss over the temperature range of 25 to 200°C. Without being bound by any particular theory, the mass loss was likely related to the loss of solvent (16.9% is equivalent to 1 molar equivalent of heptane or TFE) that was gradually released. The heat flow curve showed three endothermic events consistent with the mass loss. Without being bound by any particular theory, Form 17 is believed to be a likely stoichiometric TFE or heptane solvate. In the DSC curve of Form 17 (Figure 79), three endothermic events, likely related to solvent loss, were recorded at 97, 135, and 153°C. A small endothermic event was observed at 257°C, which is attributed to the melting of Form 1. The HPLC chromatogram of Form 17, shown in Figure 80, revealed the presence of 100% chemical purity (area percent) of the API.
[0258] Form 18 From antisolvent experiments carried out in N,N-dimethylformamide / isopropyl acetate (Experiment ID Form 18 was obtained in solid form upon drying at ambient conditions. During drying under vacuum, the solid became amorphous. Form 18 became less crystalline upon exposure to AAC (40°C / RH 75%) for 2 days. HT-XRPD patterns of the material with Experiment ID AS7 before and after exposure to AAC are shown in Figure 81.
[0259] Form 19 Form 19 was obtained from an evaporation experiment conducted in methanol / diisopropyl ether 20 / 80 (vol / vol) and used for characterization (Experiment ID ECP45 / PSM13). Form 19 was physically stable upon exposure to AAC (40°C / RH 75%) for 2 days. HT-XRPD patterns of the material from Experiment ID ECP45 / PSM13 before and after exposure to AAC are shown in Figure 82. TGMS analysis of Form 19 (Figure 83) showed a 4.5% mass loss over the temperature range of 25-120°C. The mass loss was likely associated with diisopropyl ether (0.23 molar equivalents of diisopropyl ether). The heat flow curve showed a broad endothermic event consistent with the mass loss. After solvent loss, an exothermic recrystallization event to Form 1 was observed, followed by melting of Form 1 (endotherm near 250°C). Without being bound to any particular theory, it is believed that Form 19 is likely a non-stoichiometric solvate.
[0260] Example 2: Polymorphism screening - voruciclib salts The objective of this study was to identify alternative salts of voruciclib with better and / or different physicochemical properties compared to voruciclib HCl. Without being bound by any particular theory, it is believed that the HCl salt has complex pseudopolymorphic behavior and is prone to gelation in aqueous media. The salt screening presented in this study included 25 acidic counterions and was performed according to the saturated solution method in THF, ethanol, and acetone.
[0261] Common abbreviations: AAC: accelerated aging conditions (40°C and RH 75%); Am: amorphous; API: active pharmaceutical ingredient; CI: counterion; DSC: differential scanning calorimetry; HPLC: high-performance liquid chromatography; HR-XRPD: high-resolution X-ray powder diffraction; HT-XRPD: high-throughput X-ray powder diffraction; LCMS: liquid chromatography mass spectrometry; MS: mass spectrometry; RH: relative humidity; RT: room temperature; SM: starting material; SSm: experiment ID for salt screening experiments; TGA: thermogravimetric analysis; TGMS: thermogravimetric mass spectrometry; EtOH: ethanol; THF: tetrahydrofuran.
[0262] Characterization of starting materials Approximately 5 grams of voruciclib free base (Figure 84), available as a pale yellow powder, was used. For reference purposes, the starting material was analyzed by XRPD, DSC, TGMS, LCMS, and 1 The starting material was analyzed by H-NMR. High-throughput XRPD (HT-XRPD) analysis confirmed the crystalline nature of the starting material (Figure 85). The crystalline starting material was designated Form A. DSC analysis (Figure 86) showed a small endothermic event at 99°C, followed by a second small endothermic event at 214°C, and a final melt at 225°C. Without being bound by any particular theory, it is believed that these small endothermic events suggest that more than one polymorph of the free base may exist. TGMS analysis (Figure 87) showed a 0.3% mass loss before decomposition near 240°C. This mass loss was associated with water and possibly residual solvent (released during the small thermal event at 100°C). The heat flow signal, similar to the DSC curve, showed a sharp endothermic event at 215°C, followed by thermal decomposition that could be attributed to the melting of voruciclib free base. The chemical purity of the free base was assessed by HPLC analysis (Figure 88). The results showed that the purity of the solid was 99.3% (area %). 1 The H-NMR spectrum was recorded and is shown in Figure 89. The peak at 2.47 ppm (proton of the CH group attached to the basic N atom) shows the strongest resonance shift in the case of salt formation. Characterization results showed that the starting material was in a non-solvated anhydrous solid form.
[0263] Solvent Selection The approximate solubility of the free base was evaluated in several organic solvents (Table 17) by the solvent addition method. Aliquots of solvent were added to approximately 5 mg of free base until complete dissolution was observed or a concentration of less than 1 mg / mL was reached. 100 μL aliquots were used up to 2 mL, followed by 1 mL aliquots up to 8 mL. The free base was soluble in THF and slightly soluble in methanol, ethanol, and acetone. In other solvents, the solubility of the free base was less than 10 mg / mL, while in water, voruciclib was virtually insoluble. Based on the solubility results, in some embodiments, the crystallization solvents selected for salt formation were THF, ethanol, and acetone.
[0264] [Table 20]
[0265] Counterion The acidic counterions used in the salt screen are listed in Table 18. Counterion abbreviations were used to name the possible salt forms. Counterions were used at 1 molar equivalent, and acids with two ionizable sites were also used at 0.5 molar equivalent.
[0266] [Table 21]
[0267] Temperature Profile To select a temperature profile for the salt screening experiment, the thermal stability of the free base in solution was tested. A solution of the free base was prepared in THF, ethanol, and acetone and divided into three vials. The vials were placed at RT for 24 hours and at 50°C and 80°C for 1 hour. The solution was analyzed by HPLC. No significant difference in chemical purity was observed compared to the starting material. Therefore, the free base was considered thermally stable in solution.
[0268] Salt screening Salt screening was performed using the saturated solution method. Saturated solutions of the free base were prepared in THF, ethanol, and acetone at 50° C. Aliquots of aqueous counterion solutions were added to give free base:counterion stoichiometries of 1:1.1 or 1:0.55.
[0269] The vials were incubated at 50°C for 1 hour, then slowly cooled to 5°C, followed by The samples were aged at 5°C for 72 hours. If a solid precipitated, it was separated and dried under vacuum at 50°C. All liquid phases were evaporated at ambient conditions, and the resulting solids were then dried to dryness under vacuum. All resulting solids were analyzed by XRPD. The solids were then subjected to accelerated aging conditions (40°C / 75% RH, AAC) for 2 days to assess their physical stability. The nomenclature used was the abbreviation for the counterion, followed by either "0" if a pure counterion was observed or a number if a novel XRPD pattern was obtained. For example, a recovery of pure glutamic acid was designated Glm0, and the unique XRPD patterns obtained from the experiment with 1,2-ethanedisulfonic acid were designated Edy1 and Edy2. XRPD patterns with very small differences were grouped under a single number and distinguished by letters, e.g., Nds1a and Nds1b. If the free base was recovered, the solid was classified as Form B or Form C (because they were different from the Form A starting material).
[0270] The results of the salt screen are summarized in Table 19. Evidence of salt formation was observed for almost all 25 counterions used (counterions are listed alphabetically). Only experiments performed with glutamic acid resulted in the recovery of a mixture of the free base and counterion. With citric and gluconic acids, only amorphous or poorly crystalline solids were recovered.
[0271] Only one crystalline salt form was obtained with hydrobromic acid, benzenesulfonic acid, oxalic acid, and 1-hydroxy-2-naphthoic acid. For all other counterions, more than one solid form was identified, even though only three crystallization solvents were tested. Most solids were physically stable upon exposure to stress conditions.
[0272] [Table 22-1]
[0273] [Table 22-2]
[0274] Malonic acid The malonate salt Mao1 was obtained by evaporation from ethanol and was physically stable upon exposure to AAC. THF and acetone gave a poorly crystalline solid (Mao2), some of which was converted to Mao1 during AAC, suggesting, without being bound by any particular theory, that Mao1 is a more stable salt than Mao2. Mao1 was analyzed by DSC, TGMS, HPLC, and HPLC. 1 Further analysis was carried out by H-NMR, the results of which are described herein. 1 H-NMR confirmed the integrity of the compound, and the NMR spectrum confirmed salt formation with a 1:1 stoichiometry of free base:malonic acid. Thermal analysis revealed that the salt contained approximately 0.2% residual solvent. Decomposition began near 140 °C, while an endothermic melting / decomposition event was observed at 180 °C in the DSC curve. Furthermore, the solubility of the salt was determined in water and in 0.2 M phosphate buffer at pH 6 by incubation at 37 °C for 4 hours. In water, Mao1 formed a very fine suspension, with a determined solubility of 4.4 mg / mL, and the recovered solid remained identical to Mao1. In phosphate buffer, dissociation of the salt occurred, with a solubility of 0.07 mg / mL. The salt initially appeared to oil out, but then dissolved at approximately 100 °C. After 20 minutes a yellow suspension was obtained, with no gelation or increase in viscosity observed.
[0275] Dibenzoyl-L-tartaric acid Salt formation with benzoyltartaric acid in ethanol resulted in the precipitation of DiTr1, while in THF and acetone a mixture of DiTr1 and DiTr2 was formed. The solid was physically stable under AAC. Without being bound to any particular theory, it is believed that DiTr2 is only found in mixture with DiTr1. DiTr1 was further characterized and analytical results are reported herein. The solid contained 0.9% residual solvent. DiTr1 has a stoichiometric ratio of 2:1, free base:DiTr, and decomposed at temperatures above 180 °C. HPLC and NMR spectroscopic analyses confirmed the integrity of the compound, indicating a 2:1 stoichiometry of free base:DiTr. DiTr1 is a hemi-dibenzoyl tartrate salt. The solubility of the salt was determined in water and in pH 6 phosphate buffer. In both media, the solubility was approximately 0.03–0.04 mg / mL. The salt had low wettability and poor miscibility with the aqueous phase, and DiTr1 was recovered after 4 hours of incubation. In both media, the color of the solid did not change, and the suspension remained pale yellow.
[0276] Orthophosphoric acid Crystalline salt forms were obtained from acetone using phosphoric acid. Experiments performed in THF resulted in the formation of a poorly crystalline solid (Pho2), while the free base form (Form D) was recovered from ethanol. All solid phases were physically stable under AAC for 2 days. The crystalline salt Pho1 was further analyzed, and its characterization is described herein. TGMS analysis showed a 1.9% mass loss between 25 and 160 °C, likely due to residual solvent or moisture, with thermal decomposition beginning around 200 °C. DSC curves showed a melting event at 202 °C, followed shortly thereafter by decomposition. The integrity of the compound was confirmed by HPLC and NMR analysis. 1H-NMR spectra confirmed salt formation, and HPLC data indicated a 1:1 stoichiometry. The solubility of the phosphate salt was determined in water and in 0.2 M phosphate buffer at pH 6 after 4 hours at 37 °C. A suspension was prepared using approximately 5 mg of solid, and an initial aliquot of 200 μL of water was added, resulting in the formation of an oil. Further addition of water to a volume of 800 μL and simple mixing of the oil with a spatula resulted in a clear solution (pH 3.7). Therefore, the exact solubility was not determined; the actual solubility is likely higher than 5 mg / mL. Although an oil formed, gelation was not observed due to the high solubility. In phosphate buffer, the solubility was approximately 0.03 mg / mL, and XRPD of the subsequently recovered solid indicated that the salt dissociated in the buffer solution.
[0277] oxalic acid Only one crystalline salt form, Oxa1, was found with oxalic acid. This form was obtained from experiments using 0.5 or 1 molar equivalent. Oxa1 was physically stable under short-term stress conditions. The solid obtained from experiments with half a molar equivalent of oxalic acid in THF was used for characterization and is described herein. HPLC analysis confirmed the integrity of the compound and identified a 1:0.5 stoichiometry of free base:oxalic acid, suggesting, without being bound by any particular theory, that Oxa1 is a hemi-oxalate salt. Thermal analysis and 1 H-NMR spectra indicated that the solid contained water. TGMS analysis showed a 3.2% mass loss over two steps. Therefore, without being bound by any particular theory, the hemioxalate salt is believed to be either a monohydrate or a hemihydrate (containing residual solvent / water). The solubility of Oxa1 was determined to be 0.03 mg / mL after 4 hours at 37 °C in 0.2 M phosphate buffer at pH 6. The salt dissociated in the buffer. Attempts to determine the solubility in water were unsuccessful, as very fine particles were still observable after filtering the sample. The residual solid in the suspension was identical to Oxa1. In both media, the suspension was bright yellow.
[0278] 1,5-Naphthalenedisulfonic acid Several forms were observed for 1,5-naphthalenedisulfonic acid, suggesting that the salt exhibits polymorphic / pseudopolymorphic behavior. However, Nds1a was mostly obtained by precipitation, while evaporation afforded Nds2. Nds1a was stable upon exposure to AAC for 2 days. Nds1b had the same pattern as Nds1a but with a slight shift in peak position, hence the name Nds1b. Nds1b was converted to Nds2 upon exposure to accelerated aging conditions. Nds1a, obtained from a salt formation experiment with 1 molar equivalent of 1,5-naphthalenedisulfonic acid in ethanol, was selected for further characterization. Thermal analysis revealed that the solid contained 1.1% residual solvent / moisture, and the It was also found that the melting and decomposition of the salt began at around 250°C. 1 From the H-NMR spectrum, the stoichiometry of free base:Nds was determined to be 1:0.5. Therefore, without being bound by any particular theory, Nds1a appears to be a nonsolvated anhydrous hemi-napadisylate salt. The solubility of Nds1a in water and 0.2 M phosphate buffer after 4 hours at 37°C was 0.02 mg / mL in both media. The suspension in water was white (pH 3.4), whereas the suspension at pH 6 was yellow. The residual solid was identical to Nds1a, indicating that the salt was stable in both media.
[0279] solvated salts Other crystalline salts (physically stable and / or exhibiting limited polymorphic behavior) were characterized by thermal analysis. Salts with the following acids (in alphabetical order) were identified: 1-hydroxy-2-naphthoate, Xin1; benzoate, Ben2; besylate, Bes1; esylate, Esyl / Form D; gentisate, Gen1; hydrobromide, HBr1; maleate, Mae1; sulfate, Sul1; and toluenesulfonate, Tos2. All of these salt forms contain large amounts of solvent, and melting or thermal decomposition was observed immediately after solvent loss (Table 20). Without being bound by any particular theory, it is believed that this behavior may indicate that, in some embodiments, these solids are stable only as solvates and are not converted to crystalline nonsolvated salt forms by desolvation.
[0280] [Table 23]
[0281] Polymorphic forms of the free base Control samples (no counterion) resulted in the recovery of a different form from the starting material. Ethanol and acetone yielded the same form, designated Form B, while the solid obtained from THF was designated Form C. Form B appeared to be a nonsolvated form, melting near 220°C. The small endothermic events in heat flow (100°C and 214°C) seen in Form A were absent, suggesting that Form B is more stable than Form A. Form C appeared to be a solvated form, melting at 220°C, consistent with the melting of Form B.
[0282] Solubility evaluation Solubility evaluation was performed according to the aliquot addition method and assessed visually. Approximately 5 mg of free base was weighed into an 8 mL glass vial. Aliquots of 100 μL were added up to 2 mL, followed by 1 mL aliquots up to 8 mL. The experimental conditions are listed in Table 21. Additionally, the suspension in water was heated at 60° C. for 30 minutes, but did not dissolve.
[0283] [Table 24]
[0284] thermal stability Solutions of voruciclib (0.2 mg / mL) were prepared in tetrahydrofuran, ethanol, and acetone. These solutions were divided into three vials. The vials were placed at RT for 24 hours and at 50°C and 80°C for 1 hour. The solutions were then analyzed by HPLC. The experimental conditions and results are shown in Table 22.
[0285] [Table 25]
[0286] Salt screening Salt screening was performed using the saturated solution method. Saturated solutions of the free base were prepared in tetrahydrofuran, ethanol, and acetone at 50°C (Table 23). These stock solutions were divided into 33 glass vials (1.8 mL). L(+)-glutamic acid was added as a solid, while fumaric acid and 1-hydroxy-2-naphthoic acid were added from 0.3 M and 0.4 M ethanolic solutions, respectively. All other counterions were added as 1 M aqueous solutions, resulting in a free base:counterion stoichiometry of 1:1.1 or 1:0.55. The experimental conditions and results are listed in Table 24.
[0287] The experiments involved heating at 50°C, followed by cooling from 50°C to 5°C and aging at 5°C for 72 hours. After the aging period, if a solid precipitated, it was separated and dried under vacuum at 50°C. The liquid phase was evaporated at ambient conditions for 2 days and under vacuum at 50°C for 24 hours. All resulting solids were analyzed by HT-XRPD. Subsequently, the solids were exposed to accelerated aging conditions (40°C / RH 75%, AAC) for 2 days and analyzed again by HT-XRPD.
[0288] XRPD nomenclature uses the abbreviation for the counterion, followed by either a "0" if a pure counterion was observed, or a number if a new XRPD pattern was obtained. For example, the recovery of pure glutamic acid was designated Glm0, and the recovery of pure glutamic acid from the experiment with 1,2-ethanedisulfonic acid was designated Glm0. Unique XRPD patterns obtained are designated Edy1, Edy2, etc. XRPD patterns with very little difference are grouped under a single number and distinguished by a letter, e.g., Nds1a and Nds1b. If the free base was recovered, the solid was classified as Form B, C, D, or E (because they were different from the starting material, Form A).
[0289] [Table 26]
[0290] [Table 27-1]
[0291] [Table 27-2]
[0292] [Table 27-3]
[0293] [Table 27-4]
[0294] [Table 27-5]
[0295] Salt solubility The solubility of five candidate salts was determined in 0.2 M phosphate buffer at pH 6 and in water. Two sets of solubility experiments were performed. In one set of solubility experiments, approximately 1 mg of salt was weighed into a 1.8 mL glass vial and immediately added with 1 mL of medium. In the second set of solubility experiments, approximately 5 mg of salt was weighed into a standard 1.8 mL HPLC vial. Subsequently, 200 μL aliquots of aqueous medium were added up to 1 mL while observing the salt's dissolution behavior. The vials were equilibrated at 37°C with continuous stirring (see Table 25 for details). After 4 hours, the solid was separated from the liquid by centrifugation, and the liquid phase was further filtered through a 0.2 μM PTFE filter to remove any particulate matter. The solute concentration was determined by HPLC-DAD analysis. A calibration curve was generated from two independent stock solutions of voruciclib prepared in acetonitrile / water. The pH was recorded at the end of the equilibration period.
[0296] [Table 28]
[0297] X-ray powder diffraction XRPD patterns were obtained using a Crystallics T2 high-throughput XRPD instrument. Plates were mounted on a Bruker D8 Discover General Area Detector Diffraction System (GADDS) equipped with a VÅNTEC-500 gas area detector corrected for intensity and shape variations (manufactured by Sigma-Aldrich). (Product Sheet XRD 37, DOC-S88-EXS037V3, Figure 297). Measurement accuracy (peak position) was calibrated using the NIST SRM1976 standard (corundum). Data collection was performed at room temperature using monochromatic CuKα radiation in the 2θ region from 1.5° to 41.5°, which is the most characteristic part of the XRPD pattern. Diffraction patterns for each well were collected in two 2θ ranges (1.5° ≤ 2θ ≤ 21.5° for the first frame, and 19.5° ≤ 2θ ≤ 41.5° for the second frame) with an exposure time of 45 seconds for each frame. No background subtraction or curve smoothing was applied to the XRPD patterns.
[0298] TGA / SDTA and TGMS analysis Mass loss due to solvent or water loss from the crystals was determined by TGA / SDTA. Weight versus temperature curves were obtained by monitoring the sample weight during heating in a TGA / DSC 3+ STARe system (Mettler-Toledo GmbH, Switzerland). Temperature calibration of the TGA / DSC 3+ was performed using indium and aluminum. Samples (approximately 2 mg) were weighed into 100 μL aluminum crucibles and sealed. A pinhole was drilled in the seal, and the crucibles were heated in the TGA from 25 to 300 °C at a heating rate of 10 °C / min. Dry N2 gas was used for purging.
[0299] The gases evolved from the TGA samples were analyzed using an Omnistar GSD 301 T2 mass spectrometer (Pfeiffer Vacuum GmbH, Germany), a quadrupole mass spectrometer capable of analyzing masses in the range of 0 to 200 amu.
[0300] DSC analysis Melting characteristics were obtained from DSC thermograms recorded on a heat-flux DSC3+ STARe system (Mettler-Toledo GmbH, Switzerland). DSC3+ was used to characterize the melting properties of indium (mp = 156.6 °C; δH f = 28.45 J / g) and zinc (mp = 419.6 °C; δH f = 107.5 J / g) was used to calibrate for temperature and enthalpy. Samples (approximately 2 mg) were sealed in standard 40 μL aluminum pans, pinhole-punched, and heated in the DSC from 25 °C to 300 °C at a heating rate of 10 °C / min. The DSC instrument was purged with dry N2 gas at a flow rate of 50 mL / min during the measurements.
[0301] Proton NMR DMSO-d 6 Inside 1H-NMR spectroscopy was used to characterize compound integrity and to identify salt stoichiometry. Spectra were recorded at room temperature on a 500 MHz instrument (Bruker BioSpin GmbH) using standard pulse sequences (32 scans). Data were processed using the software Spectrus Processor 2016.2.2 (Advanced Chemistry) from ACD Labs. Development Inc. Canada).
[0302] LCMS analysis method Method name: S18099_01; HPLC system: Agilent 1200; Detector 1: DAD set at 264 nm; Detector 2: HP1100 LC / MSD in positive ion scan mode. HPLC conditions: Autosampler temperature: 15°C; Column: Waters Sunfire C18 (100 x 4.6 mm; 3.5 μm); Column temperature: 35°C; Flow cell: 10 mm path length; Gradient: Table 26; Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1% TFA in acetonitrile; Flow rate: 1.0 ml / min.
[0303] [Table 29]
[0304] Sample: Concentration: approximately 0.5 mg / ml; Solvent: water:acetonitrile:TFA (50:50:0.1 v / v / v); Injection volume: 5 μL. The integrity of the compound is expressed as a peak area percentage calculated from the area of each peak other than the "injection peak" in the chromatogram and the total peak area as follows:
[0305]
number
[0306] The peak area percent of the compound of interest is used as an indicator of the purity of the components in the sample. Calculation of the free base:CI stoichiometry in the salt was based on the area (free base recovery) versus sample weight. The sample weight was corrected for the mass loss observed in the TGMS analysis.
[0307] Malonate, Mao1 Malonic acid gave two distinct XRPD patterns. The experiment in ethanol yielded a crystalline salt, Mao1. A less crystalline solid, Mao2, was recovered from acetone and THF. The XRPD patterns of the two forms are shown in Figure 90. Based on its crystallinity and physical stability, Mao1 was selected for further characterization. Figure 91 presents the powder patterns of Mao1 before and after exposure to AAC for two days. The peak list for Mao1 is shown in Table 27. The stable, crystalline malonate salt, Mao1 (Experiment ID SSm53), was further characterized by DSC, TGMS, HPLC, and 1H-NMR analysis.
[0308] [Table 30]
[0309] Without being bound by any particular theory, TGMS analysis of Mao1 (Figure 92) indicated that this form was a nonsolvated anhydrous form, as only 0.2% mass loss occurred before the onset of decomposition. Decomposition began around 140 °C. The DSC curve of Mao1 (Figure 93) showed an endothermic event with a peak temperature of 180 °C, attributed to melting / decomposition. The proton NMR spectrum obtained for Mao1 (Figure 94) confirmed the formation of the salt, as the proton resonances of the salt were shifted compared to the starting material. The specified stoichiometry of free base:malonic acid was 1:1. The HPLC chromatogram obtained for Mao1 (Figure 95) confirmed the integrity of the compound with a chemical purity (area %) of 99.3%.
[0310] Dibenzoyl tartrate, DiTr1 Dibenzoyl-L-tartaric acid exhibited two distinct XRPD patterns. The solid was crystallized from ethanol, and DiTr1 was identified. A mixture of DiTr1 and DiTr2 was recovered from acetone and THF. The XRPD patterns of the two forms are shown in Figure 96. DiTr1 was selected for further characterization and was physically stable upon exposure to AAC for 2 days (Figure 97). The peak list for DiTr1 is shown in Table 28. The pure form of DiTr1 (Experiment ID SSm46) was characterized by DSC, TGMS, HPLC, and 1 It was further characterized by H-NMR analysis.
[0311] [Table 31]
[0312] Without being bound by any particular theory, it is believed that TGMS analysis (Figure 98) indicated that DiTr1 was in a nonsolvated anhydrous form with a residual solvent / water content of 0.9%. This mass loss was observed before the onset of thermal decomposition (around 180 °C). The DSC curve of DiTr1 (Figure 99) showed a small endothermic event at 172 °C, preceding the decomposition process with a peak temperature of 207 °C. The proton NMR spectrum of DiTr1 (Figure 100) confirmed the formation of the salt, as the proton resonances of the salt were shifted compared to the starting material. The stoichiometry determined for the free base:dibenzoyl-L-tartaric acid was 1:0.5. The HPLC chromatogram obtained for DiTr1 (Figure 101) confirmed the integrity of the compound with a chemical purity (area %) of 95.7%.
[0313] Phosphate, Pho1 Two distinct XRPD patterns were observed for phosphoric acid. The experiment conducted in acetone yielded the crystalline salt Pho1. A less crystalline solid, Pho2, was recovered from THF. The XRPD patterns of the two forms are shown in Figure 102. Pho1 was obtained with high crystallinity, and it was physically stable upon exposure to AAC for 2 days (Figure 103). The peak list is shown in Table 29. The stable crystalline phosphate salt Pho1 (Experiment ID SSm81) was further characterized by DSC, TGMS, HPLC, and 1H-NMR analysis.
[0314] [Table 32]
[0315] TGMS analysis of Pho1 (Figure 104) showed a 1.9% mass loss, likely related to water. Mass loss was observed between 25 and 160 °C before melting. Thermal decomposition was observed above 200 °C. The DSC curve of Pho1 (Figure 105) showed a series of small thermal events (related to water / solvent loss) before melting at 202 °C and subsequent decomposition. The proton NMR spectrum obtained for Pho1 (Figure 106) confirmed salt formation, as the salt proton resonances were shifted compared to the starting material. The HPLC chromatogram obtained for Pho1 (Figure 107) confirmed the integrity of the compound, with a chemical purity (area %) of 99.8%. The stoichiometry of the salt was determined based on the area of the main chromatographic peak (attributed to the free base) and was 1:1 free base:phosphate.
[0316] Oxalate, Oxa1 For oxalic acid, only one crystalline salt, Oxa1, was found. This form was identified regardless of the molar equivalent of oxalic acid used in the experiment. Oxa1 was physically stable upon exposure to AAC for 2 days. The XRPD of Oxa1 is shown in Figure 108, and the peak list is given in Table 30. The solid obtained from THF with half a molar equivalent of oxalic acid (Experiment ID SSm12) was further characterized by DSC, TGMS, HPLC, and 1H-NMR analysis.
[0317] [Table 33]
[0318] TGMS analysis of Oxa1 (Figure 109) showed a 1.4% mass loss from 25 to 100 °C and a second 1.9% mass loss from 100 to 150 °C. The mass loss above 160 °C is associated with the decomposition of this salt. The total mass loss of 3.3% corresponds to approximately 1 molar equivalent of water. Therefore, the salt is either a monohydrate or hemihydrate due to residual solvent / water. The DSC curve of Oxa1 (Figure 110) showed two endothermic events from 25 to 130 °C associated with the loss of solvent or water, and a broad endothermic event with a peak temperature of 213 °C was assigned to the thermal decomposition of the salt. The proton NMR spectrum obtained for Oxa1 (Figure 111) confirmed the formation of the salt, as the proton resonances of the salt were shifted compared to the starting material. The HPLC chromatogram obtained for Oxa1 (Figure 112) confirmed the integrity of the compound with a chemical purity (area %) of 99.6%. The calculation of the salt stoichiometry was based on the main chromatographic peak assigned to the free base. The stoichiometry of free base:oxalic acid was 1:0.5.
[0319] Napadisilate, Nds1a Several different XRPD patterns were obtained with 1,5-naphthalenedisulfonic acid. Experiments in ethanol precipitated the crystalline salt Nds1a, while Nds2 was obtained after evaporation of the mother liquor. Other forms were obtained from acetone and THF. The different XRPD patterns obtained from experiments with 1,5-naphthalenedisulfonic acid are shown in Figure 113. Nds1a was highly crystalline and physically stable upon exposure to AAC for 2 days (Figure 114). For this reason, Nds1a (experiment ID SSm35) was further characterized by DSC, TGMS, HPLC, and 1H-NMR analysis. The XRPD is shown in Figure 114, and the peak list is given in Table 31.
[0320] [Table 34]
[0321] Without being bound by any particular theory, it is believed that TGMS analysis (Figure 115) showed that Nds1 was in a nonsolvated anhydrous form with a residual solvent content of 1.1% between 25 and 100 °C. Decomposition began around 250 °C. The DSC curve of Nds1a (Figure 116) showed a series of small endothermic events due to residual solvent loss between 25 and 100 °C. The endothermic event with a peak temperature of 280 °C was attributed to melting / decomposition. The proton NMR spectrum obtained for Nds1a (Figure 117) confirmed the formation of the salt, as the proton resonances of the salt were shifted compared to the starting material. The stoichiometry of free base:1,5-naphthalenedisulfonic acid determined for Nds1a was 1:0.5.
[0322] Form D / esylate, Esy1 Ethanesulfonic acid gave Esyl or Form D. Without being bound by any particular theory, the same XRPD pattern was observed from experiments with phosphoric and oxalic acids, and for that reason, it is believed that it can be attributed to the solid form of the free base, rather than a salt. The different XRPD patterns obtained from experiments with ethanesulfonic, phosphoric, and oxalic acids are shown in Figure 118. In all cases, very similar powder patterns were obtained, with small shifts in some diffraction peaks. Without being bound by any particular theory, TGMS analysis of Esyl or Form D obtained from ethanesulfonic acid in THF (Figure 119) indicated that this form is likely a solvated or hydrated form. A 4.6% mass loss was observed between 25 and 200 °C, followed by decomposition starting around 250 °C. The proton NMR spectrum obtained for Esyl / Form D (Figure 120) showed that the proton resonances were shifted compared to the starting material, suggesting the formation of a salt. The stoichiometry of free base:ethanesulfonic acid could not be determined.
[0323] 1-Hydroxy-2-naphthoic acid salt, Xin1 For 1-hydroxy-2-naphthoic acid, all three solvents yielded the same XRPD pattern, Xin1. Xin1 was physically stable upon exposure to AAC; Figure 121 presents the powder patterns of Xin1 before and after exposure to AAC for 2 days. The stable crystalline malonate salt, Xin1 (Experiment ID SSm19), was further analyzed by TGMS. TGMS analysis of Xin1 (Figure 122) showed a gradual mass loss of 12% from 25 to 200 °C. The mass loss is associated with the loss of THF and subsequent decomposition. The endothermic event between 160 and 180 °C in the heat flow signal likely indicates dissociation / decomposition of the salt.
[0324] Benzoate, Ben2 Three distinct XRPD patterns were obtained for benzoic acid. Ben 1 was obtained from THF, and Ben 2 was obtained from ethanol and acetone. Ben 1 was physically unstable upon exposure to AAC for 2 days and converted to Ben 3. The XRPD patterns of the different forms share some similarity and are shown in Figure 123. Figure 124 presents the powder patterns of Ben 2 (Experiment ID SSm63) obtained from ethanol before and after exposure to AAC for 2 days. The benzoate salt Ben 2 (Experiment ID SSm63) obtained from ethanol was further analyzed by TGMS. TGMS analysis (Figure 125) showed a 4.5% mass loss from 25 to 100 °C, followed by decomposition. The mass loss was likely due to ethanol and water. Heat flow showed an endothermic event near 170 °C, which could be attributed to a melting / decomposition event.
[0325] Besylate, Bes1 For the benzenesulfonate salt, one salt, Bes1, was obtained from each solvent. Bes1 was physically unstable and became less crystalline upon exposure to AAC, likely due to dissociation of the salt. Figure 126 presents the powder patterns of Bes1 (experiment ID SSm10) obtained from THF before and after exposure to AAC for 2 days. The besylate salt Bes1 obtained from THF was further analyzed by TGMS. TGMS analysis of Bes1 (Figure 127) showed an immediate mass loss of 8.1% (25–180 °C), followed by a mass loss of 0.1% at around 230 °C. The besylate salt is likely a solvated form and is unstable as an unsolvated form.
[0326] Gentisate, Gen1 Gentisic acid produced two distinct XRPD patterns. The experiment in THF yielded a crystalline salt, Gen1, after evaporation of the solvent. A less crystalline solid, Gen2_lc, precipitated from acetone and ethanol. The XRPD patterns of the two forms are shown in Figure 128. Based on its crystallinity and physical stability, Gen1 was selected for further characterization. Figure 129 presents the powder patterns of Gen1 before and after exposure to AAC for 2 days. The solid obtained from THF (Experiment ID SSm21) was further characterized by TGMS analysis. TGMS analysis of Gen1 (Figure 130) showed a 9.2% mass loss from 25 to 200 °C. The mass loss is associated with solvent loss and thermal decomposition. The endothermic event observed in the heat flow signal around 130 °C may be related to solvent loss.
[0327] Hydrobromide, HBr1 Hydrobromic acid in ethanol yielded the crystalline salt HBr1. Acetone and THF yielded poorly crystalline / amorphous solids. The crystalline solid HBr1 was physically unstable upon exposure to accelerated aging conditions and converted to HBr2. Figure 131 presents the powder patterns of the solid before and after exposure to AAC for 2 days. The hydrobromide salt HBr1 (Experiment ID SSm34) was further characterized by TGMS analysis. TGMS analysis of HBr1 (Figure 132) showed a 5.9% mass loss due to the loss of ethanol. The heat flow signal recorded several endothermic events associated with mass loss, with the endothermic event at 170 °C likely associated with melting. Decomposition began around 240 °C. This result suggests that HBr1 is a solvated salt and is unstable in its unsolvated form.
[0328] Maleate, Mae1 Two distinct XRPD patterns were obtained for maleic acid. Experiments in THF and acetone yielded the pure salt phase, Mae1. Ethanol yielded a mixture of Mae1 and Mae2. The XRPD patterns for the two forms are shown in Figure 133. Mae1 was physically stable during AAC, but the mixture of Mae1 and Mae2 was converted to Mae1. Figure 134 presents the powder patterns of Mae1 before and after exposure to AAC for 2 days. The stable crystalline salt, Mae1 (Experiment ID SSm14), was further analyzed by TGMS. TGMS analysis of Mae1 (Figure 135) showed a 3.4% mass loss from 25 to 110 °C, likely due to loss of THF and / or water, followed by decomposition.
[0329] Sulfate, Sul1 Sulfuric acid experiments were performed at half-molar and full-molar equivalents. A total of four distinct XRPD patterns were observed. Sul1 and Sul4 were mostly observed in the full-molar experiment, while Sul2 was only observed in the half-molar equivalent experiment. However, evaporation of the mother liquor from the experiment that yielded Sul2 in the solid phase yielded either Sul1 or Sul3. The unique XRPD patterns obtained from the sulfuric acid experiments are shown in Figure 136. Based on its crystallinity and physical stability, Sul1 was selected for further characterization. Figure 137 presents the powder patterns of Sul1 before and after exposure to AAC for two days. The stable crystalline salt Sul1 (experiment ID SSm37) was further characterized by TGMS analysis. TGMS analysis of Sul1 (Figure 138) showed a 2.4% mass loss from 25 to 120 °C and a 5.8% mass loss from 120 to 200 °C, suggesting that the salt is in a solvated form. Decomposition is observed at temperatures above 240°C.
[0330] Toluene sulfonate, Tos2 In p-toluenesulfonic acid, two distinct XRPD patterns were observed from the experiment, with the emergence of a third form after AAC. The ethanol experiment yielded a crystalline salt, Tos2. A less crystalline solid, Tos1, was recovered from acetone and THF. The XRPD patterns of the forms observed with toluenesulfonic acid are shown in Figure 139. Figure 140 presents the powder patterns of Tos2 before and after exposure to AAC for two days. The stable, crystalline toluenesulfonate salt, Tos2 (Experiment ID SSm41), was further characterized by TGMS. TGMS analysis of Tos2 (Figure 141) showed a 4.6% mass loss from 25 to 110 °C due to the loss of ethanol, followed by immediate decomposition.
[0331] Free base form Control samples resulted in the formation of Form B in ethanol and acetone, and Form C in THF. This novel polymorphic form of the free base was physically stable upon exposure to AAC for 2 days. The XRPD pattern of the free base form is shown in Figure 142. Forms B and C were analyzed by TGMS. The TGMS analysis of Form B is shown in Figure 143 and indicates that Form B is a non-solvated anhydrous form that melts near 220°C. Decomposition occurred at temperatures above 250°C. The TGMS analysis of Form C is shown in Figure 144 and indicates that Form C is likely a solvated form. A 2.6% mass loss is observed before melting near 220°C. Decomposition is observed near 250°C.
[0332] Overview of several voruciclib salts The results of physicochemical characterization and solubility testing for the five salt candidates are summarized in Table 32, in comparison to the free base and HCl salt of voruciclib. Without being bound by any particular theory, it is believed that the salts have improved solubility compared to the free base and HCl salt, and that none of the salt candidates formed gels in aqueous media.
[0333] [Table 35]
[0334] All of these selected salt-forming acids, except for dibenzoyltartaric acid, are included in the list of pharmaceutical salts (Handbook of Pharmaceutical Salts: properties, selection and use; P. Heinrich Stahl, Camille G. Wermuth; Wiley-VCH). Malonic acid, phosphoric acid, oxalic acid and 1,5-naphthalenedisulfonic acid are commercially available products in the United States, Europe, and Japan.
[0335] Example 3: Voluciclib oxalate Previous studies performed on the HCl salt have shown that this material exhibits complex pseudopolymorphic behavior and a tendency to form gels in aqueous media. For this reason, previous salt scrambles have been The screening study evaluated the isolation of alternative salts of voruciclib with better physicochemical properties than the HCl salt. A solid-state form screen was performed on the oxalate salt to evaluate its polymorphic behavior. To this end, a polymorph screen was designed that included thermal cycling experiments in 15 solvents, as well as cooling crystallization experiments.
[0336] The material received was voruciclib oxalate, classified as Oxa2. The starting material was an anhydrous salt with a purity of 96% and an API:CI ratio of 1:1. Polymorph screening experiments began with amorphous voruciclib oxalate to allow for unbiased crystallization. A total of seven oxalate forms were identified in this study. Most oxalate forms from the polymorph screening, except for Oxa1, Oxa2, and Oxa7, were unstable when dried under vacuum or exposed to short-term stress conditions. Oxa1 was identified as a hemioxalate / hemihydrate salt, with cavities in its structure that can accommodate solvent or water molecules. The crystal structures of several Oxa1 forms were identified by single-crystal analysis. The unit cell dimensions were slightly different, and the amount of solvent or water was also varied for such structures. Oxa7 was identified as a hemioxalate hydrate. Crystals of Oxa7 were not obtained by cooling crystallization. Oxa2 (anhydrous salt) was most frequently encountered in polymorph screening and was selected as the most promising oxalate form. Therefore, further analytical data were obtained for Oxa2. The solubility of Oxa2 in water at room temperature was low (<0.1 mg / ml), and the material was moderately hygroscopic. Upon addition of water, Oxa2 became a suspension, and no gel formation was observed. Crystals of Oxa2 could not be obtained by cooling crystallization.
[0337] Within the experimental conditions investigated, Oxa2 appeared to be the most preferred crystalline form of the oxalate salt. However, Oxa2 was moderately hygroscopic and exhibited low water solubility, making cooling crystallization of Oxa2 unfeasible. In addition, polymorph screening yielded both hemioxalate and monooxalate forms, which may pose challenges in producing the oxalate salt with the desired stoichiometric counterion ratio. Based on parallel polymorph screening performed on the phosphate and malonate salts of voruciclib, Mao1 was identified as a non-hydroscopic, anhydrous form exhibiting limited polymorphism. This form was reproducible in high yield by cooling crystallization.
[0338] Abbreviation: AAC accelerated aging conditions (40°C and 75% RH for 2 days) Am amorphous API Active Pharmaceutical Ingredient DSC Differential Scanning Calorimetry DVS Dynamic Vapor Sorption H-bond Hydrogen bond 1 H-NMR Proton Nuclear Magnetic Resonance HR-XRPD High Resolution X-ray Powder Diffraction HT-XRPD High-Throughput X-Ray Powder Diffraction Lc low crystallinity LCMS Liquid Chromatography Mass Spectrometry MS mass spectrometry ML mother liquor (liquid phase) MW molecular weight Pc poor crystallinity QSA Freeze-drying experiment ID RF Response Factor RH Relative Humidity RT room temperature SAS Solubility Identification Experiment ID SM starting material SSR solid state research TCP thermal cycle experiment ID TGA thermogravimetric analysis TGMS Thermogravimetric Mass Spectrometry TMS Tetramethylsilane UPLC Ultra High Performance Liquid Chromatography Wt% Weight Percent DME 1,2-dimethoxyethane DMSO-d6 Deuterated Dimethyl Sulfoxide EtOH ethanol IPA 2-propanol Mao Malonate MeOH Methanol Oxa oxalate TBME tert-butyl methyl ether TFE 2,2,2-trifluoroethanol THF tetrahydrofuran The polymorphic behavior of the oxalate salt (Figure 145) was evaluated in a solid-state form screen. A thermal cycling screen involving 15 solvents was designed to identify novel crystalline phases of voruciclib oxalate and to select the best form for further investigation. This study consisted of the following project steps: characterization of the starting material; preparation of the amorphous oxalate salt; thermodynamic solid-state form screening in 15 solvents; and analytical characterization of the novel solid-state forms.
[0339] 29.13 grams of voruciclib oxalate (Batch ID: 19-09333-01) was provided as a crystalline powder (starting material). The high-throughput XRPD (HT-XRPD) patterns of the starting material, Oxa1, oxalic acid dihydrate, and oxalic acid are shown in Figure 146. Based on a comparison of the XRPD patterns, the starting material did not contain any oxalic acid or oxalic acid dihydrate. The material obtained from the salt screen was classified as Oxa1 and had a different XRPD when compared to the starting material received in this study. The starting material for this study was classified as Oxa2.
[0340] HR-XRPD analysis was performed on the starting material (Oxa2). Rietveld refinement (Figure 147) revealed that the starting material was a crystalline phase containing approximately 1% of an unidentified impurity.
[0341] TGMS analysis in Figure 148 showed that approximately 1.1% water was released between 40 and 100 °C, which corresponds to approximately 0.3 molecules of water per molecule of API. Between 180 and 240 °C, the material underwent thermal decomposition, as indicated by a significant mass loss. DSC analysis of the starting material is shown in Figure 149. A...
Claims
1. Crystalline forms of voruciclib, including voruciclib salts comprising a counterion corresponding to an acid selected from dibenzoyl-L-tartaric acid, orthophosphoric acid, oxalic acid, 1,5-naphthalenedisulfonic acid, 1-hydroxy-2-naphthoic acid, benzenesulfonic acid, benzoic acid, ethanesulfonic acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, sulfuric acid, and p-toluenesulfonic acid, or voruciclib free base.
2. 2. A crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from: 5.06°±0.2°, 6.42°±0.2°, 9.34°±0.2°, 10.14°±0.2°, 12.30°±0.2°, 13.66°±0.2°, 14.14°±0.2°, 15.82°±0.2°, 17.02°±0.2°, 19.74°±0.2°, 20.38°±0.2°, 21.82°±0.2°, 22.66°±0.2°, 24.62°±0.2°, 25.78°±0.2°, 26.58°±0.2°, 28.66°±0.2°, and 29.98°±0.2° 2θ.
3. 3. The crystalline form of claim 2, wherein the crystalline form comprises voruciclib dibenzoyltartrate.
4. 2. A crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 4.94°±0.2°, 6.78°±0.2°, 9.34°±0.2°, 10.94°±0.2°, 12.70°±0.2°, 13.38°±0.2°, 14.90°±0.2°, 15.66°±0.2°, 17.54°±0.2°, 18.82°±0.2°, 22.02°±0.2°, 23.98°±0.2°, 24.78°±0.2°, 25.30°±0.2°, 26.66°±0.2°, and 29.98°±0.2° 2θ.
5. 5. The crystalline form of claim 4, wherein the crystalline form comprises voruciclib phosphate.
6. 2. A crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 6.86°±0.2°, 12.66°±0.2°, 13.58°±0.2°, 14.74°±0.2°, 15.98°±0.2°, 19.38°±0.2°, 23.94°±0.2°, 24.78°±0.2°, and 25.94°±0.2°2θ.
7. 7. The crystalline form of claim 6, wherein the crystalline form comprises voruciclib oxalate.
8. 9.02°±0.2°, 10.50°±0.2°, 11.06°±0.2°, 12.30°±0.2°, 12.82°±0.2°, 13.90°±0.2°, 14.82°±0.2°, 15.30°±0.2°, 15.94°±0.2°, 17.26°±0.2°, 19.34°±0.2°, 20.62°± 2. A crystalline form of voruciclib characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from: 22.18°±0.2°, 22.86°±0.2°, 24.58°±0.2°, 25.42°±0.2°, 25.86°±0.2°, 27.38°±0.2°, and 28.66°±0.2° 2θ.
9. 9. The crystalline form of claim 8, wherein the crystalline form comprises voruciclib napadisylate.
10. 10. The crystalline form of any one of claims 1 to 9, wherein the crystalline form is a crystalline anhydrate.
11. 10. The crystalline form of any one of claims 1 to 9, wherein the crystalline form is a crystalline hydrate.
12. 6.86° ± 0.2° 2θ, 9.70° ± 0.2° 2θ, 10.84° ± 0.2° 2θ, 12.50° ± 0.2° 2θ, 12.66° ± 0.2° 2θ, 12.81° ± 0.2° 2θ, 13.41° ± 0.2° 2θ, 13.71° ± 0.2° 2θ, 14.54°±0.2°2θ, 15.35°±0.2°2θ, 15.83°±0.2°2θ, 18.70°±0.2°2θ, 19.00°±0.2°2θ, 19.43°±0.2°2θ, 19.62°±0.2°2θ, 21.75°±0.2°2θ , 22.75°±0.2°2θ, 23.35°±0.2°2θ, 23.47°±0.2°2θ, 23.81°±0.2°2θ, 23.98°±0.2°2θ, 24.36°±0.2°2θ, 24.60°±0.2°2θ, 24.86°±0.2°2θ, 25.11°±0.2°2θ, 25.60°±0.2°2θ, 25.75°±0.2°2θ, and 26.25°±0.2°2θ.
13. 4.93°±0.2°2θ, 6.79°±0.2°2θ, 9.35°±0.2°2θ, 10.58°±0.2°2θ, 10.91°±0.2°2θ, 12.64°±0.2°2θ, 13.35°±0.2°2θ, 13.58°±0.2°2θ, 1 4.81°±0.2°2θ, 15.60°±0.2°2θ, 17.18°±0.2°2θ, 17.52°±0.2°2θ, 18.32°±0.2°2θ, 18.78°±0.2°2θ, 19.34°±0.2°2θ, 19.64°±0.2°2θ , 19.78°±0.2°2θ, 22.02°±0.2°2θ, 23.20°±0.2°2θ, 23.67°±0.2°2θ, 24.00°±0.2°2θ, 24.71°±0.2°2θ, 25.21°±0.2°2θ, 25.39°±0.2°2θ, 26.55°±0.2°2θ, 27.22°±0.2°2θ, 28.07°±0.2°2θ, and 29.90°±0.2°2θ.
14. 14. A composition comprising the voruciclib crystalline form of any one of claims 1 to 13 and a pharma- ceutically acceptable excipient.
15. A dosage form comprising the composition of claim 14.
16. Chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, B-cell lymphoproliferative disorders, B-cell acute lymphoblastic leukemia, Waldenstrom's hypergammaglobulinemia, Burkitt's leukemia, Hodgkin's disease, multiple myeloma, acute myeloid leukemia, juvenile myelomonocytic leukemia, hairy cell leukemia, mast cell leukemia, mastocytosis, myeloproliferative disorders (MPD), myeloproliferative neoplasms, polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), Myelodysplastic syndrome, chronic myeloid leukemia (BCR-ABL1-positive), chronic neutrophilic leukemia, chronic eosinophilic leukemia, primary central nervous system (CNS) lymphoma, primary multifocal lymphoma of the peripheral nervous system (PNS), thymic cancer, brain cancer, glioblastoma, lung cancer, squamous cell carcinoma, skin cancer (e.g., melanoma), eye cancer, retinoblastoma, intraocular melanoma, oral and oropharyngeal cancer, bladder cancer, gastric cancer, gastric cancer, pancreatic cancer, breast cancer, cervical cancer, head and neck cancer, renal cancer, renal cell carcinoma, liver cancer, ovarian cancer, prostate cancer, colorectal cancer, bone cancer (e.g., metastatic bone cancer), esophageal cancer, testicular cancer, gynecological cancer, thyroid cancer, Skin diseases such as cancer, epidermoid carcinoma, AIDS-related cancers (e.g., lymphoma), virally induced cervical cancer (human papillomavirus), nasopharyngeal carcinoma (Epstein-Barr virus), Kaposi's sarcoma, primary humoral lymphoma (Kaposi's sarcoma-associated herpesvirus), hepatocellular carcinoma (hepatitis B virus and hepatitis C virus), T-cell leukemia (human T-cell leukemia virus type 1), benign hyperplasia of the skin, restenosis, benign prostatic hyperplasia, tumor angiogenesis, chronic inflammatory diseases, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, psoriasis, eczema, and scleroderma.
16. The composition of claim 14 or the dosage form of claim 15 for use in treating a patient's disease selected from the group consisting of diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, ulcerative colitis, atopic dermatitis, pouchitis, spondyloarthritis, uveitis, Behcet's disease, polymyalgia rheumatica, giant cell arteritis, sarcoidosis, Kawasaki disease, juvenile idiopathic arthritis, hidradenitis suppurativa, Sjogren's syndrome, psoriatic arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, lupus, and lupus nephritis.
17. 16. The composition of claim 14 or the dosage form of claim 15 for use in treating a patient with a hyperproliferative disorder selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, B-cell lymphoproliferative disorders, B-cell acute lymphocytic leukemia, and Waldenstrom's hypergammaglobulinemia.
18. 16. A composition according to claim 14 or a dosage form according to claim 15 for use in treating a hematological cancer in a patient.
19. 20. The composition or dosage form of claim 18, wherein the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic lymphoma (ALL), and chronic lymphocytic leukemia (CLL).
